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“Let’s swim to the moon
Let’s climb through the tide
Surrender to the waiting worlds
That lap against our side.” 
—  Jim Morrison
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Introduction
GENERAL INTRODUCTION
Type 2 diabetes mellitus (T2D) has become one of the main threats to human health 
in the 21st century[1]. Insulin resistance is an important characteristic, but abnormal 
function of the pancreatic beta cell is thought to play a crucial role in T2D as well[2, 
3]. In this introduction, I summarize the research related to the normal physiology of 
insulin biosynthesis, the factors leading to beta cell dysfunction and the subsequent 
development of T2D. In addition, the currently available functional beta cell tests will 
be reviewed, and hereafter I will give the aims of this thesis, with the primary focus 
on my novel method based on labelling of newly synthesized insulin and C-peptide 
with stable isotopes, which can be used to assess in vivo human beta cell synthesis 
and secretion as part of function in more detail. Such tests are potentially valuable for 
research on the mechanisms causing T2D and for monitoring the effects of drugs on 
the beta cells. The end of this chapter is the outline of the thesis.
Regulatory mechanisms of insulin secretion
Of all circulating nutrients, variation in the concentration of glucose is the most 
important signal for beta cell response[3, 4]. Transport of glucose into the beta cell 
through the glucose transporter elevates intracellular glucose concentrations, which 
are sensed and phosphorylated by glucokinase with subsequent aerobic glycolysis. 
This increases the cellular ATP/ADP ratio, resulting in closure of ATP-dependent K+ 
channels and depolarization of the beta cell membrane. This results in opening of 
voltage dependent Ca2+ channels causing a rise in intracellular Ca2+ levels[5]. The 
latter triggers fusion of large insulin-containing granules with the cell membrane and 
subsequent secretion of insulin. This rapid insulin response is called the triggering 
pathway. When this triggering pathway is insufficient to achieve normal blood glucose 
concentrations, the insulin secretion continues by the amplifying pathway (figure 1) in 
which distant granules are transported toward the cell membrane for fusion and insulin 
release.  This second insulin response lasts longer, and is mainly modulated by glucose. 
This glucose stimulated insulin secretion is potentiated by lipid signalling molecules 
derived from glycerolipid-fatty acid cycling[6] and other metabolic or neurohormonal 
signalling mechanisms also play a role in this amplifying pathway.
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Introduction
Finally, glucose and its intracellular metabolites induce de novo synthesis of insulin, 
which results in the maintenance of an intracellular insulin storage pool, and when 
blood glucose levels remain elevated, in immediate secretion of newly synthesized 
insulin from new granules. After transcription of the insulin gene, proinsulin is 
synthesized in the ER (figure 2).  Proinsulin is then transported through the trans-
Golgi network and stored in immature granules, where proteolytic enzymes convert 
proinsulin into intermediate insulin products and finally into insulin and C-peptide. 
Insulin consists of an A- and B-polypeptide chain connected by two disulfide bonds 
with an additional intra-molecular disulfide bond in the A chain. Cleavage efficiency 
is optimized by intragranular increase of calcium concentration and acidification. 
Simultaneously, the granules migrate towards and fuse with the cell membrane, lose 
their clathrin coat, and release the content of granules containing insulin and C-peptide 
into the blood. As a result insulin and C-peptide are secreted in a 1:1 ratio. When de novo 
synthesized insulin is secreted rapidly, insulin maturation may not have completed, and 
also insulin precursors including proinsulin are secreted and become detectable in the 
circulation [7]. 
In addition to glucose, human in vivo insulin secretion and biosynthesis of insulin by 
beta cells are regulated by complex extracellular mechanisms involving circulating 
neurohormonal and fuel signals, and parasympathetic and sympathetic innervation 
pathways[8].  Amino acids like leucine, lysine and arginine, enhance glucose stimulated 
insulin secretion [9-11]. Compared to these amino acids, the role of lipid signalling 
seems less potent[12]. Gastrointestinal hormones including Glucagon-Like Peptide-1 
(GLP-1) and Glucose-dependent Insulinotropic Peptide (GIP), play an important 
role during oral food intake within the entero-hormonal axis and have a direct 
stimulatory effect on insulin secretion primarily through activation of cAMP signalling 
in beta cells[13] whereas acylated ghrelin reduces insulin secretion[14]. In addition, 
insulin itself and other hormones like growth factors affect insulin secretion[15, 16]. 
Somatostatin from delta-cells acts as a suppressor and glucagon from alpha-cells 
acts as a secretagogue of insulin [17, 18]. Under conditions of increased metabolic 
demand, not infrequently insulin resistance, insulin secretion is increased by both intra- 
and extracellular regulation mechanisms either through proliferation of beta cells or 
by enhanced function of individual beta cells. Worsening insulin sensitivity is initially 
compensated by increased insulin secretion. Genetic and acquired beta cell defects, 
however, preclude indefinite adaptation of beta cells, finally resulting in T2D. Better 
insights into beta cell function and regulatory mechanisms are therefore crucial for 
improving prevention and treatment of T2D.
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Figure 2 | Amino acid pattern of proinsulin, precursor of both insulin and C-peptide.
Biphasic pattern of insulin secretion in vivo and in vitro
One characteristic aspect of insulin secretion is its biphasic pattern in response to 
a challenge with glucose, observed both in vivo and in vitro (figure 3). This biphasic 
insulin secretion is pronounced in in vitro studies and in vivo during an intravenous 
glucose tolerance test, but hardly present during an oral glucose tolerance test[19]. 
The biphasic response is according to the storage-limited model thought to be the 
result of the triggering and amplifying pathways described above[5], involving the 
readily releasable pool (RRP) and the storage granule pool (SGP), respectively. The RRP 
consists of the granules located close to cell membrane, and is responsible for a rapid 
and transient first phase of insulin release. Granules from the SGP are subsequently 
recruited to the RRP, resulting in a sustained second phase of insulin release[20]. 
Distinct mechanisms are thought to be involved in granule kinetics, involving the 
actin cytoskeleton and related remodelling proteins that are responsible for granule 
translocation, and SNARE proteins, which are involved in the process of fusion of 
granules with the cell membrane.[21], The glucose-induced insulin secretion is much 
higher and faster during oral glucose tolerance tests than during an intravenously 
administered glucose load. The biphasic nature of insulin secretion is hardly discernable 
17
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during oral glucose tolerance tests. Due to neurohormonal signalling elicited among 
others by vagal stimulation and incretines released during oral glucose delivery, the 
amplification pathway is probably accelerated [22]. It should be emphasized that the 
reported mechanisms of insulin secretion by RRP and SGP are mainly based on in vitro 
studies of pancreatic beta cells involving island perfusion, capacitance measurement 
and internal reflection fluorescence microscopy. These studies provide crucial 
information on the intracellular mechanisms involved in insulin secretion. However, 
development of novel in vivo beta cell function tools is highly relevant, as insights 
derived from primary or clonal animal beta cell cultures as well as results from in vitro 
single beta cell experiments do not necessarily translate to human (patho)physiology.  
Upon glucose induction, insulin de novo synthesis is upregulated in parallel with 
exocytosis and insulin secretion[4]. Upregulation of insulin synthesis occurs at a lower 
glucose threshold compared to that of insulin secretion, ensuring maintenance of 
insulin reserve in the granules [23, 24]. In vitro, newly synthesized insulin is secreted 
preferentially after stimulation by high glucose concentrations [25]. This suggests 
heterogeneity among the granules in the storage granule pool. In vitro, under conditions 
of high glucose concentration exposure of beta cells, secretion of newly synthesized 
insulin, was delayed with the time needed for vesicular transport from the ER to the 
cell membrane, which is estimated to be ~60 minutes[24, 26]. However, whether or not 
newly synthesized insulin is secreted under high glucose concentrations and/or alters 
in T2D pathogenesis in the in vivo situation in humans, is unknown.
Evidence for beta cell dysfunction during T2D development
T2D is characterized by the failure of beta cells to compensate for insulin resistance[2]. 
In the past decade, it has become clear that without this beta cell dysfunction T2D 
does not occur[27, 28]: beta cells undergo various alterations during T2D development 
and the role of beta cell dysfunction is substantiated by genetic studies.  Initially, the 
pancreas compensates for insulin resistance with hyperinsulinemia to maintain normal 
glucose tolerance, both by increased beta cell mass and function of individual cells [29]. 
Eventually, the beta cells decompensate through multiple mechanisms, and this results 
in raised plasma glucose levels (figure 4). It is not fully known whether the failure is 
primarily due to a reduction in number of beta cells or to reduced function per cell. 
However, there are a number indications that a decrease in individual cell function, 
which is more relevant for short-term adaptation, is the main contributor to T2D[30]. 
18
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Figure 3 | Biphasic insulin release as observed in in vitro beta cell function studies and in vivo after 
intravenous glucose challenge.
Figure 4 | Time-course of beta cell changes in relation to insulin resistance during T2D development. 
Characteristics of deterioration of either beta cell function or mass are listed. The fate of insulin synthesis 
during this time-course is unknown.
19
Introduction
Signs of beta cell impairment have also been observed in the prediabetic stage. 
The main changes are relative loss of insulin pulsatility[31, 32] and impaired insulin 
maturation reflected by the increased concentrations of circulating insulin precursor 
metabolites. With regard to the loss of circulating insulin, in in vivo beta cell function 
tests impairment of the first phase insulin response is observed, eventually followed by 
a decrease of the second phase insulin response[31, 33, 34]. Histological examination 
of the pancreas of patients with T2D reveals decreased beta cell mass, due to increased 
dedifferentiation and/or apoptosis. In addition, higher levels of amyloid deposition 
compared to age-matched controls have been observed [29, 35, 36].  The amyloid 
deposition might result from increased insulin secretion and is thought to be cytotoxic 
to beta cells [37].  
Genetic and acquired factors make beta cells susceptible to failure, contributing to 
beta cell exhaustion and T2D development[3]. A genetic predisposition for T2D has 
been demonstrated by twin and family studies, as well as by genome wide association 
studies (GWAS) in the general population[38-41]. Interestingly, the majority of T2D-
associated genes identified in GWAS are related to pathways involved in beta cell 
development and function[41]. The identified risk gene variants have been associated 
with reduced beta cell development, reduced glucose stimulated insulin secretion, 
impaired membrane depolarization and increased apoptosis, all resulting in increased 
risk for T2D development[42]. Acquired factors that may lead to reduced beta cell 
function or mass are related to diet and lifestyle, and include lack of physical exercise 
and increasing body weight. These factors contribute to the development of insulin 
resistance. With prolonged or worsening of the insulin resistance, beta cells fail to 
further compensate and eventually decompensate, resulting in dysfunction, failure and 
cell death by apoptosis. This process depends on beta cell modulating factors, which 
may start or enhance the progression of beta cell dysfunction. They may include intra-
uterine and epigenetic factors up to chronic fuel excess leading to glucotoxicity and 
lipotoxicity [3, 29]. 
In vivo assessment of total beta cell function and whole body insulin sensitivity.
A number of function tests are available to examine total beta cell function, which 
is explained by the product of individual cell function and number of functional 
beta cells. A number of measures are available that reflect the steady state condition 
and with dynamic function tests beta cell secretion patterns in response to insulin 
secretagogues can be followed in time. They are performed with oral or intravenous 
beta cell stimuli (figure 5). Oral function tests are more physiological as they include 
20
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activation of the entero-insular axis [1]. Intravenous function tests are useful in 
assessing insulin secretion responses to stimuli without direct involvement of the 
cephalic or gastrointestinal signals. 
Whole body insulin sensitivity can be measured in the fasting state, and in the dynamic 
state following a standard glucose load given either orally or intravenously[43].  The 
intravenous euglycemic hyperinsulinemic clamp has been accepted as the gold 
standard for whole body insulin sensitivity. In this method, glucose removal from 
the circulation during intravenous administration of exogenous insulin is taken as 
a measure of whole body insulin sensitivity. In contrast to insulin sensitivity, there is 
no gold standard for beta cell function. The disposition index, which is calculated as 
insulin secretion corrected for glucose concentration and insulin sensitivity, is probably 
the best estimate currently available for beta cell function[44]. Studies on the glucose 
potentiation of the first-phase insulin response induced by non-glucose nutrients 
currently provide the best estimate of beta cell mass[45].
For the assessment of beta cell function, C-peptide levels are a better proxy of insulin 
secretion than peripheral insulin concentrations, as insulin undergoes both hepatic and 
peripheral extraction [55]. In contrast, C-peptide is mainly cleared by renal extraction 
and has a much longer plasma half-time value than insulin. Deconvolution techniques 
based on plasma C-peptide concentrations have been used to estimate pancreatic 
insulin secretion rate (figure 6)[56]. Part of the cleared C-peptide appears unaltered 
in the urine. In this thesis, I provide literature and demonstrate that urinary C-peptide 
levels correspond well to estimated C-peptide clearance rates obtained from plasma-
based beta cell kinetic models[57], and that urinary C-peptide can be used as a target 
peptide for stable isotope labelling techniques for detailed beta cell function analysis 
which is central to this thesis.
21
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Figure 5 | Dynamic and steady-state methods for assessing beta cell function[46-53] and insulin 
sensitivity[43, 45, 46, 52, 54].
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Figure 6 | Schematic overview of insulin and C-peptide extraction after pancreatic release with C-peptide 
kinetics as preferred choice for calculation of insulin secretion rate (ISR) and thus beta cell function.
AIMS AND OUTLINE OF THE THESIS
This thesis is aimed at exploring beta cell function in-depth in T2D high-risk families, this 
includes developing and applying a novel stable isotope based test to measure in vivo 
insulin synthesis. This setup enables us to explore pathogenetic effects of genes related 
to pathways involved in insulin synthesis and secretion, as family analyses offer the 
opportunity to analyse association while considering transmission of genetic variants, 
they enhance matching of cases and controls, and avoid confounders that frequently 
disturb case-control studies. Beta cell function comprises multiple aspects of glucose-
23
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stimulated insulin secretion, including the amount of insulin secreted, which consists 
of already available insulin in different pools of granules, and the rate of secretion of 
newly synthesized insulin. Stable isotope labelling of proinsulin enables to determine 
the contribution of the secretion of stored insulin versus newly synthesized insulin.  My 
method is based on a bolus dose method[58], using the stable isotope 13C- labelled 
leucine administered prior to an oral glucose load. As the stable isotope is incorporated 
into proinsulin, both de novo synthesized insulin and C-peptide will be enriched with 
13C-leucine. Subsequently, the enrichment factor can be determined in plasma insulin 
and C-peptide at different times during the OGTT, and in urinary C-peptide. With 
both measurements and the changes in the plasma or the urinary concentrations, the 
relative contribution of insulin (and C-peptide) secreted from storage pools versus de 
novo synthesis can be estimated. 
Before assessment with stable isotopes, I investigated beta cell function in relation to 
glucose disposal and insulin sensitivity with classical indices derived from prolonged 
oral glucose tolerance tests in family analyses and according to the stages of glucose 
tolerance in chapter 2. I also included South Asian families living in the Netherlands 
as they are heavily burdened by type 2 diabetes. Although lifestyle, social factors, 
diet and other environmental factors have been studied extensively, the role of beta 
cell function in T2D development has been relatively undervalued in this population. 
In chapter 3 I further phenotyped our families and determined their metabolic 
syndrome state, which is a major health problem contributing to type 2 diabetes 
and cardiovascular disease. The effects of metabolic syndrome parameters on insulin 
sensitivity and beta cell indices, derived from oral minimal modelling were assessed. 
As additional part of this metabolic profiling in chapter 4, I determined the effects of 
their fasting amino acid profiles, and also screened for the predictive capability of these 
profiles for determining glucose tolerance state. In chapter 5, as part of the work-up 
towards a novel stable isotope test, I explored C-peptide and glucose excretion in urine 
during OGTT. Surprisingly, data were not available in the literature on how urinary 
C-peptide and glucose secretion during OGTT might affect plasma based indices of 
insulin sensitivity and beta cell function, through various stages of glucose tolerance. 
This is highly relevant for interpretation of pharmacokinetic models in general that 
provide plasma based beta cell function and insulin sensitivity indices, as the role of 
renal extraction compared to hepatic and peripheral tissue extraction is relatively 
unknown. Apart from this, as urinary measurements are non-invasive, I also explored 
their correlation with plasma based indices and their predictive capability to detect 
glucose tolerance state. In chapter 6, I describe a novel stable isotope method to follow 
insulin biosynthesis and release by the pancreatic beta cells in detail during an oral 
glucose tolerance test, using urinary C- peptide as the target peptide. Stable isotopes 
24
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have not previously been used to examine insulin kinetics in man in vivo. In healthy 
volunteers, I show that it is possible to quantitate insulin synthesis and secretion in vivo. 
Furthermore, I used this method in individuals from T2D high-risk families, enabling us 
to investigate the mechanisms of beta cell dysfunction in type 2 diabetes in-depth as 
described in chapter 7. Also in this chapter, I determined if the T-allele of the rs7903146 
in the transcription factor 7-like 2 gene, which is the main susceptibility gene for T2D, 
increases T2D risk based on insulin synthesis rate. Finally in chapter 8, I discuss my 
main findings, propose a pathophysiological model and make suggestions for future 
research options. 
25
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CHAPTER 2
Failing beta-cell adaptation in South Asian 
families with a high risk of type 2 diabetes
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ABSTRACT
We performed an extended oral glucose tolerance test (OGTT) to investigate the 
relationship between early and late beta-cell response and type 2 diabetes (T2D) 
in families of South Asian origin and indigenous Dutch, burdened by T2D. Based on 
the OGTT, 22 individuals were normoglycemic, 12 glucose intolerant and 23 had 
T2D in the South Asian families; these numbers were 34, 12 and 18 in the Caucasian 
families, respectively. The OGTT had 11 blood samplings in 3.5 h for glucose, insulin 
and C-peptide measurements. Through early and late insulin secretion rate (ISR), the 
above basal glucose area-under-the-curve after glucose load (glucose disposal)  and 
insulin sensitivity index (ISI), we obtained early and late disposition indices (DI). South 
Asians on average had lower ISI than Caucasians (3.8±2.9 vs 6.5±4.7, respectively 
P < 0.001), with rapid decline of their early and late DI between normal glucose 
tolerance versus impaired fasting glucose/impaired glucose tolerance (late DI; P < 
0.0001). Adjusted for ISI, age, gender and waist-to-hip ratio, early ISR was significantly 
associated with glucose disposal in South Asians (β=0.55[0.186; 0.920]), but not in 
Caucasians (β=0.09[-0.257; 0.441]). Similarly, early ISR was strongly associated with late 
ISR (β=0.71[0.291; 1.123];R2=45.5%) in South Asians, but not in Caucasians (β=0.27, 
[-0.035; 0.576];R2=17.4%), with significant interaction between ethnicity and early ISR 
(β=0.341, [0.018; 0.664]). Ordinal regression analyses confirmed that all South Asian 
OGTT subgroups were homogenously resistant to insulin and solely predicted by early 
ISR(β=-0.782[-1.922; 0.359], β=-0.020 [-0.037; -0.002], respectively), while in Caucasian 
families both ISI and early ISR were related to glucose tolerance state(β=-0.603[-1.105; 
-0.101], β=-0.066 [-0.105; -0.027] respectively). 
In South Asian individuals, rapid beta-cell deterioration might occur under insulin 
resistant conditions. As their early insulin response correlates strongly with both 
glucose disposal and late insulin response, alterations in beta-cell dynamics may give 
an explanation to their extreme early onset of T2D, although larger prospective studies 
are required.
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INTRODUCTION
Dutch citizens of South Asian origin have a nearly fivefold higher prevalence of type 2 
diabetes (T2D) than the indigenous Dutch population (further described as Caucasian) 
[1, 2]. The increased susceptibility to T2D is also evident from the early onset of the 
disorder at relatively low body mass and the remarkably high incidence of cardiovascular 
and microvascular damage among the South Asians [2, 3]. A number of factors have 
been proposed to account for this strikingly high risk in South Asians, including a high 
prevalence of metabolic syndrome, impaired maternal lipid profile conditions, low 
birth weight causing central obesity later in life, dysfunction of adipocytes, as well as 
educational, social and economic inequalities [4-14]. These factors all enhance insulin 
resistance and promote hyperinsulinemia [14, 15]. In addition, T2D is characterized by 
beta-cell dysfunction. Genetic loci predisposing individuals to T2D affect both beta-cell 
function and insulin action [16, 17]. 
The ancestors of South Asian families in the Netherlands moved from a circumscribed 
region in India to Surinam. During the past 150 years, these South Asian families 
lived largely in genetic isolation before arriving in the Netherlands. The conservation 
of susceptibility loci may have contributed to the strong aggregation of T2D in these 
families. We hypothesized that, in addition to severe resistance to insulin, these South 
Asian families are also predisposed to develop beta-cell dysfunction. Therefore, we 
investigated beta-cell function and insulin sensitivity simultaneously in South Asian 
and Caucasian patients with T2D and first-degree relatives. In effect, we assessed the 
contribution to the risk of T2D of changes in early and late insulin secretion rates (ISR) 
and insulin sensitivity during an extended oral glucose tolerance test (OGTT) with 
insulin and C-peptide measurements.
METHODS
Subjects
The study was conducted during a time period between August 2007 and January 
2011. Patients with T2D and first-degree relatives without T2D were recruited from 
36 South Asian families and 24 Caucasian families (Scheme 1). Power calculation was 
performed with Quanto version 1.0 [31] and was based on differences in early phase 
ISR (described further on in Methods section)  between healthy South Asian and 
Caucasian performed in a pilot phase of the study among, with alpha 0.05 and power 
80%.  All probands were attending the outpatient clinic of the Department of Internal 
Medicine of the Erasmus Medical Center in Rotterdam. T2D was diagnosed according to 
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World Health Organization (WHO) criteria [18]: plasma glucose level ≥7.0 mmol/L in a 
fasting state and/or ≥11.1 mmol/L in a non-fasting state. Inclusion criteria for probands 
were age of 18 years or older and T2D in at least 1 sibling. Both parents of the South 
Asian probands were of South Asian origin and Caucasian probands were born in 
The Netherlands with both parents of Caucasian Dutch origin. Exclusion criteria were 
insulin-dependent diabetes mellitus, using medication other than metformin, a history 
of pancreatitis, insulinoma or other reasons that made participation impossible. Written 
informed consent was obtained from all participants. The study protocol was approved 
by the Erasmus Medical Center Medical Ethics Review Board.
T2D patients, metformin
20 SA (M10F10)
17 Cau(M9F8)
36 South Asian families (n=84)
24 Caucasian families (n=81)
De novo T2D
3 SA (M1F2)
1 Cau (1F)
Overt T2D*
25 SA(M15F10)
17 Cau (M8F9)
IFG/IGT
12 SA (M8F4)
12 Cau (M4F8)
NGT
24 SA (M10F14)
34 Cau (M11F23)
+
NGT
22 SA (M10F12)
34 Cau (M11F23)
IFG/IGT
12 SA (M8F4)
12 Cau (M4F8)
T2D patients
23 SA (M11F12)
18 Cau (M9F9)
…………………………………………………………………………………………………………………………………………….
Used for current study
All excluded from current study, 
(did not meet criteria for study)
n=2
excluded from current study,
due to incomplete OGTT 
(3 and 6 time-points 
post glucose load, respectively)
* Using medication other than metformin (e.g. insulin), 
or other contra-indications
Patients from outpatient clinic. 
Families  were obtained through them
…………………………………………………………………………………………………………………………………………….
OGTT of a priori non-diabetic individuals
Scheme 1 | Inclusion flow chart of individuals from South Asian and Caucasian families.
Physical examination
Body height and weight were measured to the nearest 0.1 cm and 0.1 kg  for the 
determination of body mass index (BMI). Waist circumference was measured in cm 
halfway between the lowest rib and the iliac crest, the maximum circumference of the 
hips was measured in the standing position in cm, and, from these measurements, the 
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waist-to-hip ratio (W/H) was calculated. Systolic and diastolic blood pressures  were 
measured with an electronic blood pressure monitor (Datascope Accutorr Plus Inc., 
Montvale, NJ) after 5 min rest in the sitting position. 
Oral glucose tolerance test (OGTT) 
Glucose, 75 g dissolved in 200 ml H2O, was administered orally after a 10 h overnight 
fast. Venous blood was drawn via an intravenous canula, 60 min and 15 min before the 
glucose load and 15, 30, 45, 60, 90, 120, 150, 180 and 210 min after glucose loading. 
WHO criteria based on OGTT were used to define family members with normal glucose 
tolerance (NGT), impaired fasting glucose/impaired glucose tolerance (IFG/IGT) and 
T2D [18].
Assays
Plasma glucose was measured by a hexokinase-based method (Gluco-quant; Roche 
Diagnostics, Mannheim, Germany). Plasma insulin and C-peptide were measured 
separately by a competitive chemiluminescent immunoassay, supplied by Euro/DPC 
(Diagnostic Product Corporation, Los Angeles, CA). The assay was performed on a DPC 
Immulite 2000 analyzer (Euro/DPC) according to the manufacturer’s recommended 
protocol. 
Calculation of indices
Beta-cell function indices
For the assessment of early, late and overall beta-cell function, we calculated 
incremental ISR area-under-the-curves (AUCs); ISR t0-30 and ISR t60-210 and ISR t0-210 
respectively based on plasma C-peptide concentrations with ISEC software [19]. The ISR 
reflects the prehepatic secretion rate, as C-peptide has negligible hepatic clearance. 
Hereafter, we investigated early, late and overall beta-cell function in relation to glucose 
concentrations and insulin sensitivity to obtain early, late, and overall disposition 
indices (DI), respectively. 
Insulin sensitivity 
The insulin sensitivity index (ISI) was determined according to [20, 21]
ISI = 10.000 / (G
0
 × I
0
 × meanG
0-30-60-90-120
 × meanI
0-30-60-90-120
)½
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Early, late and overall Disposition Indices
Early, late and overall DI were calculated as follows:  ISR t0-30/ glucose disposal t0-30 
×ISI, ISR t60-210/ glucose disposal t60-210 × ISI, and ISR t0-210/ glucose disposal t0-210 
× ISI, respectively.[22] In addition, we calculated the ratio of late phase DI to early phase 
DI, based on earlier observations marking their relationship [23].
To improve comparison with previous studies, we also added a large number of 
classical indices to online supplemental Table 1 and supplemental Figure 1. All formulae 
are described below the online supplemental Table 1. All OGTT indices were derived 
from insulin and C-peptide concentrations in pmol/L and glucose concentrations in 
mmol/L, with the exception that insulin concentrations were converted to μU/mL for 
the calculation of HOMA and ISI  and, subsequently, DIs were both calculated with 
glucose in mg/dL. All AUCs were calculated according to the trapezoid method, and 
incremental AUCs were calculated by subtracting basal values from total calculated 
AUC values between given time points [24].
Statistical analyses
We performed family-based analyses with the SOLAR software package [25]. 
Comparison between ethnicities was performed with variance component analyses 
adjusted for a number of covariates within SOLAR. For the prediction of NGT, IFG/IGT 
or T2D stage (WHO OGTT subgroup) in both ethnicities we used ordinal regression 
analyses with SPSS version 15.0 for Windows (SPSS Inc., Chicago, IL, USA), adjusted 
for family ties, using a variable grouping each family with their own distinct number 
in SPSS. Data are expressed as mean ± SD, unless otherwise indicated. ANOVA were 
used for differences within given WHO OGTT subgroups and performed with SPSS; for 
each WHO OGTT subgroup, three comparisons were performed with ANOVA (unless 
otherwise stated); with the other two WHO OGTT subgroups of same ethnicity and with 
the corresponding other ethnic WHO OGTT subgroup. Inverse or log transformations 
were used when normality or equal variance assumptions were not met. P value < 0.05 
was considered significant, unless otherwise stated.
RESULTS
In 36 South Asian families, 15 out of 37 (41%) apparently healthy first-degree relatives 
were classified as IFG (n=4), IGT (n=5), the combination of IFG and IGT (n=3) or newly 
diagnosed T2D (n=3). In 24 Caucasian families, 13 (28%) out of 47 apparently healthy 
first-degree relatives were classified as IFG (n=3), IGT (n=5), the combination of IFG and 
IGT (n=4), while one was newly identified as T2D. For both ethnic groups, individuals 
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with IFG and/or IGT were combined into one group of intermediate phenotypes and 
newly identified individuals with T2D were included with the original T2D cases in the 
diabetes group. The general characteristics of the three groups according to ethnicity 
are shown in Table 1. Waist circumference and W/H  were lower in the groups with NGT 
compared with the other groups in both ethnicities. However, the relation of increasing 
W/H with glucose intolerance appeared to be less clear in South Asians when 
compared to Caucasians Notably, the South Asians with T2D were on average 10 years 
younger than the Caucasians with T2D and they already had a substantial prevalence 
of macrovascular disorders. Results from the OGTT demonstrated the following results; 
in both ethnicities with increasing glucose intolerance, glucose disposal increased, 
while both ISR t0-30 min and ISI decreased. Both ISR t0-210 min and ISR t60-210min 
increased from NGT toward IFG/IGT, but decreased from IFG/IGT towards T2D. In 
general, ISR derived parameters in South Asians were markedly higher compared with 
the Caucasians, while ISI was lower with an overall between-ethnicity difference of 
3.8±2.9 vs 6.5±4.7, respectively (P < 0.001).
Disposition indices, first/second phase beta-cell function
The unadjusted relationships between glucose disposal t0-210 min, ISR t0-30 min and 
ISR t60-210 min, are shown in ternary plots (Supplementary Fig. 1a, c). We determined 
the relationship between ISR t0-30 and ISR t60-210 with glucose disposal t0-210 using 
variance component analyses; after adjustment for ISI, age, W/H and gender the effect 
of early beta-cell function on glucose disposal t0-210 remained present in the South 
Asians but disappeared in the Caucasian families, explaining the variance of glucose 
disposal t0-210 in our final model by 22.7 and 8.9% in South Asian and Caucasian 
families, respectively (Table 2, Model 1). We also explored the effect of ISR t0-30 and 
ISI on ISR t60-210. The unadjusted relationships between ISI, ISR t0-30 and ISR t60-210 
are shown in the ternary plots of Supplementary Figure 1b, d. After adjustment for age, 
W/H,WHO OGTT subgroup and gender, ISR t0-30 in South Asians had an effect on ISR 
t60-210, but such effects were not observed in Caucasian families, explaining 45.5 and 
17.4% of the variance of ISR t60-210 in our final model in South Asian and Caucasian 
families, respectively (Table 2, Model 2). We combined both ethnicities into an overall 
group and applied both Model 1 and 2, and tested for interaction between ethnicity 
and ISR t0-30 to glucose disposal t0-210 or ISR t60-210, respectively; only in Model 2 
this interaction was significant (β=0.341, [0.018;0.664]).
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Table 1 | Clinical characteristics of the NGT, IGT and/or IFG and T2D subgroups.
  NGT SA NGT Cau IFG/IGT SA IFG/IGT Cau T2D SA T2D Cau
n 22 34 12 12 23 18
Sex(male/female), n%(male) 10/12(45.5) 11/23(32.4) 8/4(66.7) 4/8(33.3) 11/12(47.8) 9/9(50.0)
Age (years) 39.6±11.6¶ 38.9±9.4‡ 46.3±8.8 44.5±11.4‡ 52.3±8.8‡§ 63.2±7.6*†¶
Weight (kg) 78.7±13.8 81.1±15.7 78.7±14.5 94.1±30.4 74.4±12.4 90.5±15.0¶
Length (cm) 1.69±0.1 1.75±0.1 1.67±0.1 1.75±0.1 1.61±0.1‡ 1.76±0.1¶
BMI (kg/m2) 27.6±4.1 26.3±4.1 27.9±2.9 30.4±8.5 28.6±4.1 29.3±4.9
Waist (cm) 94±10 91±15‡ 98±13 105±20 97±11 105±14*
Hip (cm) 105±5 108±8 103±6 116±20 104±9 112±10
W/H 0.90±0.07 0.84±0.09‡ 0.95±0.10 0.90±0.07 0.93±0.08 0.94±0.08*
RR systolic (mmHg) 122.6±14.1 123.2±12.5 125.9±15.0 129.6±20.2 132.4±15.1 135.6±13.0
RR diastolic (mmHg) 77.0±9.7 76.3±9.1 85.0±10.8 79.4±10.3 80.4±8.4 83.4±12.2
Smoking, n% D 2(11.8) 13(40.6) (5)55.6 (5)50.0 8(50.0) 5(50.0)
Antihypertensives, n% 2(9.1) 0‡ 2(16.7) 3(25.0) 9(39.1) 9(50.0)*
Lipid treatment, n% 3(13.6) 1(2.9)‡ 3(25.0) 0‡ 11(47.8) 11(61.1)*†
Macrovascular history,n% 4.5 3.0 16.7 0 8.7 12.5*
Microvascular history,n% 13.0B 25.0B
Metformin usage 20(87%) 17(94.4%)
Age of diagnosis 44.3±7.3A,B 56.1±7.2A,B
Period of having T2D 9.9±7.3A,C 8.5±8.4A,C
Fasting glucose(mmol/L) 5.3±0.4¶ 5.2±0.3†‡ 6.0±0.5¶ 6.0±0.6*‡ 7.2±1.1§|| 8.0±1.1*†
120min glucose (mmol/L) 5.4±1.1¶ 5.5±1.1‡ 7.8±1.1¶ 7.7±2.3*‡ 12.5±4.4§|| 14.1±3.6*†
ISI 5.0±3.9 8.2±5.1‡ 3.2±1.8 5.0±3.2 2.9±1.6 4.2±3.3*
ISR t0-210 1647±852 1153±385 1873±862 1369±561 1645±513‡ 1060±478
ISR t0-30 297±122*¶ 208±82‡ 254±158¶ 166±69 116±64§|| 124±75
ISR t60-210 921±632 595±296 1217±699 900±524 1225±430‡ 744±360
Glucose disposal t0-210 169±95¶ 211±126‡ 394±138¶ 446±176‡ 830±438§|| 1035±445*†
Glucose disposal 0-30 33±17 35±14‡ 40±14 44±27‡ 51±22§ 70±23*†
Glucose disposal 60-210 73±60¶ 99±81‡ 239±107¶ 281±162‡ 611±383§|| 764±405*†
Data are means± SD, n or n(%). P values are from ANOVA, P values between subgroups in post hoc Bonferroni analysis 
denoting statistical significance (P < 0.0125) are shown with symbols; *=versus Cau NGT, † =versus Cau IFG/IGT, ‡ = versus 
Cau T2D, § = versus SA NGT, || = versus SA IFG/IGT, ¶ = versus SA T2D. Anewly identified individuals with T2D excluded , B 
significance, Cnon-significance with Student’s t test or  χ² test P <0.05, Dincomplete data, however with a >75% response 
rate
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Table 2 | SOLAR multiple regression analysis within family matrices. 
beta se wald test 95% CI P value
Model 1
SA ISR t0-30 0.553 0.187 8.745 [0.186; 0.920] 0.003
ISRt60-210 -0.211 0.197 1.147 [-0.597; 0.175] 0.284
ISI -0.101 0.217 0.217 [-0.526; 0.324] 0.642
Age -0.677 4.641 0.021 [-9,773; 8.419] 0.884
W/H -0.00001 0.0002 0.003 [-0.0005; 0.0004] 0.956
Gender 6.649 111.197 0.0036 [-211,297; 224,595] 0.952
R2 (%) 22.7
Cau ISRt0-30 0.092 0.178 0.267 [-0.257; 0.441] 0.605
ISRt60-210 -0.057 0.188 0.092 [-0.425; 0.311] 0.762
ISI -0.040 0.056 0.510 [-0.150; 0.070] 0.475
Age 2.909 4.182 0.484 [-5.288; 11.106] 0.487
W/H 0.0003 0.0003 1.778 [-0.0002; 0.0008] 0.182
Gender -46.69 120.990 0.149 [-283.830; 190.450] 0.700
R2 (%) 8.9
Model 2
SA ISRt0-30 0.707 0.212 11.122 [0.291; 1.123] <0.001
ISI -0.245 0.190 1.663 [-0.617; 0.127] 0.197
age -2.338 4.595 0.259 [-11.344; 6.668] 0.611
W/H -0.0002 0.0002 1.000 [-0.0006; 0.0002] 0.317
WHO OGTT 0.402 1.872 0.046 [-3.267; 4.071] 0.830
Gender -4.134 117.477 0.001 [-234.389; 226.121] 0.972
R2 (%) 45.5
Cau ISRt0-30 0.270 0.156 2.996 [-0.035; 0.576] 0.083
ISI -0.055 0.045 1.494 [-0.143; 0.033] 0.222
age -2.080 3.701 0.316 [-9.334; 5.173] 0.574
W/H 0.0003 0.0003 1.000 [-0.0003; 0.001] 0.317
WHO OGTT -0.020 0.030 0.444 [-0.079; 0.039] 0.505
Gender -125.358 93.631 1.793 [-308.975; 58.159] 0.181
R2 (%) 17.4
Model 3
SA DIratio 0.316 0.115 7.551 [0.091; 0.541] 0.006
age 1.989 5.480 0.132 [-8.752; 12.730] 0.717
W/H -0.001 0.001 2.778 [-0.002; 0.0001] 0.096
WHO OGTT 2.456 2.240 1.202 [-1.934; 6.846] 0.273
Gender 12.557 115.011 0.012 [-212.865; 237.979] 0.913
R2 (%) 19.2
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beta se wald test 95% CI P value
Cau DIratio 0.090 0.040 5.063 [0.012; 0.168] 0.024
age 0.866 3.643 0.057 [-6.274; 8.006] 0.812
W/H 0.0002 0.0003 0.444 [-0.0004; 0.001] 0.505
WHO OGTT -0.030 0.030 1.000 [-0.089; 0.029] 0.317
Gender -192.943 95.45 4.086 [-380.025; -5.861] 0.043
R2 (%) 27.1
Model 1) Trait glucose disposal t0-210, covariates ISR t0-30, ISR t60-210, ISI, age, W/H, gender Model 2) Trait ISR t60-210, 
covariates ISR t0-30, ISI, age, W/H, WHO OGTT subgroup, gender. Model 3) Trait glucose disposal t0-210, covariates DI ratio, 
age, W/H, WHO OGTT subgroup, gender. Bold values indicate the significance of P values
The overall DIs after logarithmic transformation of the three WHO OGTT subgroups 
according to ethnicity are shown in Fig. 1a. In both ethnicities, the overall DI decreased 
from the NGT to the IFG/IGT and further to the T2D groups. Illustrated in Fig. 1b, the 
early and late DIs of the South Asian WHO OGTT subgroups were higher than those 
of the equivalent Caucasian WHO OGTT subgroups, although a more rapid decline 
could be observed between South Asian NGT toward the IFG/IGT subgroup. In both 
ethnicities, early as well as late DI of  both NGT and IFG/IGT subgroups differed 
significantly from their T2D subgroup. We examined the ratio of early and late phase 
DI in the WHO OGTT subgroups (Fig. 1b). In both the South Asian and the Caucasian 
families, the IFG/IGT group had lower ratios compared with the NGT group. This ratio 
was substantially higher in the South Asians with T2D compared with their relatives 
with IFG/IGT, whereas in the Caucasian families, a very low late phase DI resulted in the 
lowest ratio.
Adjusted for age, W/H, WHO OGTT subgroup and gender, DI ratio had an effect on 
glucose disposal t0-210 in both ethnicities, with the explained variances of glucose 
disposal t0-210 in our final model of 19.2 and 27.1% in South Asian and Caucasian 
families, respectively (Table 2, Model 3). However, gender also played a role in Caucasian 
families, but not in South Asian families.
Finally, to explore the differences in glucose handling in the WHO OGTT 
subgroups within the ethnicities, ternaries based on early DI are shown in Fig. 2a-
b. (for total overview, three ternaries based on overall, early and late DI are shown in 
Supplementary Fig. 2a-f ). We used ordinal regression analyses to examine the nature 
of the components forming early and late DI. The ordinal analyses based on early DI 
parameters to predict WHO OGTT subgroups, adjusted for family ties, are given in Table 
3. In contrast to Caucasians, there was an exclusive role for early beta-cell function, 
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and not ISI, in predicting glucose tolerance in the South Asian families. Even when 
including early glucose disposal (glucose disposal t0-30) as an additional covariate 
in the analysis, ISR t0-30 remained the single significant predictor. In the Caucasian 
families, both ISR t0-30 and ISI contributed significantly. For both ethnicities, similar 
ordinal analyses based on late DI parameters did not show significant effects with 
the exception of late glucose disposal t60-210 (data not shown). Figure 2a-b suggest 
that the groups with T2D occupy a more distinct area toward the left corner of the 
ternaries, whereas the other two groups overlap more in the center. Therefore, we also 
performed logistic regression, adjusted for family ties, with the T2D groups versus the 
other relatives, the results can be found in Table 3; again, ISR t0-30 remained the most 
important discriminating variable in South Asians, even when glucose disposal t0-30 
was included. For both ethnicities, similar binary logistic regression analyses based on 
late DI parameters demonstrated glucose disposal t60-210 as the most discriminating 
variable (data not shown).
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Figure 1a | Overall DI (DI t0-210) for all WHO OGTT subgroups (mean ±SEM) of both South Asian (closed) 
and Caucasian (open) families (triangle represents NGT, square IFG/IGT and circle T2D for both ethnicities). P 
values between subgroups in post hoc Bonferroni analysis denoting statistical significance (P < 0.0125) are 
shown with symbols; *=versus Cau NGT, † =versus Cau IFG/IGT, ‡ = versus Cau T2D, § = versus SA NGT, || = 
versus SA IFG/IGT, ¶ = versus SA T2D
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Figure 1b | early DI (DI t0-30) and late DI (t60-210) on left Y-axis in mean±SEM , and ratio of late phase/early 
phase DI (right Y-axis, mean±SEM ) for NGT, IFG/IGT and T2D of both South Asian (closed) and Caucasian 
(open) families (triangle represents NGT, square IFG/IGT and circle T2D for both ethnicities). South Asians: In 
early DI there was a significant difference between NGT versus T2D and IFG/IGT versus T2D (P < 0.0001). In 
late DI, there was a significant difference between NGT versus IFG/IGT, NGT versus T2D and IFG/IGT versus 
T2D (P < 0.0001). In DI ratio, no significant differences were found (P = 0.14). Caucasians: In both early 
and late DI, there was a significant difference between NGT versus T2D and IFG/IGT versus T2D (both P < 
0.0001, respectively). In DI ratio, there was a significant difference between NGT vs T2D (P = 0.016).
Figure 2 | Ternary plot of relationship between insulin sensitivity (ISI), early phase beta-cell function 
(ISR t0-30) and glucose disposal (glucose AUC t0-30) based on OGTT from South Asian (figures left) and 
Caucasian families (triangle represents NGT, square IFG/IGT and circle T2D for both ethnicities).
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Table 3 | Ordinal and binary logistic regression analysis in both ethnicities predicting WHO OGTT 
subgroups, adjusted for family ties 
Independent B SE Wald  95% CI P value
Ordinal regression analysis with NGT, IFG/IGT and T2D as dependent variables
SA ISR t0-30 -0.020 0.009 5.246 [-0.037;-0.002] 0.022
ISI -0.782 0.582 1.806 [-1.922;0.359] 0.179
Cau ISR t0-30 -0.066 0.020 11.128 [-0.105;-0.027] 0.001
ISI -0.603 0.256 5.556 [-1.105;-0.101] 0.018
Binary logistic regression analysis with T2D/non T2D as dependent variable
SA ISR t0-30 -0.029 0.009 11.350 [-0.047;-0.011] 0.001
ISI -0.338 0.275 1.516 [-0.877;0.201] 0.218
Cau ISR t0-30 -0.017 0.006 7.859 [-0.029;-0.005] 0.005
ISI -0.319 0.124 6.630 [-0.562;-0.076] 0.01
Bold values indicate the significance of P values
DISCUSSION
Across WHO OGTT subgroups from South Asian families, including the NGT group, 
we observed more insulin resistance, with more rapid decline of both early and late 
DI in NGT toward IFG/IGT, suggestive of early onset beta-cell failure. Across the WHO 
OGTT subgroups in Caucasian families, we observed a clear trend from normal insulin 
sensitivity to insulin resistance, while the DI decreased. Among the South Asians, the 
early insulin response explained at least partly the late insulin response as well as the 
overall glucose disposal. The ratio of the late over early DI decreased in both ethnicities 
from NTG to IFG/IGT, but waxed in the South Asian T2D and waned in the Caucasian 
T2D group, resulting in significant, but opposing effects in both ethnicities on the 
overall glucose disposal. The South Asians developed overt T2D at young age, while 
they still had a relatively high DI ratios. As a result of the lack of variance between the 
South Asian WHO OGTT subgroups in insulin sensitivity, only the early ISR predicted 
glucose tolerance state. Taken together, our findings confirm that changes in beta-
cell dynamics play a prominent role in the development of T2D in South Asians. In 
Caucasians, more gradual processes of increasing resistance to insulin and decreasing 
overall insulin secretion seem to take place. 
Our data confirm that - without adjustment for insulin sensitivity - South Asian 
individuals wrongly seem to have enough beta-cell capacity (Supplementary  Table 1) 
with an above-average ability to secrete insulin[15]. Unfortunately, this compensatory 
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beta-cell function is insufficient, leading to very early onset of T2D, as shown by 
the young age of manifest T2D in South Asians. These observations underline the 
important role of changes in beta-cell function, which have been reported to be the 
main contributor to abnormal glucose tolerance among a wide range of ethnicities, 
and are in line with increasing genetic evidence for beta-cell defects as an important 
predisposing factor for T2D [16, 17]. Hypersecretion of insulin may reflect beta-cell 
responses to different signals or a combination of an increased potentiating effect 
of glucose on beta-cells, long-lasting adaptation to severe insulin resistance and/or 
problems with the processing of insulin.
Clamp studies have demonstrated decreased insulin sensitivity among healthy South 
Asians when compared to other healthy controls [26-29]. We also found a decreased 
insulin sensitivity in the South Asians compared with the Caucasians. In contrast to the 
Caucasians, the degree of insulin sensitivity did not change between the three South 
Asian WHO OGTT subgroups. This very strong familial aggregation of insulin resistance 
suggests a strong contribution of environmental factors. However, we cannot infer 
from our data whether lifestyle, type of food, microbiome or other factors are involved. 
Among our families with high-risk of T2D, the South Asians had much earlier onset of 
signs and symptoms of T2D compared with the Caucasians. Notably, the burden from 
macrovascular disease was larger in our South Asian families, even in relatives who 
did not have T2D. This suggests that the severe insulin resistance of the South Asians 
contributes strongly to atherogenesis.
In addition to a demanding insulin resistant environment, failing beta-cell capacity is a 
major susceptibility factor to T2D in South Asian families, as was supported by recent 
genome wide association studies (GWAS). These studies show greater effects of SNP 
variants in beta-cell related genes in South Asians than in other populations [30]. 
The strength of the present study is that it was a family-based approach and analysis 
of two ethnic groups, among various stages of glucose tolerance. Moreover, beta-cell 
and insulin sensitivity indices were based on multiple sampled prolonged OGTT’s. The 
relatively small numbers within the WHO OGTT subgroups of the families are a potential 
weakness, but a characteristic of both extensive phenotyping and family analyses is 
that it can be performed in relatively small populations. In line, we were able to observe 
beta-cell function alterations in a very consistent way.
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CONCLUSION
Based on extended OGTT measurements, we found that insulin sensitivity is already 
lower in South Asian than in Caucasian people with NGT. Insulin resistance in the South 
Asians does not change much during progression of glucose intolerance and beta-cell 
dysfunction might play a dominant role in the early development of T2D among South 
Asian families in the Netherlands.
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 1 
Indices of Beta-cell function 
We calculated the fasting insulin/glucose ratio ( ), fasting C-peptide/glucose ratio 
( ) and homeostatic model assessment for beta-cell function (HOMA-B) 
using [1]. 
Early insulin response indices in OGTT were the insulin/glucose ratio at t=30min 
( ), C-peptide/glucose ratio at t=30min ( );[2, 3]the insulinogenic 
indices (IGI) for the increase in insulin and C-peptide as response to the increment in 
glucose within first 30 min after the glucose-load: , , 
 and [4] the corrected insulin response (CIR) was calculated 
as [5] and the incremental area under curve (AUC) of insulin 
and C-peptide concentrations in response to the increment in glucose during the 
OGTT as:  and [6]. 
Late insulin response indices in OGTT were calculated as: 
, , and overall 
insulin response indices as  and 
[6]. 
Estimates of beta-cell function according to Stumvoll et al. for first phase and second 
phase insulin release among NGT and IGT individuals were calculated with the 
following formulas: 
,  
[7].  
Metabolic clearance rate 
The metabolic clearance rate of insulin (MCri) was calculated from the ratio between 
the total AUC of the ISR and the AUC of total insulin measured in plasma: 
[8] 
0 0/I G
0 0/Cpep G
20× I0 / (G0 −3.5)
30 30/I G 30 30/Cpep G
0 30 0 30/I G- -D D 0 30 0 30/Cpep G- -D D
0 30 30/Cpep G-D 0 30 30/I G-D
100× I30 G30 G30 −3.89( )#$ %&
0 30 0 30/ins glucincrAUC incrAUC- - 0 30 0 30/Cpep glucincrAUC incrAUC- -
120 210 120 210/ins glucincrAUC incrAUC- - 120 210 120 210/Cpep glucincrAUC incrAUC- -
0 120 0 120/ins glucincrAUC incrAUC- -
0 120 0 120/Cpep glucincrAUC incrAUC- -
0 60 601 728 3.537 120.3 1.341 21.27st phase Ins Gluc Ins BMI= + ´ - ´ + ´ + ´
60 60 02 208 0.335 26.33 0.887 3.933d phase Ins Gluc Ins BMI= + ´ - ´ + ´ + ´
0 210 0 210/ISR insAUC AUC- -
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South Asian families
Caucasian families
Supplementary figure 1 | Ternary plot of ISR t0-30 and ISR t60-210 with glucose disposal (left) or ISI 
(right) in South Asian (top panel) and Caucasian(below) families(triangle NGT, square IFG/IGT and circle T2D 
subgroup, respectively).
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South Asian families Caucasian families
Supplementary figure 2 | Ternary plot of ISI, ISR t0-210 and glucose disposal t0-210 based on OGTT in 
South Asian and Caucasian families (left side and right side, respectively). Also, ternary plots of relationship 
between ISI, ISR t0-30 and glucose disposal t0-30 are depicted in the middle and  ternary plots of ISI, ISR 
t60-210 and glucose disposal t60-210 are depicted below ( triangle NGT, square IFG/IGT and circle T2D 
subgroup, respectively) 
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CHAPTER 3
The relationship of metabolic syndrome traits with 
beta-cell function and insulin sensitivity by oral 
minimal model assessment in South Asian and 
European families residing in the Netherlands
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ABSTRACT
Background. There are different metabolic syndrome traits among patients with 
different ethnicities.
Methods. We investigated this by studying 44 South Asians and 54 Europeans and 
classified them in three groups according to the occurrence of metabolic syndrome 
(MetS) and Type 2 Diabetes (T2D). Insulin sensitivity index (ISI), static, dynamic and total 
beta-cell responsivity indices (Φ), and disposition indices (DIs) were calculated with the 
use of oral minimal model (OMM).
Results. In both ethnicities, ISI was lower in the subgroup with MetS and T2D as 
compared to the subgroup without MetS nor T2D (P < 0.004). South Asians without 
MetS were more insulin resistant than Europeans without MetS (P = 0.033). In the South 
Asians, ISI, dynamic DI, and static DI were associated significantly (P < 0.006) with high-
density lipoprotein cholesterol and triglycerides. In the Europeans, ISI was associated 
with waist-to-hip ratio (P = 0.005) and systolic and diastolic blood pressure (P < 0.005), 
while static DI was related to the systolic blood pressure (P = 0.005).
Conclusions. MetS was linked with insulin resistance and reduced capacity to handle 
glucose regardless of ethnicity. ISI and DIs were associated with lipid traits in South 
Asians and with blood pressure in Europeans suggesting that insulin resistance 
enhances different metabolic syndrome traits among different ethnicities.
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INTRODUCTION
Overweight and physical inactivity enhance each other and decline the sensitivity to 
insulin. Resistance to insulin is characteristic of metabolic syndrome (MetS), which 
is defined as a cluster of the following cardiovascular risk factors: central obesity, 
impaired glucose tolerance, dyslipidemia and hypertension. MetS constitutes a major 
health problem, as it is strongly associated with type 2 diabetes mellitus (T2D) and 
cardiovascular disease [1-3]. Furthermore, insulin resistance is a consistent finding in 
T2D and appears to contribute to the development of T2D. However, T2D develops 
only if there is dysfunction of beta-cells [4]. In the absence of beta-cell dysfunction 
individuals can compensate indefinitely for resistance to insulin action with the 
appropriate hyperinsulinemia. Therefore, many people with remarkable resistance to 
insulin may never develop T2D [5, 6].
Lifestyle factors clearly underlie MetS incidence, but genetic susceptibility may be 
important as well [7]. For example, specific ethnic groups are more susceptible to 
MetS than others [8, 9]. In particular, South Asians are predisposed to develop MetS 
and subsequently T2D and cardiovascular disease at a younger age [10-12]. They also 
have a higher prevalence of abdominal obesity, are less sensitive to insulin, and have 
a lower glucose disposal rate than Europeans [12-14]. In addition, South Asians have 
lower plasma levels of HDL and adiponectin and higher levels of glucose, insulin, 
leptin, complement C3, plasminogen activator inhibitor-1, fibrinogen and tissue 
plasminogen activator compared to Europeans [15-20]. However, traditional risk factors 
such as smoking, hypertension, and dyslipidemia do not explain the increased risk for 
cardiovascular disease in South Asians [21, 22]. Insulin resistance itself has been held 
responsible for the high rates of T2D and cardiovascular disease in this ethnic group 
[10, 12].
Oral minimal modeling is a pharmacokinetic/pharmacodynamic algorithm developed 
to estimate beta-cell function and insulin sensitivity index (ISI) from dynamic data 
[23]. In the present study, we used this oral minimal model (OMM) to investigate the 
relationship between MetS traits and beta-cell function in South Asian and European 
families with prevalent T2D.
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MATERIALS AND METHODS
Subjects
The recruitment of patients with T2D and their relatives at our university outpatient 
clinic has been described in detail previously [24]. In brief, 48 South Asians and 54 
Europeans that are residing in the Netherlands were initially recruited for the present 
study and we used an oral glucose tolerance test (OGTT) to group the subjects in 
T2D or noT2D according to the WHO criteria. In addition, the International Diabetes 
Federation (IDF) criteria were used to define MetS [25]. Four South Asians had T2D but 
not MetS and were excluded from the study as the number of subjects was too small for 
meaningful analyses and there were no European counterparts for comparison. Hence, 
98 subjects were included in our analyses (44 South Asians and 54 Europeans) from 
25 families (25 patients with T2D but not on insulin therapy and 73 relatives) and they 
were distributed among 3 groups; no metabolic syndrome/no type 2 diabetes mellitus 
(noMetS/noT2D), metabolic syndrome/ no type 2 diabetes mellitus (MetS/noT2D) and 
metabolic syndrome/ type 2 diabetes mellitus (MetS/T2D).
Written informed consent was obtained from all participants. The Erasmus Medical 
Ethics Review Board approved the study protocol.
Physical Examination
Body height and weight were measured in light clothing without shoes and were used 
to estimate body mass index. Waist circumference was measured halfway between 
the lowest rib and the iliac crest while the maximum circumference of the hips was 
measured in the standing position; from these measurements the waist-to-hip ratio was 
calculated. Systolic and diastolic blood pressures were measured in the sitting position 
with an electronic blood pressure monitor (Datascope Accutorr Plus Inc., Montvale, NJ), 
after five minutes’ rest.
Samples and Measurements
All participants underwent a 210 min OGTT. A 75g glucose load was administered (t=0), 
after an overnight fast and 11 venous blood samples were acquired at pre-specified 
time intervals (-60min, -15min, 15min, 30min, 45min, 60min, 90min, 120min, 150min, 
180min and 210min) for the measurement of plasma glucose, insulin and C-peptide 
levels. Baseline blood samples were obtained in order to estimate glucose, insulin, 
C-peptide plasma concentrations and the lipid profile.
59
Relationship metabolic syndrome and OMM indices in T2D high-risk families
Plasma glucose was estimated using a hexokinase-based method (Gluco-quant; Roche 
Diagnostics, Mannheim, Germany). Plasma insulin and C-peptide were measured 
separately by a competitive chemiluminescent immunoassay, supplied by Euro/DPC. 
The assay was performed on a DPC Immulite 2000 analyzer (Euro/DPC) according to 
the manufacturer’s recommended protocol. Serum total cholesterol, HDL, LDL and 
triglycerides were determined with an automatic enzymatic procedure by Roche 
Diagnostics (Mannheim, Germany).
Oral Minimal Model Calculations
The OMM, which consists of the glucose OMM and the C-peptide OMM, was used to 
describe changes of plasma glucose, insulin and C-peptide concentrations during 
an oral glucose stimulus [26-28]. Glucose, C-peptide and insulin concentrations were 
measured at 11 time points before and after intake of 75g glucose. The glucose OMM 
estimated ISI with plasma glucose and insulin concentrations measured during the 
OGTT. In addition the C-peptide OMM indices were calculated during the oral glucose 
tolerance test and in terms of insulin secretion can be interpreted as follows: (1) the 
basal (Φ
basal
), that gives a basal nonstimulated measurement of insulin secretion (2) the 
dynamic (Φ
dynamic
), that provides the amount of insulin secreted during the dynamic 
phase (first phase secretion by beta-cells) (3) the static (Φ
static
), that assesses the  release 
of insulin that occurs after a time delay (second phase secretion by beta-cells) and 
represents a beta-cell response according to the prevailing glucose concentration 
and (4) the total (Φ
total
) overall secretion which is the sum of the dynamic and static 
phase release of insulin from beta-cells. The parameters of glucose OMM and C-peptide 
OMM were multiplied to obtain the disposition indices (DIs), which is a measure for 
beta-cell function corrected for insulin sensitivity. It can be considered a measure of the 
functionality of the pancreas in the intact individual: DIbasal= Φbasal x ISI, DIdynamic= Φdynamic 
x ISI, DIstatic= Φstatic x ISI and DItotal= Φtotal x ISI. We performed the analyses with SAAMII 
software [29].
Statistical Analysis
Continuous variables are expressed as mean ± SEM, unless indicated otherwise. ANOVA 
test was used to compare the mean of raw data presented in Table 1 and the figures of 
different subgroups within the two ethnicities. Adjusted analyses were performed with 
multiple regression models in which all covariables were entered synchronously. 
A P<0.05 was considered statistically significant. All statistical tests were conducted 
with SPSS software, version 20 (SPSS Inc., Chicago, IL).
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RESULTS
Baseline Characteristics
32 out of 44 South Asians (72.7%, 95% CI 58.0 to 83.8%) and 23 out of 54 Europeans 
(42.6%, 95% CI 30.3 to 55.9%) had MetS according to the IDF criteria. In Table 1, the 
general characteristics of the 3 subgroups are shown according to ethnicity. The 
systolic blood pressure, fasting and 2 h plasma glucose levels were increased in South 
Asians with MetS and T2D compared to the noMetS/noT2D group. South Asians with 
MetS and T2D were on average 10.4 years younger than Europeans with MetS and 
T2D. Compared to the analyses of the South Asian subgroups, we observed a larger 
heterogeneity among the 3 subgroups of the Europeans in clinical and biochemical 
characteristics with significant differences in age, weight, body mass index, waist, 
waist-to-hip ratio, blood pressure and fasting and 2 h plasma glucose levels. 
Insulin Sensitivity
The ISIs of the three subgroups according to ethnicity are shown in Figure 1. Subjects 
without MetS had higher ISI than those with MetS. On average and adjusted for sex 
and age, the Europeans had 7.18 x 10-4 dL/kg/min per μU/mL (95% CI 0.58 to 13.78, P 
= 0.033) higher ISI than the South Asians. This was fully explained by the differences 
between the two subgroups without MetS (after excluding this subgroup to the 
analysis the effect of ethnicity disappeared, P = 0.367). 
Beta-cell Responsivity Indices
The fitting of both C-peptide and glucose OMM was satisfactory as the average 
weighted residuals did not deviate systematically from the zero value (Supplementary 
Figures 1 and 2). Figure 2 shows the beta-cell responsivity indices estimated by the 
C-peptide OMM during the OGTT. Adjusted for sex and age, ethnicity was significantly 
related to the basal responsivity index: β = 0.086 x 10-9/min, 95% CI 0.17 to 0.155, P = 
0.016; but not to the other responsivity indices, P > 0.7. Within the South Asian group 
adjusted for sex and age, the MetS/noT2D group had 0.164 x 10-9/min (95% CI 0.045 
to 0.282, P = 0.008) higher basal responsivity index compared to the other subgroups. 
The basal responsivity index was not significantly different between the European 
subgroups. The dynamic, the static and the total responsivity indices showed all the 
same trend of a lower beta-cell response (in effect less insulin secretion) in the MetS/
T2D groups in both ethnicities: -191.9 x 10-9 (95% CI -282.2 to -101.6, P=0.001), -12.1 
x 10-9/min (95% CI -16.1 to -8.0, P=0.001) and -14.3 x 10-9/min (95% CI -18.9 to -9.6, 
P=0.001), respectively. The South Asian noMetS/noT2D and MetS/noT2D had similar 
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values in the dynamic, the static and the total responsivity indices, whereas in the 
Europeans there was a clear trend to gradually lower values over these groups in the 
direction of the MetS/T2D subgroup: P
for trend = 0.005, 0.001 and 0.001, respectively.
Disposition Indices
The DIs according to subgroup and ethnicity are shown in Figure 3. Adjusted for sex 
and age the four DIs did not differ significantly between the ethnicities (P > 0.11). 
Both ethnicities showed the same gradual course of the different DI from high to 
intermediate and low over the noMetS/noT2D, MetS/noT2D and MetS/T2D subgroups, 
respectively (P
for trend
 < 0.002). There were no clear differences between the ethnicities, 
although the European noMetS/noT2D subgroup had relatively high DI compared to 
the same South Asian subgroup. 
MetS Traits and OMM Indices
The relationships between the MetS traits and OMM indices adjusted for sex and age 
according to ethnicity are shown in Table 2. The MetS traits were not used in a large 
“holistic” multiple linear regression model since they are correlated. Therefore, each trait 
was analyzed separately in a multiple linear regression model adjusted for sex and age. 
Waist-to-hip-ratio was strongly associated with ISI in both ethnicities, but it may have 
a more detrimental effect of the glucose disposition in Europeans than in the South 
Asians. The dyslipidemia characterized by high triglycerides and low HDL was related 
to ISI and the DIs solely in the South Asians, whereas blood pressure, both systolic and 
diastolic, was solely related to ISI and the DIs in the Europeans. As expected, fasting 
glucose was associated with ISI and DIs as these indices are calculated with glucose 
values.
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Figure 1 | Insulin sensitivity index (ISI) assessed by the OMM in South Asian (SA) and European (EUR) 
subgroups. * indicates a statistically significant difference between noMetS/noT2D and other subgroups.
Figure 2 | beta-cell insulin responsivity indices in South Asian (SA) and European (EUR) subgroups.* 
indicates a statistically significant difference in comparison with the noMetS/noT2D subgroup; ** indicates 
a statistically significant difference between the MetS/noT2D and MetS/T2D subgroup.
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Figure 3 | Disposition indices in South Asian (SA) and European (EUR) subgroups.
* indicates a statistically significant difference in comparison with the noMetS/noT2D subgroup.
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DISCUSSION
In the present study, we found a clear trend for increasing insulin resistance from 
noMetS/noT2D to MetS/noT2D and to MetS/T2D. We also found that South Asians 
without MetS were more resistant to insulin than a corresponding group of Europeans. 
In the European families, the dynamic, static and total beta-cell responsivity indices 
followed the trend of ISI in the same direction over the three subgroups towards 
decreasing insulin secretion by the beta-cells in the T2D group. The South Asian 
noMetS/noT2D and MetS/noT2D subgroups both had high beta-cell responsivity 
indices and the MetS/T2D subgroup had low values. The DIs are the product of ISI and 
beta-cell responsivity indices and independent of ethnicity followed a decreasing trend 
over the subgroups in the direction of T2D. Notably, a number of separate MetS traits 
had different associations in the two ethnicities: dyslipidemia had a strong relationship 
with ISI and DI in the South Asians, whereas blood pressure was associated with ISI and 
DI in the Europeans.
Over the last years several studies have examined the effect of lifestyle, dietary habits, 
and genetic polymorphisms on the development of MetS in different ethnicities, 
in order to identify high-risk populations such as the South Asians, who appear to 
have an increased predisposition for T2D [30-32]. Most of these reports focused on 
epidemiological analyses and evaluations of the impact of biochemical and physical 
characteristics (e.g. total abdominal fat, intra-abdominal adipose tissue) on the 
development of MetS. In a number of studies, ISI and beta-cell function were assessed 
in different ethnicities using fasting blood glucose and plasma insulin concentrations 
(for instance homeostatic model assessment - HOMA) [33-35]. These methods do not 
assess the dynamic response of beta-cells to glucose stimuli [36, 37]. Our study is the 
first to employ OMM in order to examine the relationships between MetS traits and 
ISI and beta-cell response. The estimations of ISI and insulin secretion by OMM are 
reasonably well correlated with those assessed by the hyperinsulinemic euglycemic 
clamp method [38]. 
We demonstrated for the first time, to our knowledge, that in South Asians and 
Europeans both ISI and beta-cell function are lower in subjects with MetS and in 
subjects with MetS and T2D compared to noMetS/noT2D subjects. In addition, we 
confirmed an increased insulin resistance in noMetS/noT2D South Asians compared 
to noMetS/noT2D Europeans [39, 40]. Moreover in South Asians with noMetS/noT2D 
the disposition indices were lower comparing to the disposition indices in Europeans 
and not statistically different from the disposition indices in South Asians with MetS/
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noT2D. These findings indicate that South Asians are a vulnerable population and have 
an increased risk to develop chronic diseases such as MetS and T2D, in which insulin 
resistance and beta-cell function are key pathogenetic factors.
Our study showed that OMM could be used to evaluate glucose homeostasis in different 
populations and to examine associations between insulin resistance, abnormal beta-
cell function and MetS traits. Waist-to-hip ratio reflects the association between visceral 
obesity and the causal path from insulin resistance to T2D [41-43]. Hypertriglyceridemia 
and increased enzymes involved in triglyceride transport and metabolism may have 
a toxic effect on beta-cells [44], but hypertriglyceridemia can be a consequence of 
insulin resistance and T2D as well. Remarkably, triglycerides and HDL were associated 
with ISI and DIs in South Asians. Unfortunately, we cannot infer from our data whether 
dyslipidemia was the cause or the consequence of insulin resistance and reduced 
DIs. In the European families, insulin resistance and reduced DI were associated with 
raised blood pressure. This suggests that disorders of carbohydrate metabolism 
were complicated by higher levels of blood pressure. A possible explanation is 
an impaired insulin signaling through PI3K signaling pathway and the increased 
vascular inflammation noted in insulin resistance which can decrease nitric oxide (NO) 
production and increase Endothelin-1 (ET-1) secretion leading to raised blood pressure 
[45,46]. The differences in the associations between metabolic syndrome traits, beta 
cell function and insulin sensitivity in different ethnicities have not been fully explained 
yet. A possible etiology is the different genetic profile of Europeans and South Asians; 
however further research is required towards this direction in order to understand the 
metabolic pathways and the effect of the genome on these associations. 
In the present analysis, we investigated associations between metabolic syndrome traits 
and insulin sensitivity and beta cell function after adjusting for age and sex. Of note the 
results did not change significantly when we adjusted also for BMI. The only differences 
that we noticed were in Europeans where there was no longer an association between 
ISI, waist-to-hip ratio and diastolic blood pressure as well as a correlation between 
fasting glucose and ISI and DIstatic (Supplementary Table 1).
Strengths and Limitations
We have recruited subjects through families with prevalent T2D. Family studies avoid a 
number of serious selection biases, but the findings cannot easily be generalized to the 
general population. Moreover, we prefer to analyze family data using a family matrix 
for instance SOLAR, but unfortunately there were too many small cells. Adjustment 
for family ties in regression analyses suffered from the same problem; therefore, 
we restricted the adjustment of all primary analyses to age, which correlates with 
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generation in kindreds. We did not analyze genetic variation, and transmission was not 
a topic of our research. Moreover, separate analyses of small and large families did not 
change the results (data not shown).
We chose the comparison between the MetS/T2D status groups and not between the 
two ethnic groups because South Asians and Europeans differ in many aspects and 
therefore we tried to avoid bias due to the ethnicity differences.  
We have used the IDF criteria for MetS, because they take ethnic specific cut-off points 
for central obesity, in effect waist circumference, into account. South Asians residing 
in the Western world differ in lifestyle and phenotype from the South Asians living 
in South Asia, and therefore we tested the necessity of such ethnicity specific cut-
off points: if the European cut-off points were used for all subjects, only three male 
South Asians would have not been classified as MetS. Still a number of arguments 
could be made to include analyses using a single cut-off point, but the effects on our 
results were negligible (data not shown) and therefore we decided to follow the IDF 
recommendations.
A limitation of the study was the relatively small sample size and for this reason these 
findings cannot be generalized to the broader community. Furthermore, we excluded 
the noMetS/T2D subgroup, because meaningful analysis was not possible, as there 
were only 4 South Asians and no Europeans counterparts.
CONCLUSIONS
In our study, we observed low ISIs in the MetS/T2D group relative to the noMetS/
noT2D group in both ethnicities; a finding that indicates an association between 
insulin resistance and a pathologic metabolic state (T2D). The pathogenic mechanisms 
that lead to insulin resistance appear to differ among ethnicities, as ISI and DIs 
were associated with different metabolic traits in each ethnicity. The simultaneous 
assessment of insulin sensitivity and beta-cell function allowed us to study metabolic 
profiles that promote T2D and glucose intolerance. We used this primarily to explore 
the underlying mechanisms of disturbances in glucose metabolism, but also to explore 
the potential of designing ethnicity-specific risk models for early identification of 
subjects that are at risk for developing diabetes mellitus. In this study, South Asians, 
in contrast to Europeans, appear to be predisposed to insulin resistance and exhibit 
impaired beta-cell function at an earlier age. Dyslipidemia related to insulin resistance 
and pancreatic dysfunction may underlie or enhance this susceptibility of South Asians. 
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SUPPLEMENTARY MATERIAL
Supplementary Figure 1 | Average weighted residuals for the C-peptide oral minimal model.
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Supplementary Figure 2 | Average weighted residuals for the glucose oral minimal model.
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CHAPTER 4
Discriminative ability of plasma branched-
chain amino acid levels for glucose intolerance 
in families at-risk for type 2 diabetes 
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ABSTRACT
Background– Insulin resistance and glucose intolerance have been associated with 
increased plasma levels of branched-chain amino acids (BCAA). BCAA levels do not 
predict T2DM in the population. 
We determined the discriminative ability of fasting BCAA levels for glucose intolerance 
in nondiabetic relatives of patients with T2DM of two different ethnicities. 
Methods– Based on oral glucose tolerance test (OGTT), first-degree relatives of patients 
with T2DM were categorized as normal glucose tolerance, prediabetes, or T2DM. 
Included were 34, 12, and 18 Caucasian and 22, 12, and 23 Asian Indian participants, 
respectively. BCAA levels were measured in fasting plasma together with alanine, 
phenylalanine and tyrosine. Insulin sensitivity and beta-cell function were assessed 
by indices derived from an extended OGTT and their relationship with plasma BCAA 
levels was assessed in multivariate regression analysis. The value of the amino acids for 
discriminating prediabetes among nondiabetic family members was determined with 
the area under the curve  of receiver-operated characteristics (c-index). 
Results–BCAA levels were higher in diabetic than in normoglycemic family members 
in the Caucasians (P = 0.001) but not in the Asian Indians. In both groups, BCAA 
levels were associated with waist-hip ratio (β = 0.31; P = 0.03 and β = 0.42; P = 0.001, 
respectively) but not with indices of insulin sensitivity or beta-cell function. The c-index 
of BCAA for discriminating prediabetes among non-diabetic participants was 0.83 and 
0.74 in Caucasians and Asian Indians, respectively, which increased to 0.84 and 0.79 by 
also including the other amino acids. The c-index of fasting glucose for discriminating 
prediabetes increased from 0.91 to 0.92 in Caucasians and 0.85 to 0.97 (P = 0.04) in 
Asian Indians by inclusion of BCAA + alanine, phenylalanine and tyrosine.
Conclusions. Adding fasting plasma BCAA levels, combined with phenylalanine, 
tyrosine and alanine to fasting glucose improved discriminative ability for the 
prediabetic state within Asian Indian families at risk for T2DM. BCAA levels may serve as 
biomarkers for early development of glucose intolerance in these families.
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INTRODUCTION
The incidence of obesity and type 2 diabetes (T2DM) is increasing worldwide, and the 
onset of the disease occurs at steadily earlier age. Biomarkers for early development 
of glucose intolerance and T2DM are highly needed to identify individuals at risk and 
initiate early preventive strategies. Raised plasma levels of branched-chain amino acids 
(BCAA) have long been linked to obesity, insulin resistance and T2DM [1-3]. In addition 
to BCAA, phenylalanine, tyrosine, and alanine are also associated with insulin resistance 
and glucose intolerance. In predominantly lean Chinese and Asian Indian men, this 
combined amino acid profile correlated with insulin resistance[4]. In healthy young 
adults, fasting plasma levels of BCAA, phenylalanine, and tyrosine were associated with 
an increase of the HOMA-insulin resistance index at 6 years follow-up [5]. Similarly, in 
obese children, elevated BCAA levels were positively associated with an increase in 
HOMA-insulin resistance index during the following 18 months [6]. In two independent 
prospective cohorts with normoglycemic adults followed for 12 years, elevated levels 
of these amino acids at baseline were associated with future development of T2DM 
[7]. Although fasting plasma amino acid levels have limited predictive value for future 
glucose intolerance and T2DM in the general population [5, 7], it may have a strong 
value for at-risk individuals [7]. Patients with the early onset of T2DM often descend 
from families with high risk of T2DM. This holds particularly for the Asian Indians 
living in the Netherlands, who develop T2DM at a young age and relatively low BMI, 
resulting in a fivefold increased risk of T2DM compared to Dutch Caucasians [8, 9]. We 
approached first-degree family members of these patients and identified individuals 
with normal and impaired glucose tolerance. We hypothesized that the fasting amino 
acid profile with raised BCAA, phenylalanine, tyrosine, and alanine levels is a potential 
biomarker for the development of early glucose intolerance or insulin resistance in 
family analyses. 
In the present study, we determined the value of fasting BCAA and other amino acid 
levels in discriminating glucose-intolerant from glucose-tolerant subjects in families 
with a high risk of T2DM.
MATERIALS AND METHODS 
Subjects
Index cases (individuals with T2DM) had been referred to the Outpatient clinic 
of Internal Medicine at the Erasmus University Medical Center in Rotterdam for 
complications associated with their T2DM. First-degree relatives were invited for the 
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study; this resulted in participation of individuals from 24 Caucasian families and 36 
Asian Indian families living in the Netherlands, with two generations taken into account 
and an average of approximately two members of each family. Power calculation was 
performed with Quanto version 1.0[10], and was based on differences in early phase 
insulin secretion response (described further on in Materials and Methods section) 
between healthy South Asian and Caucasian individuals , during a pilot phase of the 
study, with alpha 0.05 and power 80%. At least 17 individuals with normal glucose 
tolerance, based on oral glucose tolerance test (OGTT) were required. Caucasian 
subjects had to be born in the Netherlands and both their parents had to be of ethnic 
Dutch Caucasian origin. Asian Indian subjects were eligible for the study if they 
were born in Surinam or the Netherlands and when both their parents were of Asian 
Indian origin. Subjects had to be at least 18 years old. The exclusion criteria were as 
follows: insulin-dependent diabetes mellitus, use of antidiabetic medication other 
than metformin, a history of pancreatitis, insulinoma, or other reasons, which made 
participation impossible. All participants underwent an OGTT and were diagnosed to 
have normal glucose tolerance, impaired glucose tolerance, or T2DM (normoglycemic, 
prediabetic, and diabetic) according to the WHO OGTT criteria[11]. Details about the 
study setup have been previously reported[12]. Written informed consent was obtained 
from all participants. All procedures followed were in accordance with the ethical 
standards of the responsible committee on human experimentation (institutional 
and national) and with the Helsinki Declaration of 1975, as revised in 2008. The study 
protocol was approved by the Erasmus University Medical Center Medical Ethics Review 
Board (MEC-2009-242).
In vivo measurements 
After an overnight fast, each participant underwent an extended OGTT and venous 
blood samples were collected at 15 min before and 15, 30, 45, 60, 90, 120, 150, 180 
and 210 minutes after the oral administration of 75 grams glucose. Fasting blood was 
collected at 60 min before administration of glucose and used to reflect the t=0 value. 
Body length and weight were measured to the nearest 0.1 cm and 0.1 kg, respectively. 
Waist and hip circumferences were measured to the nearest cm in the standing 
position, halfway between the lowest rib and the iliac crest, and the maximum hip 
circumference, respectively. 
Assays
Plasma glucose was measured by a hexokinase-based method (Gluco-Quant, 
Roche Diagnostics). Plasma insulin and C-peptide were measured by a competitive 
chemiluminescent immunoassay, supplied by Euro/DPC. The assay was performed 
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on a DPC Immulite 2000 analyzer (Euro/DPC) according to the manufacturer’s 
recommendations. Serum creatinine was measured in fasting blood with the Creatinine 
Plus assay on a Roche/Hitachi analyzer.
Amino acid analysis
The amino acid concentrations in fasting plasma samples were determined by HPLC 
after precolumn derivatization with ortho-phthaldialdehyde/3-mercaptopropionic 
acid (OPA/MPA) and detection by fluorescence [13]. In short, 25 μl of plasma was 
deproteinized with 25 μl 6 % sulfosalicylic acid and, thereafter, derivatized with OPA/
MPA in the borate buffer (pH 10). After 2 min, the reaction was neutralized with citric 
acid (1 M) and 5 μl was applied to a 4.6 x 50 mm 1.8 µm Eclipse C18 column (Agilent). 
The HPLC system consisted of two LC-10ADvp pumps, a SIL-10ADvp autosampler and a 
RF-10Axl fluorescence detector (Shimadzu). The mobile phase A was 40 mM NaPi buffer 
(pH 7.8) and mobile phase B consisted of acetonitrile/methanol/water (45/45/10, v/v/v). 
A linear gradient with a flow rate of 0.5 ml/min was started at 2% B in A, ending at 
45.7% B in A at 16 min. Thereafter, the column was re-equilibrated. Concentrations of 
BCAA, alanine, phenylalanine, and tyrosine in plasma were calculated as the average of 
duplicate work-up. 
Calculations
Indices for whole body insulin sensitivity and beta-cell function were derived from the 
extended OGTT, which included 11 blood samplings in 3.5 hr for glucose, insulin, and 
C-peptide measurements, as described in detail previously[12] .The clamp-validated 
insulin sensitivity index (ISI) was calculated according to Matsuda.[14] As a marker of 
beta-cell function, the overall disposition index (DI) was calculated as the product of ISI 
and the insulin secretion response [15]. As a measure of renal function, the estimated 
Glomerular Filtration Rate (eGFR) was calculated with the Modification of Diet in Renal 
Disease (MDRD) formula [16, 17].
Statistical analyses
Data are expressed as mean ± SD, unless indicated otherwise. Differences between 
subgroups were analyzed with ANOVA, followed by Bonferroni, and considered 
significant when P value < 0.0125. Inverse or log transformations were used when 
normality or equal variance assumptions were not met. Pearson correlation coefficients 
were determined by multivariate regression analysis and considered significant when 
P value < 0.05. As glucose intolerance and T2DM progresses with age in affected 
individuals, age was not included as an independent parameter in the multivariate 
regression analysis. The value of BCAA and other parameters in discriminating the 
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individual’s state of glucose intolerance was determined by binary logistic regression 
analysis adjusted for family ties [18]. Differences between the area under the curve 
of receiver-operated characteristics (ROC AUC, concordance index or c-index) were 
calculated according to Hanley and McNeil[19] and considered significant when P < 
0.05. All statistical tests were conducted using SPSS software, version 15.0, for Windows 
(SPSS Inc.).
RESULTS
Subject characteristics
Family members of 24 Caucasian and 36 Asian Indian index patients were included in 
the study. From the Caucasian families 34, 12, and 18 participants were normoglycemic, 
prediabetic and diabetic, respectively. These numbers were 22, 12, and 23 for the 
Asian Indians. The characteristics of these groups are shown in Table 1; OGTT AUC of 
plasma glucose, insulin, and C-peptide concentrations for all groups is depicted in 
Fig 1. Among the Caucasians, there were significant differences between the diabetic 
and the normoglycemic subgroups with respect to age, waist circumference, waist-
hip ratio (WHR), ISI and DI, but not for body weight, BMI, or eGFR MDRD. For the DI, 
the prediabetic subgroup was intermediate between the normoglycemic and diabetic 
subgroup. The diabetic subgroup was significantly older than the prediabetic subgroup. 
For the other parameters, the prediabetic subgroup did neither differ significantly from 
the normoglycemic nor the diabetic subgroup. The Asian Indian family members were 
more homogeneous, as only differences were observed among subgroups for age 
and for the DI. Compared to the Caucasian T2DM patients, the Asian Indian patients 
with T2DM were younger (P = 0.004), shorter (P < 0.001) and weighed less (P = 0.005). 
No other remarkable differences between similar subgroups of both ethnicities were 
evident.
Fasting plasma amino acid levels
In the Caucasians, plasma levels of leucine, isoleucine, valine, alanine, phenylalanine, and 
tyrosine were all significantly higher in the T2DM than in the normoglycemic subgroup 
(Table 1). Although a similar trend is observed among the Asian Indians for most amino 
acids, none of the differences was significant. The Caucasian T2DM group had higher 
BCAA levels than the Caucasian normoglycemic group (P = 0.001). In contrast, the 
Asian Indian T2DM group did not have significantly higher total BCAA than the Asian 
Indian normoglycemic group (P = 0.21). There were no significant differences between 
fasting plasma amino acid levels between similar subgroups of the two ethnicities, 
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except that most amino acids, including total BCAA, were higher in the normoglycemic 
Asian Indians than in the normoglycemic Caucasians. Notably, levels of total BCAA, 
phenylalanine, and tyrosine in the normoglycemic Asian Indians were not statistically 
different from the diabetic Caucasians. To replicate known relationships between BCAA 
and a number of traits, illustrated in Fig. 2, we have performed multivariate analyses 
that are shown in Table 2. In Caucasians, WHR significantly explained 15.4% (P  = 0.03) 
of the variance in BCAA concentrations. In Asian Indians, WHR explained 32.5% (P = 
0.001) and eGFR MDRD 9.5% (P = 0.009) of the variance in BCAA concentrations.
Figure 1 | Incremental (Incr.) plasma AUC of glucose, insulin, and C-peptide during the 210 min oral 
glucose tolerance test (OGTT) (mean±SEM) among WHO OGTT subgroups with normal glucose tolerance 
(NGT), impaired fasting glucose, and/or impaired glucose tolerance (IFG/IGT) and Type 2 Diabetes (T2D) 
from South Asian (SA) or Caucasian (Cau) origin. Incr. plasma glucose AUC; SA NGT versus T2DM SA P < 
0.001, SA IFG/IGT versus T2DM P < 0.001, Cau NGT versus Cau T2DM P < 0.001, and Cau IFG/IGT versus Cau 
T2DM P < 0.001. Incr. plasma insulin AUC; SA NGT versus Cau NGT P < 0.01.
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Discriminative ability of amino acid profile for glucose intolerance
Before we tested the discriminative ability of BCAA between normoglycemia and 
prediabetes, we repeated our univariate analyses of BCAA with the earlier mentioned 
traits, but now restricted to the normoglycemic and prediabetic subgroups for both 
ethnicities. Even when we excluded their respective T2DM subgroups, our regression 
analyses remained significant (data not shown). The ability of the amino acid profile 
to discriminate between glucose-tolerant and glucose-intolerant family members 
was determined by the ROC curves (Table 3). The c-index of total BCAA was 0.83 in 
the Caucasians and 0.74 in the Asian Indians, which increased when combining BCAA 
levels with those of alanine, phenylalanine, and tyrosine to 0.84 and 0.79, respectively. 
The corresponding c-indices for fasting glucose were 0.91 and 0.85. When amino acid 
levels were combined with fasting glucose, the c-index increased to 0.92 and 0.97 (P 
= 0.04 vs. fasting glucose alone) for the Caucasian and Asian Indian family members, 
respectively (Fig. 3).
Table 2 | Stepwise Regression Analysis Explaining Variance in % of BCAA Concentrations in Both Ethnicities, 
with WHR, eGFR MDRD, ISI, and DI as Determinants
 
Determinant
Caucasians Asian Indians
b (95% CI) β % b β %
WHR 260.71 (25.69 to 495.72) 0.31 15.4(P = 0.03) 543.61 (242.38 to 844.85) 0.42 32.5(P = 0.001)
eGFR MDRD Excluded from model - - -1.12 (-1.94 to -0.30) -0.30 9.5  (P = 0.009)
ISI Excluded from model - - -7.69 (-16.12 to 0.74) -0.21 3.8  (P = 0.073)
DI -20.52 (-43.19 to 2.15) -0.25 5.5(P = 0.075) Excluded from model - -
In South Asians, WHR explained 32.5% and eGFR MDRD 9.5% of the variance in BCAA concentrations. ISI explained 3.8% 
in this model, although statistical significance was not reached (P = 0.073). DI did not contribute to the variance observed. 
In indigenous Dutch, WHR explained 15.4% of the variance in BCAA concentrations. DI may explain 5.5% in this model, 
however, this was not significant (P = 0.075). eGFR MDRD and ISI did not contribute to the differences observed. DI, 
disposition index; eGFR MDRD, estimated Glomerular Filtration Rate by Modification of Diet in Renal Disease; ISI, insulin 
sensitivity index; WHR, waist–hip ratio
Table 3 | Ability to Discriminate Between Normoglycemic and Prediabetic Relatives Within Families with 
T2D
BCAA Amino acids Fasting glucose
Fasting glucose+
BCAA
Fasting glucose+
Amino Acids
Caucasians 0.83 0.84 0.91 0.92 0.92
Asian Indians 0.74* 0.79* 0.85* 0.89 0.97*
The c-index (ROC AUC) of BCAA, amino acids (BCAA, phenylalanine, tyrosine, and alanine), fasting glucose and BCAA or 
amino acids as add-on to fasting glucose, for prediabetes. *c-Index of fasting glucose+ amino acids versus BCAA (P = 0.01), 
amino acids (P = 0.02) or fasting glucose (P = 0.04)  
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Figure 2 | relationships of branched-chain amino acids (BCAA) with waist/hip ratio (W/H), glomerular 
filtration rate (eGFR), insulin sensitivity index (ISI) and insulin disposition index (DI) in Caucasian (left, 
open circles) and Asian Indian (right, closed circles) families (triangles are normal individuals, squares are 
individuals with prediabetes and circles individuals with T2DM, respectively).  In Asian Indians, the 
relationship between BCAA and W/H (R2= 0.25; P < 0.001), eGFR (R2= 0.19; P = 0.001), and ISI (R2=0.14; P 
< 0.001) was significant; the relationship between BCAA and DI (R2=0.03; P = 0.18) was not significant. In 
Caucasians, the relationship between BCAA and W/H (R2=0.18; P < 0.001), BCAA and ISI ( R2=0.14; P < 0.001)
and BCAA and  DI (R2=0.16; P < 0.001) was significant; the relationship between BCAA and eGFR (R2=0.007; 
P = 0.54) was not significant
Figure 3 | ROC curves for prediabetes among nondiabetic members of  Caucasian (A) and Asian Indian 
(B) families with high T2DM risk. For both ethnicities, the ROC curve for fasting glucose  alone (grey short 
dashed line) and  fasting glucose+amino acids (BCAA, phenylalanine, tyrosine, and alanine, black continuous 
line) to discriminate between OGTT-defined prediabetic from normoglycemic condition, are depicted. 
DISCUSSION
We found that fasting BCAA, aromatic amino acids and alanine levels were correlated 
with glucose intolerance and well discriminated between the prediabetic and the 
normoglycemic members of the Caucasian and fairly well for the Asian Indian families. 
However, in the Caucasian families, fasting glucose had high discriminative ability that 
was not improved by adding amino acid levels, whereas in the Asian Indian families, 
adding of amino acid levels to fasting glucose substantially improved the ability to 
discriminate normoglycemic from prediabetic family members in the Asian Indian 
families. 
A B
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Prediabetes is defined by impaired fasting glucose and/or impaired glucose tolerance. 
We restricted the criteria for subgroups within the families to the OGTT measurements. 
Compared to prediabetic Caucasians, more Asian Indians had impaired glucose 
tolerance without impaired fasting glucose. This is the reason that an elevated level of 
plasma amino acids was a predictor of impaired glucose tolerance on top of the fasting 
glucose levels in Asian Indians but not in Caucasians. We also tested the discriminative 
ability of branched-chain alpha-keto acids, but we did not observe an improvement 
over BCAA (data not shown).
The Asian Indians living in the Netherlands have a high propensity to develop obesity 
and T2DM. They develop T2DM at an earlier age and at lower BMI than Caucasians [8, 
9]. In both ethnicities, ISI and adequate beta-cell function became less going from 
the normoglycemic through the prediabetic to the diabetic state, but ISI was not 
significantly different between the Asian Indian subgroups. In multivariate regression 
analysis, BCAA levels marginally associated with the ISI among Asian Indians and 
with the beta-cell function index among Caucasians. High BCAA levels are the result 
of impaired BCAA catabolism occurring in parallel with resistance to insulin, as has 
been observed during hyperinsulinemic euglycemic clamping of nonobese and T2DM 
subjects[20]. In line, metabolites related to BCAA catabolism associate with impaired 
fasting glucose and T2DM[21]. Moreover, insulin resistance decreases the hepatic 
expression of branched-chain alpha-keto acid dehydrogenase, the rate-limiting 
enzyme of BCAA catabolism[22]. Nonetheless, the causes for high BCAA levels may 
differ between ethnicities and an effect of beta-cell function has not been excluded.
We found that WHR was a stronger determinant of fasting plasma BCAA levels in 
our Asian Indians than in Caucasian subjects. A number of studies support a role of 
visceral fat in the BCAA catabolism: insulin resistant, obese sisters and brothers of 
monozygotic twins discordant for obesity had downregulated mitochondrial pathways 
for BCAA degradation in adipose tissue [23]; expression of enzymes involved in BCAA 
catabolism in visceral fat was lower in obese women with than those without T2DM 
[24]; and BCAA levels are reduced by bariatric surgery[25, 26]. Visceral fat is clearly 
involved in the development of the metabolic syndrome among normoglycemic Asian 
Indians[27]. Moreover, large differences have been observed in distributions of fat 
tissue among Asian Indian neonates compared to other ethnic groups[28]. Intriguingly, 
our normoglycemic Asian Indians had fasting plasma BCAA and other amino acid levels 
that were already in the range of the Caucasian patients with T2DM. This may result 
from these differences in fat tissue distribution early in life. 
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Our work has a number of potential weaknesses: inherent to the used methodology of 
family screening we studied relatively small groups. We did not assess prior food intake. 
However, fasting plasma BCAA originate predominantly from endogenous sources [29, 
30] and diet does not influence fasting BCAA levels.[4, 7] Screening of families with 
prevalent diabetes at our outpatient clinic resulted in selection on a high a priori chance 
of diabetes. In line, family ties increased the c-indices. However, we need to emphasize 
that our findings cannot be generalized to population-based screening approaches 
that are not based on family screening. Our findings are of interest to clinicians, who 
screen relatives of patients in high-risk families.
In conclusion, we found that BCAA levels increase with the degree of glucose 
intolerance in families at-risk for T2DM of Caucasian descent, but not in Asian Indian 
families living in the Netherlands. However, when combined with fasting glucose, 
BCAA levels together with the other amino acids reliably discriminated normoglycemic 
from prediabetic family members in both ethnicities, and significantly improved the 
discriminative ability of fasting glucose alone among the Asian Indian families. Amino 
acid profiles in fasting blood, particularly of BCAA, may be used as biomarkers to 
improve detection of the glucose-intolerant subject at risk for development of T2DM.
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CHAPTER 5
Post glucose-load urinary C-peptide and glucose 
concentration obtained during OGTT do not 
affect Oral Minimal Model based plasma indices
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ABSTRACT
The purpose of this study was to investigate how renal loss of both C-peptide and 
glucose during oral glucose tolerance test (OGTT) relate to and affect plasma derived 
oral minimal model (OMM) indices. All individuals were recruited during family screening 
between August 2007 and January 2011 and underwent a 3.5 h OGTT, collecting nine 
plasma samples and urine during OGTT. We obtained the following three subgroups: 
normoglycemic, at risk and T2D. We recruited South Asian and Caucasian families 
and we report separate analyses if differences occurred. Plasma glucose, insulin and 
C-peptide concentrations were analyzed as AUCs during OGTT, OMM estimate of renal 
C-peptide secretion, and OMM beta-cell and insulin sensitivity indices were calculated 
to obtain disposition indices. Post-glucose load glucose and C-peptide in urine were 
measured and related to plasma-based indices. Urinary glucose corresponded well 
with plasma glucose AUC (Cau r = 0.64, P < 0.01, SA r = 0.69, P < 0.01), S
I
 (Cau r = -0.51, 
P < 0.01, SA r = -0.41, P < 0.01), Φ
dynamic
 (Cau r = -0.41, P < 0.01, SA r = -0.57, P < 0.01), 
 
and Φ
oral
 (Cau r = -0.6, P < 0.01, SA r = -0.73, P < 0.01). Urinary C-peptide corresponded 
well to plasma C-peptide AUC (Cau r = 0.45, P < 0.01, SA r = 0.33, P < 0.05) and OMM 
estimate of renal C-peptide secretion (r = 0.42, P < 0.01). In general, glucose excretion 
plasma threshold for the presence of glucose in urine was ~10-10.5mmol/L in non-T2D 
individuals, but not measurable in T2D individuals.  Renal glucose secretion during 
OGTT did not influence OMM indices in general nor in T2D patients (renal clearance 
range 0-2.1%, with median 0.2% of plasma glucose AUC). C-indices of urinary glucose 
to detect various stages of glucose intolerance were excellent (Cau 0.83-0.98; SA 0.75-
0.89).
The limited role of renal glucose secretion validates the neglecting of urinary 
glucose secretion in kinetic models of glucose homeostasis using plasma glucose 
concentrations. Both C-peptide and glucose in urine collected during OGTT might be 
used as non-invasive measures for endogenous insulin secretion and glucose tolerance 
state.
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INTRODUCTION
Mathematical approaches based on compartmental pharmacokinetic/ 
pharmacodynamic (PK/PD) principles are used to describe the biphasic glucose-insulin 
system in oral function tests[1, 2], with the oral minimal model (OMM) as one of the 
most widely accepted approaches [3]. However, the contribution of renal clearance of 
endogenous glucose, insulin and C-peptide during oral glucose tolerance test (OGTT) 
in various stages of glucose tolerance remains largely unclear. As renal extraction of 
insulin is negligible[4], we focused on the relationship between plasma and urine 
concentrations of both C-peptide and glucose, collected during OGTT in the post-
glucose load phase. This was performed in families to obtain groups with different 
risk for T2D and we recruited families of South Asian and Caucasian origin to enable 
generalization of our findings. Especially, South Asians with T2D may be at high risk 
for chronic kidney disease[5]. We questioned to which degree C-peptide and glucose 
excretion in urine influence OGTT based plasma indices. Moreover, we compared the 
OMM derived estimates of renal C-peptide excretion with actual urinary C-peptide 
concentration. In addition, renal loss of glucose is not taken into consideration in OMM, 
and the extent to which renal clearance might require correction of plasma-derived 
OMM calculations is unknown.
METHODS
Subjects and anthropometric data
Patients were recruited from South Asian and Caucasian families with high risk of T2D 
after family screening from the Outpatient Clinic of the Erasmus Medical University 
Centre as described previously[6]. The first-degree relatives of patients with T2D 
attending our Clinic (index cases), who did not have T2D were recruited from 36 South 
Asian families and 24 Caucasian families, with 2 generations taken into account. Data 
were obtained from 57 (M29 F28) South Asians and 64 (M24 F40) Caucasians who 
all underwent an OGTT. Index cases were on metformin use only, and had at least 
one sibling with T2D. Informed written consent to the study was obtained from all 
participants. The study protocol was approved by the Erasmus University Medical 
Center Medical Ethics Review Board. All procedures followed were in accordance 
with the ethical standards of the responsible committee on human experimentation 
(institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. 
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OGTT 
Venous blood was drawn via an intravenous canula, at time-points 60 and 15 min 
before 75g glucose load and 15, 30, 45, 60, 90, 120, 150, 180 and 210 minutes after 
glucose load to measure glucose, insulin and C-peptide concentrations. The WHO 
criteria for the OGTT were used to define normal glucose tolerance (NGT), impaired 
fasting glucose and/or impaired glucose tolerance (IFG/IGT) or Type 2 Diabetes (T2D) 
status among subjects. After emptying their bladder prior to glucose load, urine was 
collected until 210 minutes after glucose-load. As there were no significant differences 
between baseline values of plasma glucose, insulin or C-peptide obtained at -60 min 
or -15 min, and as -60 min was sampled before our study subjects had emptied their 
bladder prior to glucose load, we chose -60 min as the representative baseline value. 
In 7 of 18 Caucasians with T2D, urine was not collected, because it was not included in 
our protocol at that time. As this group did not significantly differ from the remaining 
group, we used data of n=18 for all plasma indices, but data of n=11 for all analyses 
with urinary glucose and C-peptide measurements in Caucasians.
Immunoassay 
Plasma and urine glucose was measured by a hexokinase-based method (Gluco-quant; 
Roche Diagnostics, Mannheim, Germany). Plasma and urine C-peptide, and plasma 
insulin were measured separately by a competitive chemiluminescent immunoassay, 
supplied by Euro/DPC. The assay was performed on a DPC Immulite 2000 analyzer 
(Euro/DPC) according to the manufacturer’s recommended protocol. Serum creatinine 
was measured with an enzymatic procedure based on creatinine conversion with the 
Creatinine Plus assay on a Roche/Hitachi analyzer. Urine creatinine was measured 
based on the Jaffe alkaline picrate method. 
Calculations for OMM
The OMM was used to describe the plasma glucose, insulin and C-peptide 
concentrations after oral glucose stimulus[7]. With C-peptide minimal model we 
assessed parameters for beta-cell function;  basal responsivity of beta-cells due to 
basal glucose potentiation Φ
basal
(min-1), static responsivity of beta-cells due to glucose 
potentiation Φ
static
 (10-9 min-1) , dynamic responsivity of beta-cells due to glucose 
potentiation Φ
dynamic
 (10-9), total responsivity of beta-cells due to glucose potentiation 
Φ
oral (10
-9 min-1) and delay in response to glucose potentiation T (min). With glucose 
minimal model we assessed parameters for insulin sensitivity; insulin sensitivity S
I 
(10-5 dl*kg-1 *min-1 per pM). Parameters from both models were multiplied with each 
other for calculation of disposition indices (DI), which are beta-cell function measures 
corrected for insulin sensitivity;  DI
basal
 = Φ
basal
* S
I
, DI
static
= Φ
static
* S
I
, DI
dynamic
 = Φ
dynamic
* S
I
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and DI
oral
 = Φ
oral
*S
I
 . Parameters of OMM were estimated with SAAM2 software[8]. 
Incremental plasma AUC of C-peptide and glucose within a given time period was 
calculated according to trapezoidal rule, with subtraction of basal concentration. For 
urinary glucose, we estimated plasma glucose threshold (when exceeded glucose in 
urine is present) separately among both our T2D and non T2D (NGT+IFG/IGT) groups; 
we calculated plasma glucose AUCs from 8.5 to 11.5 mmol/L with an interval of 
0.5mmol/L to detect the most suitable plasma glucose threshold. Stepwise exclusion 
was performed of T2D and non T2D individuals, based on whether their plasma glucose 
AUC was above a given threshold or not. Also, to determine the relative renal loss of 
glucose from total plasma glucose AUC, renal clearance of glucose was calculated 
with absolute amount of urinary glucose/ total plasma glucose AUC. For comparison 
with urinary C-peptide, we used AUC from flux k01 (Fig. 1) from OMM, representing 
irreversibly metabolized C-peptide from central compartment. Estimated glomerular 
filtration rate (eGFR) was estimated with the modification of diet in renal disease 
(MDRD) formula [9, 10].
CP1 CP2
SR
k21
k12
k01
Figure 1a | Two-compartment model of C-peptide kinetics that is integrated in oral minimal model (OMM). 
SR is prehepatic insulin secretion rate, based on C-peptide curve. CP1 represents amount of C-peptide in 
central compartment, and CP2 amount of C-peptide in peripheral compartment. k21 and k12 are C-peptide 
transfer rate between CP1 and CP2; k01 describes metabolization of C-peptide from CP1. In this study, 
plasma AUC of CP1*k01 , or OMM flux k01, is related to actual measured C-peptide concentration in urine 
during OGTT. Adapted from van Cauter et al[1].
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Figure 1b | Correlation between C-peptide in urine and OMM flux k01. NGT (triangle), IFG/IGT (square) and 
T2D (circle) subgroups for South Asian (closed) and Caucasian (open) families.
Statistical analyses
Data analysis:  Data are expressed as mean ± SEM, or indicated otherwise. Comparisons 
within the subgroups of the ethnicities were done with ANOVA, with the other two 
subgroups of same ethnicity and with the corresponding other ethnic subgroup. 
Differences were considered statistically significant when the two-sided P value was 
<0.0125. Urinary glucose and C-peptide were correlated with plasma indices, with 
Spearman’s correlation within each ethnicity, with significance at P value < 0.05. For 
urinary glucose and C-peptide concentrations, AUC of receiver-operated characteristics 
(ROC) curves (concordance indices or c-indices), adjusted for family ties by binary 
logistic regression analysis [11], were calculated to detect IFG/IGT and/or T2D status. All 
statistical tests were conducted with the use of SPSS, version 15.0, for Windows (SPSS 
Inc., Chicago, IL, USA).
RESULTS
Baseline characteristics
Baseline characteristics are shown in Table 1, and incremental plasma AUC of primary 
data glucose, insulin and C-peptide during OGTT in Fig. 2. South Asian T2D individuals 
were younger (P = 0.004), shorter (P < 0.001) and weighed less (P = 0.005) than Caucasian 
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T2D individuals. W/H increased from NGT to T2D in Caucasians (P = 0.003), but not in 
South Asians. In both ethnicities, incremental plasma glucose AUCs from NGT or IFG/
IGT were significantly  lower than T2D (P < 0.001). In both ethnicities, no significant 
differences were found in incremental plasma insulin AUC between NGT, IFG/IGT and 
T2D; however, a difference was found between South Asian NGT and Caucasian NGT (P 
< 0.01). In both ethnicities, no significant differences were found in incremental plasma 
C-peptide AUC between NGT, IFG/IGT, and T2D. In both ethnicities, no significant 
differences were found in Φbasal between NGT, IFG/IGT, and T2D; whereas, Φdynamic , Φstatic 
and Φtotal decreased with increasing glucose intolerance. No significant differences 
were found in delay T. With OMM, we observed a decrease in insulin sensitivity in 
both ethnicities with increasing glucose intolerance (P < 0.001), however, differences 
were lower among the South Asian subgroups. All disposition indices decreased with 
increasing glucose intolerance. Overall, South Asian NGT and IFG/IGT demonstrated 
lower DI indices when compared to Caucasian NGT, whereas those of South Asian 
T2D were higher than their Caucasian counterparts. In both ethnicities glucose in 
urine increased with increasing glucose intolerance; both creatinine unadjusted and 
adjusted urinary glucose in T2D subgroup were significantly higher when compared 
to NGT or IFG/IGT subgroups (P < 0.001).  In Caucasians, creatinine adjusted C-peptide 
was higher in T2D when compared to NGT and IFG/IGT combined (t test P = 0.005); no 
differences were found among South Asians.
Effect of renal glucose loss on plasma-derived OMM indices
The absolute amount of glucose concentration collected in urine voids of T2D patients 
did not influence glucose minimal model measurements, as a result of the small 
variation of renal clearance (range 0-2.1%, with median 0.2% of total plasma glucose 
AUC).
Relation urine markers with plasma indices of C-peptide and glucose, OMM and 
eGFR
Relationships between urinary glucose and C-peptide with plasma indices in both 
ethnicities can be found in Table 2. In both ethnicities, urinary glucose was positively 
associated with plasma glucose AUC and negatively associated with S
I
 and DI values. 
In both ethnicities, urinary C-peptide was positively associated with plasma C-peptide 
AUC. Plasma AUC of OMM flux k01 reflecting C-peptide from central compartment that 
is irreversibly metabolized, correlated with creatinine-adjusted urinary C-peptide (Fig. 
1b; r = 0.42; P < 0.01). Creatinine unadjusted and adjusted urinary glucose as well as 
C-peptide had no significant correlation with eGFR.
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Figure 2 | Incremental (Incr.) plasma AUC of glucose, insulin and C-peptide during 210 min OGTT 
(mean±SEM) among WHO OGTT subgroups with normal glucose tolerance (NGT), impaired fasting 
glucose and/or impaired glucose tolerance (IFG/IGT) and Type 2 Diabetes (T2D) from South Asian (SA) or 
Caucasian (Cau) origin. Incr. plasma glucose AUC; SA NGT versus T2D SA P < 0.001, SA IFG/IGT versus T2D P 
< 0.001, Cau NGT versus Cau T2D P < 0.001,Cau IFG/IGT versus Cau T2D P < 0.001. Incr. plasma insulin AUC; 
SA NGT versus Cau NGT P < 0.01.
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Table 3 | Two groups, one with and one without glucose in urine. With increasing glucose threshold, 
stepwise exclusion was performed separately among non T2D (NGT+IFG/IGT) and T2D subgroups, based 
on their absence of having above threshold glucose AUC (mean+/-SEM). 
CaucasiansA South Asians
N (stepwise) Glucose AUC N (stepwise) Glucose AUC
Treshold 8.5 mmol/L Urine glucose- Non T2D 3 28.8±14.7 2 71.25±57.0
T2D 0 0 1 33.8
Urine glucose+ Non T2D 19 116.6±29.3 14 116.2±28.9
T2D 11 1012.9±143.4 20 684.5±107.0
Treshold 9 mmol/L Urine glucose- Non T2D 2 17.25±6.0 2 41.3±37.5
T2D 0 0 1 12.0
Urine glucose+ Non T2D 16 103.6±28.0 12 99.7±26.0
T2D 11 922.7±139.1 20 614.0±102.2
Treshold 9.5 mmol/L Urine glucose- Non T2D 2 2.25±1.50 1 45.8
T2D 0 0 0 0
Urine glucose+ Non T2D 11 112.1±28.5 11 75.8±23.0
T2D 11 837.8±133.8 20 545.1±97.3
Treshold 10 mmol/L Urine glucose- Non T2D 0 0 1 16.5
T2D 0 0 0 0
Urine glucose+ Non T2D 9 99.0±25.6 8 67.5±22.4
T2D 11 759.3±128.5 20 480.3±91.8
Treshold 10.5 mmol/L Urine glucose- Non T2D 0 0 0 0
T2D 0 0 0 0
Urine glucose+ Non T2D 8 77.6±20.6 7 46.9±18.6
T2D 11 683.1±123.2 20 420.5±85.8
Treshold 11.0 mmol/L Urine glucose- Non T2D 0 0 0 0
T2D 0 0 0 0
Urine glucose+ Non T2D 8 53.3±16.5 7 25.9±13.9
T2D 11 608.8±117.8 19 383.8±81.4
Treshold 11.5 mmol/L Urine glucose- Non T2D 0 0 0 0
T2D 0 0 0 0
Urine glucose+ Non T2D 7 38.6±13.4 4 21.2±13.0
T2D 11 538.9±111.8 17 367.0±78.7
ACaucasian T2D n=11, for reasons mentioned in methods section
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Estimation of glucose threshold among non-T2D and T2D subgroups
Our stepwise exclusion approach to estimate glucose threshold during OGTT can 
be found in Table 3. It led to glucose threshold of ~10 mmol/L among Caucasian 
NGT and IFG/IGT individuals. In South Asians, glucose threshold for NGT and IFG/IGT 
individuals did not differ much, being ~10.5 mmol/L. Glucose threshold during OGTT 
varied considerably among T2D patients from both ethnicities and was therefore not 
assessable.
ROC values of urine markers for detection of glucose tolerance state
We examined the areas under ROC curves of glucose and C-peptide in urine unadjusted 
as well as adjusted for creatinine (adjusted are the values between brackets), 
respectively. We have found clear differences between the two ethnicities and 
therefore performed separate analyses. Urinary glucose concentration demonstrated 
high capability to discriminate between T2D and the combination of the other two 
subgroups (NGT and IFG/IGT); 0.976 (0.996) in Caucasians and 0.893 (0.898) in South 
Asians, respectively. We also calculated c-indices of urinary glucose for NGT versus the 
combination of IFG/IGT and T2D; 0.904 (0.908) in Caucasians and 0.894 (0.877) in South 
Asians, and c-indices for NGT versus the IFG/IGT subgroup; 0.826 (0.827) in Caucasians 
and 0.748 (0.736) in South Asians, respectively (Fig. 3).
Figure 3 | Receiver-operated characteristics  (ROC) curve for discriminatory ability between individuals 
with normal glucose tolerance (NGT) versus impaired fasting glucose/ impaired glucose tolerance (IFG/
IGT) with urinary glucose (closed line) or C-peptide (dashed line) concentration obtained from urine 
collected during OGTT (both unadjusted for urine creatinine), in Caucasians (A) and South Asians (B).
A B
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The c-indices of urinary C-peptide concentration for the detection of glucose tolerance 
status were for discrimination between T2D and the combination of two other 
subgroups; 0.658 (0.742) in Caucasians and 0.503 (0.565) in South Asians, respectively. 
The c-indices for NGT versus the combination of IFG/IGT and T2D were; 0.692 (0.733) 
in Caucasians and 0.556 (0.584) in South Asians. The c-indices for NGT versus IFG/IGT 
were; 0.792 (0.792)in Caucasians and 0.595 (0.599) in South Asians, respectively (Fig. 3). 
DISCUSSION
We found that urinary C-peptide collected during OGTT correlated with plasma 
C-peptide indices and OMM-derived estimates of renal C-peptide excretion. Urinary 
glucose collected during OGTT also correlated well with plasma indices, especially 
with plasma glucose AUC. Urinary glucose was mainly present in urine of patients 
with T2D, however, the loss of glucose in the urine was too small to influence general 
OMM calculations. Among the patients with T2D the urinary glucose concentration 
showed large variation but discriminated well between normal and abnormal glucose 
tolerance.
Both glucose minimal model as C-peptide minimal model assess plasma glucose 
concentrations during OGTT with the first model also applying an area under the curve 
constraint; the amount of circulating glucose is expected to be a fixed parameter based 
on the amount of glucose load used as stimulus. The knowledge about the effects of 
dynamic glucose loss on OMM based parameters due to renal handling after stimulus is 
limited[7]. We hypothesized that the variance of the urinary glucose excretion could  be 
a serious confounder, but we found that renal loss of glucose does not influence OMM 
based parameters of insulin sensitivity and beta-cell function. This finding is highly 
relevant for glucose homeostasis based kinetic models in general.
Overnight, 24 h fasting and after a mixed meal urine collection studies demonstrated 
the value of urinary C-peptide as non-invasive measure for endogenous insulin 
secretion in people with and without diabetes[12-17]. As stricter metabolic control 
affects urinary C-peptide, it might be of use to follow-up the insulin secretory 
function[18-20]. In line, we found that during OGTT, urinary C-peptide correlated 
well with plasma values reflecting the endogenous pancreatic secretion. For urinary 
C-peptide, we did not observe a relationship between eGFR MDRD. This is in agreement 
with previous studies, where the presence of micro albuminuria, or renal impairment 
with reduced filtration rate did not alter the relationship between urinary and plasma 
C-peptide[21, 22]. 
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Glucose is cleared by the kidney and predominantly reabsorbed by the sodium-
glucose co-transporter 2 (SGLT2) in the proximal tubules. The urinary glucose excretion 
threshold is believed to be around 10 mmol/L in individuals without T2D[23, 24], which 
is in accordance with our estimations, with the exception of our individuals with T2D. 
Our patients with T2D did not use SGLT2 inhibitors. With clamp steady state studies it 
was demonstrated that a glucose threshold is not applicable to individuals with T2D 
due to a large variation in their glucose excretion; and glucosuria is present even when 
treated patients with T2D return to euglycemic conditions [25, 26]. Hence, using the 
OGTT the post glucose load urinary glucose concentration may be useful as non-
invasive marker to detect abnormal glucose tolerance, but it is not suited to monitor 
treatment.
The strength of the present study lies in the fact that we used OMM and assessed urine 
parameters in two different ethnicities and in all stages of glucose tolerance. Among 
the weaknesses of our study are the limited sample size, the limited possibilities 
to translate our findings of the extended OGTT into clinical applications and using 
estimate eGFR MDRD instead of measuring GFR directly as a measure for renal function. 
Although our groups were relatively small, differences between subgroups and 
ethnicities became apparent with this relatively simple and low-cost test procedure. In 
contrast to the customary 24 h urine collections obtained at home, we collected urine 
in the hospital setting, during an extended version of OGTT. Validity of reduced amount 
of sampling and sampling time after stimulus has been demonstrated previously in 
healthy individuals, resulting in a more practical application of OMM[27]. We were also 
able to reduce amount of sampling, as we found no significant differences between 
plasma indices obtained from our above-described final 210min-post-glucose load 
nine samples OGTT versus an earlier performed pilot with 210min-post-glucose load 
13 samples OGTT, which also included sampling at t=5, t=10, t=20 and t=25min (data 
not shown). The participants in our study had no severe kidney failure and no history of 
renal disease. 
In conclusion, urinary C-peptide corresponded well to OMM-derived estimates of renal 
C-peptide clearance and the renal glucose secretion during OGTT did not influence 
OMM indices. 
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CHAPTER 6
A stable isotope method for in vivo assessment 
of human insulin synthesis and secretion
114
Chapter 6
ABSTRACT
Aims. In vitro, beta cells immediately secrete stored but readily releasable insulin in 
response to a rise of glucose. During a prolonged insulin response this is followed by 
newly synthesized insulin. Our aim was to develop an in vivo test to determine the ratio 
between readily available and newly synthesized insulin after a stimulus in humans by 
labelling newly synthesized insulin. 
Methods. A stable isotope tracer of 1.0 g 13C leucine with C-peptide as target peptide 
was administered 45 min prior to 75 g glucose load of a frequently blood sampled 210 
minutes oral glucose tolerance test (OGTT). Our OGTT also encompassed collection 
of urine, which has a high content of C-peptide. Prior, the optimal conditions under 
which the tracer 13C leucine was administered for enrichment of (pre) proinsulin 
were established. Also, techniques to obtain urinary C-peptide under highly purified 
circumstances were set up. Our main outcome measure was the stable isotope 
enrichment of de novo C-peptide, which we related to early plasma insulin and glucose 
AUC. Twelve healthy Caucasian individuals (M4F8, age 41.8±2.3, BMI 28.3±1.7) with 
normal glucose tolerance underwent our OGTT.  
Results. We found that during a 75 g OGTT, newly synthesized insulin contributed 
approximately 20% of total insulin secretion. The pattern of isotope enrichment 
obtained by collecting multiple urine voids was suggestive that the newly synthesized 
insulin contributes to the late phase of insulin secretion. De novo C-peptide correlated 
negatively with both early plasma insulin AUC (r = -0.629, P = 0.028) and early plasma 
glucose AUC (r = -0.605, P = 0.037).
Conclusions. With stable isotope technique added to OGTT, we were able to measure 
newly synthesized insulin in healthy individuals. This new technique holds the promise 
that it is feasible to develop a direct in vivo beta cell function test.
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BACKGROUND
Abnormal function of the pancreatic beta cells is crucial to the development of type 2 
diabetes (T2D)[1]. An in vivo test of the dynamics of insulin excretion could be used in 
pathogenetic studies and to examine drug effects in patients with T2D. In the present 
study, we explored whether it is feasible to develop a test with a stable isotope tracer to 
quantify the newly synthesized insulin.
Insulin synthesis and secretion by beta cells is regulated predominantly by changes 
in plasma glucose concentrations and in particular by the rate of these changes 
(supplemental figure 1)[2, 3]. Following an acute rise of glucose concentrations, a 
biphasic insulin secretion response occurs[4-6]. This results from the glucose transport 
into beta cells through the glucose transporter 2 (GLUT2) [7] , which activates calcium-
dependent triggering as well as calcium-independent amplifying pathways[8] . In the 
so-called storage-limited model[9-13], insulin is secreted by exocytosis of two distinct 
pools of granules, which are the storage and trafficking units for insulin within beta 
cells as well as the site of conversion from predecessor (pre)proinsulin to insulin and 
co-secreted C-peptide [14] . A ‘readily releasable pool’ (RRP) of granules near the 
plasma membrane is responsible for the rapid first-phase release (via the triggering 
pathway) and the translocation of a more distal ‘storage granule pool’ (SGP) serves as 
replenishment of the RRP and results in the more sustained second phase [15, 16] . 
After an in vitro glucose stimulus, rat pancreatic islets have a biphasic insulin response 
and synthesize de novo proinsulin, which is stored in newly synthesized granules and 
subsequently secreted after 1 h [17, 18] . However, the dynamics of newly synthesized 
insulin and granular secretion of (de novo) insulin have not yet been investigated in 
humans in vivo. 
In the present study, we determined insulin secretory function with a novel method 
by following insulin kinetics during an oral glucose tolerance test (OGTT) preceded 
by administration of a bolus of the stable isotope tracer 13C leucine. We hypothesized 
that the in vitro findings would be reflected in the time course of changes in labelled 
and unlabelled insulin and C-peptide, providing an in vivo test to characterize beta cell 
dynamics in humans. 
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METHODS
Study design
Firstly, we optimized our method using 13C leucine during an OGTT according to an 
earlier described bolus dose technique[19-21], by examining, dosage and distribution. 
The equilibrium phase between the isotope enrichment in the extracellular fluid 
was assessed by measuring 13C leucine in plasma and the isotope enrichment in the 
intracellular fluid assessed by measuring the transamination product of intracellular 
leucine α-ketoisocaproic acid (KIC) in both plasma and saliva. We also assessed the 
potential stimulatory effects of 13C leucine on insulin or C-peptide, as doses with 
essential amino acids may affect various metabolic processes in tissues [22, 23]. 
C-peptide de novo synthesis was calculated by its fractional synthesis rate (FSR). We 
tested whether 13C enrichment was derived from purified C-peptide accurately by 
comparing several procedures. After standardization of our protocol, we used the 
13C leucine OGTT among subjects with normal glucose tolerance and compared 
the enrichment results with standard OGTT parameters. On top of basal enrichment 
of C-peptide, an increase in this ratio during OGTT represents de novo synthesized 
insulin(illustrated schematically in Fig 1a).
Subjects
We had two study groups of healthy volunteers, one for the pilot phase (n = 12) 
in which we explored, developed, and tested the method and thereafter a group (n 
= 12) to perform the newly developed analyses. In the pilot phase, with subgroups 
obtained from the 12 healthy individuals, we tested a number of components of the 
method, regarding dosage, equilibrium stage and final precursor enrichment (KIC) 
curves, based on the availability of samples on a given time point. These individuals 
were not on medication known to influence glucose metabolism and did not have 
endocrine, hepatic and renal disease. The WHO criteria for fasting and 120-min plasma 
glucose values were used to categorize the study subjects as being in a normal glucose 
tolerance state. The 13C leucine OGTT was performed at the clinical research unit of 
the department of Internal Medicine of Erasmus MC. Informed written consent for 
the study was obtained from all participants, and the Erasmus Medical Centre Medical 
Ethics Review Board approved the study protocol.
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Figure 1 | (A) Model of 13C leucine tracer incorporation in precursor amino acid pool for enrichment of de 
novo insulin and C-peptide; and (B) Schematic overview 13C leucine OGTT sampling.
Anthropomorphic measurements
Body height and weight were measured to the nearest 0.1 cm and 0.1 kg, respectively. 
Waist was measured in cm halfway between the lowest rib and the iliac crest, hip was 
measured as the maximum circumference of the hips in the standing position in cm and 
from these measurements the waist-to-hip-ratio was calculated. Systolic and diastolic 
blood pressures were measured with an electronic blood pressure monitor (Datascope 
Accutorr Plus Inc., Montvale, NJ) after 5-min rest in the sitting position. 
Standardized 13C leucine OGTT
The timing of sampling is shown in Fig. 1b. A total of 75 g glucose was dissolved in 
200 ml H2O and administered orally after a 10-h overnight fast. A bolus dose of 1 g 13C 
leucine was dissolved in 150 ml H2O and administered orally 45 min (-45 min) prior 
A
B
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to this oral glucose load. Venous blood samples were drawn before the oral intake of 
the 13C leucine solution (-60 min) and thereafter (-15 min). After glucose load, venous 
blood samples were drawn at time-points 15, 30, 45, 60, 90, 120, 150, 180 and 210 min 
for measurement of glucose, insulin and C-peptide concentrations (11 sampling time-
points in total). Urine voids were collected in the fasting state (before oral 13C leucine 
solution intake) and during OGTT (total urine collected in period after 13C leucine 
solution intake until 210 min post-glucose load). In these two collections, C-peptide 
concentrations were measured. For a subset of individuals, urine collection during 
OGTT was performed in multiple portions, enabling us to observe possible trends over 
time. In supplementary material we explain how enrichment was measured in purified 
urinary C-peptide. For all subjects, we performed these analyses in triplicate from the 
start of solid phase extraction.
Measurements
Insulin and C-peptide concentrations are given in pmol/l and glucose concentrations 
given in mmol/l. Area under Curve (AUC) of C-peptide and glucose was calculated 
according to the trapezoid method[24] . 
Calculations of beta cell function enrichment parameters
1) Dependency on de novo insulin
Enrichment expressed in tracer/tracee ratio (t/T) in purified C-peptide in urine at 
baseline and in urine collected during the 13C leucine OGTT was used as initial 
measurement. These numbers were used for correlation analyses with routine OGTT 
parameters. Leucine and precursor KIC enrichment are expressed in mole per cent 
excess (MPE).
2) FSR of de novo insulin
The FSR of C-peptide de novo synthesis was calculated; FSR was expressed as 
percentage (%) during OGTT and calculated with the following formula[19, 22] ; 
FSR(%/hr) = (E
collected 
- E
basal
)/A x 60min x 100%
where  is the enrichment of leucine in purified C-peptide from urine collected during 
the total duration of the 13C leucine OGTT, is the natural enrichment in baseline urine, 
and Area (A) is the AUC in enrichment of  KIC from 90 to 210 min during OGTT, and 
used as substitute for enrichment of precursor pool. The factor 100 is used to convert 
FSR into %/h. Tracer-based synthesis measurement is based on a series of events: firstly 
the secretion time, which in this is case the period between oral administration of 13C 
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leucine and first appearance of enriched C-peptide; secondly the period of de novo 
synthesis of C-peptide. This period is used for calculation of A; and thirdly the period 
of disappearance of stable isotope 13C leucine and decrease in precursor enrichment. 
Regarding these events, FSR calculation was based on a fixed model: this model is 
based on earlier in vitro literature regarding biphasic responses, with a period of 
secretion time for de novo synthesis within OGTT estimated as 0-90 min post-glucose 
load [19]; period of de novo synthesis was estimated as 90-210 min, and we assumed 
this time period based on 1) previous literature where in vitro isolated rodent islet cells 
exposed to high glucose concentrations produced de novo insulin after 60 min  [17, 18] 
2) and taking into account both leucine and glucose absorption in our gut; period of 
disappearance of stable isotope is not taken into consideration in this model. 
3) Estimated absolute de novo C-peptide concentration in both urine and plasma 
Total urinary C-peptide concentration was multiplied with the overall fractional 
synthesis (FS) during the 2 h of OGTT (t90-210min)  to obtain absolute de novo C-peptide 
estimated in urine. Total plasma C-peptide AUC was multiplied with FS during the 2 h of 
OGTT (t90-210min) to obtain absolute de novo C-peptide estimated in plasma.
Statistical analyses
Data are expressed as mean ± SD, or indicated otherwise. Comparisons within persons 
were made with paired t test. For correlation analyses, Spearman’s rho was used. 
Differences were considered statistically significant when P value was < 0.05. All 
statistical tests were conducted with the use of SPSS, version 15.0, for Windows (SPSS 
Inc., Chicago, IL, USA). 
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Figure 2 | Final leucine and KIC enrichment curves (MPE, mean± SD) in healthy individuals (n = 9)
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RESULTS
Dosage, distribution, single pool kinetics and final conditions of the bolus dose 
method
First, the optimal conditions for stable isotope administration during an OGTT were 
determined. We studied the effect of 1.0 g 13C leucine administration on plasma insulin 
concentrations among non-diabetics (n = 7, M4 F3, age 31.2±16.1, BMI 23.2 ±2.2), 
with paired t test of insulin concentration in both groups before and 15 min after 
administration. Since no significant increase in insulin or C-peptide concentration was 
observed, this dosage was maintained (supplemental figure 2a). To test whether 1.0 g 
13C leucine and timing of administration would result in enough precursor enrichment, 
we examined isotope enrichment in the extracellular fluid (leucine MPE) and isotope 
enrichment in the intracellular fluid (KIC MPE) in both plasma and saliva in non-diabetics 
during OGTT (n = 6, M4 F2, age 35.5 ±17.4 BMI 23.9 ± 3.3). No significant difference in 
the amount of average leucine MPE and KIC MPE/min between plasma and saliva was 
observed after 13C leucine administration: equilibrium with KIC MPE as valid surrogate 
marker was assumed with high precursor enrichment (supplemental figure 2b). With 
this final protocol, we combined the data of total nine non-diabetic individuals (M4F5, 
age 31.9±10.5, BMI 24.8±3.0) into a final KIC MPE and leucine MPE curve (Fig 2). From 
this curve, the AUC from t=90 to t=210 min was used to estimate A. As we observed a 
small variance in A, with a value of 0.109 ± SEM 0.016 (t120-210 min), we used this as a 
fixed parameter in our final model. Single-pool kinetics of both 13C leucine and 13C KIC 
in both plasma and saliva are mentioned in supplemental table 1. 
13C leucine enrichment and OGTT based plasma/urine parameters
We used our final model in 12 subjects with normal glucose tolerance. Their general 
characteristics as well as their enrichment measurements are described in Table 1, 
detailed individual characteristics in supplemental table 2, and their OGTT curves in 
Fig. 3ac. In general, 13C/12C enrichment in C-peptide from basal urine (the naturally 
occurring enrichment) did not differ much between subjects. It was estimated that on 
average, de novo synthesis represented ~20% of total C-peptide released during a 210 
min OGTT. In correlation analyses with OGTT parameters, 13C/12C  leucine enrichment 
was negatively correlated with early C-peptide release (Fig. 3d), and also negatively 
correlated with excesses of glucose concentrations (Fig. 3e). Finally, in order to 
demonstrate the trend of enrichment post-glucose load, we collected multiple urine 
voids during OGTT. Supplemental Fig. 3 illustrates that 13C/12C leucine enrichment had 
its maximum more towards the late phase of the OGTT.
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Table 1 | Clinical characteristics of individuals with normal glucose tolerance 
  NGT
n 12
Sex(male/female) 4/8
Age (years) 41.8±2.3
Weight (kg) 88.2±6.21
Height (m) 1.76±0.03
BMI (kg/m2) 28.3±1.7
Waist (cm) 101.8±4.7
Hip (cm) 113.0±2.85
W/H ratio 0.90±0.02
RR systolic (mmHg) 121±4
RR diastolic (mmHg) 76±2
Basal C-peptide enrichment (t/T) 0.273±0.0004
Collected C-peptide enrichment (t/T) 0.295±0.002
FSR(%/hr), total FS (%) during 210min OGTT between brackets 9.9±1.0 (19.8±1.9)
Total urinary C-peptide (pmol/L*210min) 8746±1585
De novo urinary cpep (pmol/L*210min) 1633±305 
Total plasma C-peptide AUC (pmol/L*210min) 388129±35252
De novo plasma C-peptide AUC (pmol/L*210min) 74367±8727 
Data are means± SEM. BMI is Body Mass Index. W/H ratio is waist/hip ratio. RR is Riva-Rocci (blood pressure). FSR is 
Fractional Synthesis Rate. FS is fractional synthesis. OGTT is oral glucose tolerance test. AUC is area under curve.
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Figure 3 | OGTT curves (mean±SEM) for (A) glucose, (B) insuline and (C) C-peptide. Spearman’s correlation 
of C-peptide enrichment (t/T) obtained from urine collected during OGTT with OGTT parameters d 
C-peptide 0-60 min AUC; and e glucose disposal 0-60 min AUC
A B
C D
E
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Insulin transcription/translation
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2nd phase 
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Biphasic insulin secretion
Figure 4 | Schematic overview of assessment of beta cell function with stable isotope method during 
OGTT. Oral glucose load initiates beta cell response in a biphasic secretion modus. Two pools of granules 
(oval shaped) are responsible for insulin secretion (sphere shaped): 1st phase insulin release (dark spheres) is 
delivered by a readily releasable pool located at the cell periphery (1), and second more sustainable phase 
(light spheres) is delivered by a storage granule pool located more distantly (2). The storage granule pool 
contains pre-existing insulin and insulin that is newly synthesized during OGTT. This newly synthesized 
insulin (light spheres with 13C labelling) can be measured with stable isotope techniques, adding a novel 
beta cell function test to investigate T2D development within classical OGTT.  
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DISCUSSION
Using 13C-leucine to label peptides during a 75 g OGTT in healthy volunteers, we found 
that newly synthesized insulin contributed a substantial portion (approximately 20%) 
to the secreted insulin during 210 min. The pattern of isotope enrichment suggested 
that the newly synthesized insulin contributed mainly to the second phase of insulin 
secretion: the negative association of post glucose load C-peptide enrichment with 
early plasma C-peptide AUC might imply that a low first phase of insulin secretion is 
followed by a relatively high dependency on de novo synthesis. This is the first in vivo 
study where stable isotope labelling has been used to explore synthesis and release of 
insulin in humans.
Early in vitro studies following radioactive labelled insulin in pancreatic islets in 
response to high glucose concentration demonstrated an increase in radioactive insulin 
release after more than 1 h delay [17, 18] . Moreover, we had to consider both leucine 
and glucose absorption in the gut . The observed enrichment during our OGTT from 
90 to 210 min suggests an increase in de novo insulin production, while it has been 
assumed that roughly only 15% of stored insulin is being secreted by the pancreas when 
exposed to high glucose levels. The enrichment of C-peptide in the presence of a large 
insulin storage capacity of the pancreas supports the idea of a preferential secretion of 
de novo insulin under high glucose load conditions [25, 26] . In line, late phase in vivo 
insulin release in our healthy volunteers was not fully explained by de novo synthesis, 
as had been observed in vitro [27] . In Fig. 4, we propose a schematic overview of insulin 
synthesis including labelling with 13C-leucine, SGP, RRP and secretion of granules.
C-peptide was preferred to insulin as a measure of insulin biosynthesis and enrichment 
measurement. Both are secreted in equimolar rate, but C-peptide is more stable than 
insulin, is cleared predominantly by the kidneys, and has a higher availability due to 
its longer half time in plasma as well as being secreted in higher amounts into urine. 
In addition and in contrast to insulin, C-peptide does not have a significant first-pass 
liver clearance or other peripheral tissue degradation pathways, which vary largely 
between individuals with different metabolic conditions influencing insulin synthesis 
and turnover. Urine was sampled during OGTT, as urine is easily available and contains 
C-peptide in higher abundance than plasma, which is an advantage for isolation of the 
small C-peptide. Urinary C-peptide excretion reflects endogenous insulin secretion[28] 
, and provides a potential for a non-invasive method to follow beta cell dynamics with 
stable isotopes. 
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13C leucine was used as a tracer, as insulin and C-peptide contain six potential sites for 
enrichment. We assumed that there would be negligible isotopic effects or recycling of 
the stable isotope in the current setting[29-31]. We cannot exclude a contribution of 
recycling of the tracer present in basal proteins, but the isotope bolus method during 
a restricted period reduces such effects to negligible proportions. We also assumed 
that our measured general distribution of precursor surrogate 13C KIC in plasma also 
reflects enrichment in amino acid pools of pancreatic beta cells[22, 32] , and that the 13C 
leucine enriched C-peptide has the same properties during our purification procedures 
as normal C-peptide[33] . Stimulation of protein synthesis in peripheral tissue has 
been observed on administration of amino acids [19, 23, 34] . Therefore, leucine as well 
as its derivative KIC could have had effects on the beta cells, albeit to a substantially 
lesser extent than glucose[35, 36], but we did not find such a metabolic effect of 
administration of 13C leucine on insulin and C-peptide levels. We believe this metabolic 
effect is minimized by using a bolus dose technique instead of a flooding dose method 
or infusion labelling techniques, resulting in a substantial lower required amount of 13C 
leucine administration. The use of a relatively low amount, together with the timing of 
administration of 13C leucine (45 min before glucose load), differs from previous studies 
in which a metabolic effect was observed using substantially higher amounts of leucine 
simultaneously with glucose[37]. Although a continuous infusion labelling technique 
would result in a preferred constant precursor enrichment, the bolus dose method is 
less time consuming with seemingly similar results [20], and it has a proven capability 
to achieve equilibrium of intra- and extracellular pancreatic amino acid pools    [19-21] . 
There are some technical considerations regarding the use of tracer/tracee ratio in 
urinary C-peptide as marker for de novo synthesis. C-peptide 13C enrichment could be 
underestimated when there is still a demand for insulin and presumably also for de 
novo insulin synthesis in the late phase of the OGTT based on disappearance of label 
into the extravascular pool. This would result in diminished precursor enrichment. 
We have purified C-peptide from human urine. This method is not only of benefit for 
further C-peptide oriented studies, but also provides an overview of how to manage 
the purification of other low abundant peptides from human bodily fluids. SPE-
IAC demonstrated highly purified C-peptide on 1D HPLC analysis, preventing of loss 
of C-peptide by reduction in the number of steps required for purification.  Loss of 
C-peptide during work-up procedure was also reduced by optimization of the surface 
materials[38]. It remains the question whether or not this procedure will suffice in 
individuals with T2D, with possible fewer quantities of urinary C-peptide, and excessive 
urinary protein and peptide contamination due to diabetic nephropathy.
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Although our method used for enrichment measurements was reproducible, urine 
C-peptide (ELISA measured) concentration was independent, and increased enrichment 
could be observed when using 1 or 4g of  13C leucine (supplemental Fig. 3) in the same 
individual, it is not a purely quantitative method, as it is based on the ratio of labelled 
to unlabelled C-peptide, rather than the absolute amount of tracer. Considerations for 
qualitative or quantitative measurements have been discussed previously[39]. Taken 
together, the increase over time of enrichment after a leucine bolus, the increase over 
time of the production of C-peptide after a glucose load and the use of urine voidance 
instead of blood make our results an overall approximation of de novo synthesis of 
insulin during OGTT. With only two measurements to determine the enrichment, 
the current model simplifies the non-steady state nature of insulin secretion after an 
acute oral glucose stimulus for beta cell secretion. Of course, the tracer 13C leucine 
enrichment could be measured in frequently sampled plasma for more detail. Further 
technical improvements to increase the recovery of purified C-peptide (or insulin) from 
plasma and enhanced mass spectrometry efficiency for measuring de novo synthesis 
measurement are required if intravenous glucose stimulus techniques are considered 
to test beta cell function. Such an approach may make a clearer distinction between 
the first phase and the second phase insulin response and facilitates more detailed 
modelling[5].
The stable isotope labelling techniques used for this study purpose provide a base for 
improved phenotyping of individuals with metabolic syndrome and predisposition for 
T2D, which could open the opportunity for the earlier initiation of preventive beta cell 
focused strategies to inhibit the progression to T2D.  Moreover, our method could also 
be applied for monitoring of beta cell capacity during beta cell potentiating medication. 
In conclusion, we have developed an in vivo stable isotope tracer method to investigate 
beta cell dynamics in humans that is able to distinguish between already available and 
de novo synthesized insulin. Future research is required to test the value of the method 
to screen for impaired insulin secretion as part of beta cell dysfunction.
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SUPPLEMENTARY MATERIAL
Methods for measuring 13C/12C leucine ratio in purified urinary C-peptide
Materials and chemicals
All chemicals used were of analytical grade and all solvents of chromatographic grade 
and were purchased from VWR International (West Chester, Pennsylvania, USA). Buffers 
and solutions were prepared with deionized water (Milli-Q grade). OASIS HLB cartridge 
columns were purchased from Waters (Milford, MA). ZIPTIP pipette tips were purchased 
from Merck Millipore (Darmstadt, Germany). The human C-peptide mouse antibodies 
were purchased from HyTest Ltd. (Turku, Finland). Cyanogen-bromide-activated 
Sepharose  4B required for immunoaffinity columns was purchased from GE Healthcare 
(Diegem, Belgium). 
The phosphate buffered saline (PBS) was prepared according to Thevis, et al. [1]« , 
consisting out of 0.12 M Na3PO4 and 0.5 M NaCl in deionized LC-MS H2O, pH adjusted 
to 8.0 with 3 M HCL.  13C leucine (99% purity) was purchased from Cambridge Isotope 
Laboratories. Possible presence of C-peptide mouse IgG antibodies due to harsh elution 
conditions or leakage of columns in our post- immunoaffinity chromatography (IAC) 
sample elute was measured with Mouse IgG total Ready-SET-Go! ELISA from Bioscience 
(San Diego, CA) according to manufacturer’s protocol.  Urinary C-peptide was measured 
after each purification step with C/PEP/EASIA ELISA from DIAsource ImmunoAssays S.A. 
(Cat. no. KAP0401, Nivelles, Belgium). Plasma glucose was measured by a hexokinase-
based method (Gluco-quant; Roche Diagnostics, Mannheim, Germany). Plasma insulin 
and C-peptide, and urinary C-peptide were measured separately by a competitive 
chemiluminescent immunoassay, supplied by Euro/DPC. The assay was performed 
on a DPC Immulite 2000 analyzer (Euro/DPC), according to the manufacturer’s 
recommended protocol. Serum creatinine was measured with an enzymatic procedure 
based on creatinine conversion, with the Creatinine Plus assay on a Roche/Hitachi 
analyzer. Urine creatinine was measured based on the Jaffe alkaline picrate method, 
with commercially available creatinine from Merck, Darmstadt, Germany used for 
making reference values.  
Purification of urinary C-peptide
Solid phase extraction (SPE), followed by IAC was used for purification of C-peptide 
from urine. C-peptide recovery and possible contamination were evaluated at each 
step of the purification.
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Solid Phase Extraction
For our work-up procedure 100 pmol of absolute C-peptide was required, and based 
on ELISA measurements of urinary C-peptide concentration, a variable volume of 
urine was used in order to obtain the absolute amount of 100pmol . These samples 
were first loaded on a 3cc 60mg OASIS HLB cartridge columns from Waters (Milford, 
MA) for solid-phase extraction (SPE); Urine was diluted with 0.5% TFA in a ratio of 5:3.5 
and centrifuged during 10 minutes at 700 g at room temperature. The supernatant was 
loaded on SPE column, which had been preconditioned with 1 ml methanol acetonitril, 
followed by 1 ml 0.1% TFA. The cartridge was washed with 3X0.50ml 0.1% TFA and 
dried. Elution of the cartridge followed, using 2X0.25ml 50% acetonitril containing 0.1% 
TFA into an Eppendorf tube and this eluate was dried using a SpeedVac concentrator 
(Thermo Scientific Savant SPD131DDA SpeedVac concentrator, Thermo Scientific 
RVT4104 Refrigerated Vapor Trap). The dried residue was resuspended in 1ml PBS 
buffer, incubated during 15 minutes in an ultrasonic bath and transferred to an IAC 
column.
Extraction of C-peptide from urine by IAC.
IAC columns were made with anti-human C-peptide monoclonal mouse antibodies 
(HyTest). These antibodies were coupled to cyanogen-bromide-activated Sepharose  4B 
(GE Healthcare, Diegem) with a capacity of 1 mg IgG/mL (0.5 mL per column) according 
to enclosed protocol. The IAC columns were stored in PBS and were washed 3X with 
1ml PBS before use. The resuspended eluate from SPE procedure was loaded on the 
IAC column and after mixed incubation during 60 minutes, the effluent was collected 
and the column washed with 3X 0.50ml PBS and 3X 0.50ml H2O. Bound C-peptide was 
eluted with total 1.8ml 0.1% TFA. Hereafter, the IAC columns were washed with 3X 
0.50ml 0.1% TFA en 2X0.50ml LC-MS H20 and stored again in PBS.
1Dimensional (1D) High-performance Liquid Chromatography (HPLC) of the IAC elute 
IAC eluate was captured in prehydrolysed vials for gas chromatography-mass 
spectrometry (GC-MS) analysis for all final enrichment analyses. In parallel, we also 
worked up random samples with SPE and IAC for further work-up on 1D HPLC; for this 
procedure IAC eluate was captured in vials coated with different albumin concentrations 
of 1% 0.5.%,0.1%, 0.05%, 0.01%, 0.001% and 0% H20 solution  Separation of C-peptide 
in IAC hydrolysate from possible nonspecific IAC-bound contaminants including BSA 
from the work-up procedure was performed on HPLC interfaced to an UV detector 
(Spectrasystem), after establishing optimal conditions with recombinant human 
C-peptide. The HPLC was equipped with a Polaris C18, Varian column (50X2mm, particle 
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size 3μm, pore size 180 A). The mobile phase consisted of (A) H2O containing 0.1% TFA 
and (B) acetonitril. A sample volume of 100 μl was injected into the HPLC system, and a 
gradient of 15%B to 90%B in 13 min at a flow rate of 0.5 ml/min was used.
GC-MS analysis of precursor surrogate 13C/12C KIC from plasma and 13C/12C leucine from 
target peptide purified urinary C-peptide
We measured 13C/12C in KIC in plasma on all time points during OGTT. The amino 
acids of from plasma were derivatized with N-Methyl-N-tert-butyldimethyl- 
silyltrifluoroacetamide in pyridine during 60 minutes at 60°C to their t-butyldimethylsylil 
derivatives.  The 13C enrichment was determined by gas chromatography–mass 
spectrometry by measuring the fragments of natural 12C and 13C KIC, respectively. Gas 
chromatography–mass spectrometry analyses were carried out on a Carlo Erba GC8000 
gas chromatograph coupled to a Fisons MD800 mass spectrometer (Interscience BV) by 
on column injection of  1 µL on a 25-m  0.22-mm fused silica capillary column, coated 
with 0.11 µm of HT5 (SGE, Victoria, Australia).With regard to 13C/12C leucine in purified 
urinary C-peptide, 2 ml 6 M HCl was added to the remaining dried eluate after IAC, the 
tube was flushed with nitrogen and capped. After incubation during 24 hours at 110° 
C the hydrolysate was dried using a SpeedVac concentrator. The 13C enrichment was 
determined by gas chromatography–mass spectrometry by measuring the fragments 
302 and 303 of natural and 13C leucine, GC-MS analyses of all urine samples were 
performed with DSQ II Mass Spectrometer Detector (Thermo Electron Corporation) and 
GC column BPX5 column 25m, I.D. 0.22 mm, film 0.25µm (SGE Analytical Science)
Results
Purification of C-peptide, validation, inter- and intra-variability of 13C leucine 
enrichment
The recovery of C-peptide after SPE was ~100% and after SPE-IAC ~50-60% 
(supplemental figure 4a). An albumin coating with at least 0.001% BSA solution of the 
collection tube for IAC eluate was required to maintain an adequate ~40% recovery 
of C-peptide for the workup towards 1D HPLC to confirm purity (supplemental figure 
4b).  Leakage of IAC columns was present, but the amounts were negligible; sometimes 
even below detection threshold levels (supplemental figure 4c). With these procedures, 
at least 100 pmol of C-peptide was required to perform enrichment measurements. In 
order to test the purity of C-peptide we did the following:
1) OASIS-IAC method is our standard work-up procedure, we also performed 4 more 
intensive methods to isolate C-peptide ;a) OASIS-IAC followed by an additional 
OASIS method b) OASIS-IAC followed by an additional ZIPTIP method c) OASIS-
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IAC followed by an additional1D HPLC method d) same as method c, but using 
250 pmol C-peptide. In procedures c and d we added the 1D HPLC method as 
an additional separation step for C-peptide. We loaded IAC eluate onto 1D HPLC 
(supplemental figure 5a) When using this procedure as an additional purification 
step, we isolated the C-peptide peak by capturing the fractions between 5.8 
and 8.8 minutes In each fraction, we measured C-peptide concentration with 
ELISA (supplemental figure 5b). The concentrations correlated well with their 
chromatographic peak (supplemental figure 5c). When related to our original 
urine concentration, recovery rate in all HPLC fraction combined was around 30%. 
However, with these additional purification step no increase in enrichment was 
found (supplemental figure 5d), so we maintained our OASIS-IAC procedure.
2) In order to be sure that enrichment came from C-peptide, we also excluded the 
possibility of interference by free 13C leucine in collected urine, by adding 1000mg 
13C  leucine to urine prior to steps for C-peptide purification; this did not affect 
enrichment measurements (supplemental figure 6a). Addition of 500 pmol of 
recombinant C-peptide to collected urine prior to steps for C-peptide purification 
resulted in lowering op C-peptide enrichment; as recombinant C-peptide had an 
enrichment of ~ 0.273, the measured decrease in enrichment corresponded well 
with the theoretical estimated decrease (supplemental figure 6b). Oral intake 
of 4 gr 13C leucine instead of  1 gr resulted in increase of C-peptide enrichment 
(supplemental figure 6c).
3) During GC-MS analysis, we used isoleucine, an amino acid not present in C-peptide 
as a marker for the amount of contamination and compared its amount to that of 
leucine. The ratio of leucine-isoleucine peaks was in general 10-1, this would imply 
that the range of contamination does not result in substantial underestimation in 
the the range of enrichment that we measured
With our final procedure, both intra and inter-variability coefficient of variability of 
C-peptide enrichment measurements were 1.11% and 2.34%, respectively. 
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Supplemental Table 1 | Single pool model analysis of substrate kinetics
Subjects Subjects
n 9 6
Male/female M4F5 4M2F
Age (yrs) 31.9±10.5 35.5±17.4
BMI (kg/l^2) 24.8±3.0 23.9±3.2
Plasma leucine kinetics Plasma KIC kinetics Saliva leucine kinetics Saliva KIC kinetics
E(0) 1.18±0.20 0.99±0.18 0.59±0.20 0.70±0.14
k (min-1) 0.051±0.014 0.034±0.012 0.093±0.038 0.042±0.098
Q (μmol) 66277±12165 79658±14286 142044±44817 111692±19316
Ra (min-1) 51.8±13.6 34.2±12.1 93.3±37.6 42.2±9.9
T ½ (min) 14.4±4.6 23.4±11.2 8.5±3.3 17.3±4.7
TT (min) 20.8±6.6 33.8±16.1 12.3±4.8 25.0±6.8
MRT (min) 20.8±6.6 33.8±16.1 12.3±4.8 25.0±6.8
Data is in mean±SD. BMI is body mass index. Kinetic parameters mentioned in the table are isotopic enrichment of the 
first sample (E(0)) , rate constant for elimination (k), pool size (Q), rate of appearance (Ra), one half-life (T1/2), turnover time 
(TT), mean residence time (MRT)
Supplemental Table 2 | Individual characteristics
Pe
rs
on
G
en
de
r (
M
=m
al
e,
F=
fe
m
al
e)
A
ge
(y
ea
rs
)
E 
ba
sa
l (
t/
T)
E 
co
lle
ct
ed
 (t
/T
)
D
el
ta
 E
A
 (t
90
-2
10
m
in
)
To
ta
l C
-p
ep
ti
de
 
ur
in
e 
(p
m
ol
/L
) 
To
ta
l C
-p
ep
ti
de
 
pl
as
m
a 
A
U
C 
(p
m
ol
/L
)
D
e 
no
vo
 (%
 o
f 
to
ta
l) 
ur
in
ar
y 
cp
ep
 (p
m
ol
/L
)
D
e 
no
vo
 (%
 o
f 
to
ta
l) 
pl
as
m
a 
A
U
C 
(p
m
ol
/L
)
1 M 37 0.273 0.295 0.021 0.109 5091 169583 1000 19.6 33313 19.6
2 M 61 0.273 0.282 0.010 0.109 21338 598463 1874 8.8 52568 8.8
3 M 38 0.274 0.289 0.016 0.109 9879 545370 1414 14.3 78097 14.3
4 M 41 0.271 0.290 0.019 0.109 2096 359963 368 17.6 63201 17.6
5 F 39 0.273 0.294 0.021 0.109 1515 216533 296 19.6 42360 19.6
6 F 44 0.275 0.309 0.035 0.109 7544 382425 2397 31.8 121507 31.8
7 F 45 0.273 0.305 0.031 0.109 5154 322785 1486 28.8 93079 28.8
8 F 43 0.273 0.291 0.019 0.109 9422 428355 1609 17.1 73142 17.1
9 F 45 0.276 0.295 0.019 0.109 8453 404565 1451 17.2 69443 17.2
10 F 41 0.273 0.294 0.021 0.109 10251 345765 1940 18.9 65449 18.9
11 F 35 0.273 0.291 0.017 0.109 8768 401175 1382 15.8 63214 15.8
12 F 27 0.272 0.303 0.031 0.109 15437 482565 4383 28.4 137028 28.4
Inidividual characteristics of our study subjects. M=male, F=female. E basal is natural enrichment of C-peptide in urine 
obtained at baseline, E collected is enrichment of C-peptide in urine obtained during 75gr 210min OGTT, Delta E is the 
difference between E basal and E collected, A is the area under curve (AUC) of the decay in enrichment of precursor KIC 
(t/T) calculated for t90-210min (based on our earlier performed pilot study as mentioned in our original article). Total 
C-peptide in urine and plasma were obtained during the OGTT, for both we calculated the contribution of de novo 
synthesized C-peptide, in absolute amounts as well as in percentage. 
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Supplemental figure 2 | (A) Determining dosage of tracer; effect on insulin concentration (mean+/- SEM). 
T=time before glucose load in minutes, 1gr of 13C leucine was administered at T -45; (B) Distribution of 
tracer; average KIC enrichment (MPE) per minute after 13c leucine administration in plasma and saliva 
(mean+/- SD)
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Supplemental figure 3 | Illustration of urine collected over multiple time-points during OGTT. 5 schematic 
overviews of enrichment measurements (t/T) urine collected between given time-points are visible. The 2 
first overviews are from individual 1; enrichment in basal and total collected urine (A) and enrichment 
in different portions of urine collected during the OGTT (B) are mentioned. The 3 overviews below are 
from individual 2; enrichment in basal and total collected urine (C) and enrichment in different portions of 
urine collected during the OGTT (D) are mentioned. Also this individual underwent the OGTT with 4gr 13C 
leucine (E).
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Supplemental Figure 4 | (A) recovery rate of C-peptide after (Solid Phase Extraction) SPE with increasing 
concentrations loaded on the OASIS column remained ~100%. In our procedure, SPE was followed by 
Immunoaffinity Chromatography (IAC), where recovery rate of C-peptide  (tested with 2 different columns 
IAC1 and IAC2) was ~50-60%. (B) In order to prevent loss of C-peptide to surface absorption for possible 
further purification steps, at least 0.001% bovine serum albumin (BSA) was required, maintaining ~40% 
recovery of C-peptide, data in mean±SEM (addition of BSA was required when we tested an additional 
chromatographic separation step after SPE and IAC, however as we used SPE followed by IAC, this addition 
was not used in our final work-up procedure); and (C) Possible antibody leakage of IAC columns were 
tested, however the amounts measured were negligible, and occasionally the amounts were below the 
detection limit.
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B
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Supplemental Figure 5 | (A) After Solid Phase Extraction (SPE) and Immunoaffinity Chromatography 
(IAC), we performed a chromatogram of C-peptide by High-performance liquid chromatography (HPLC), 
with a retention time of 7.383. As albumin coating of tubes with 0.001% BSA capturing the IAC eluate was 
necessary for prevention of C-peptide loss, an albumin peak is visible as well. (B) Fractions around the 
1D HPLC retention time for C-peptide were collected (concentrations in duplo in mean±SEM), and with 
ELISA measurements we confirmed presence of C-peptide. (C) There was a clear relationship between the 
1D HPLC C-peptide peak AUC and the ELISA measured C-peptide concentration (r2 0.98, P<0.001). (D) We 
compared five different purification methods for their amount of C-peptide enrichment (t/T) in 7 different 
urine samples (mean±SEM): SPE followed by IAC (SPE-IAC), SPE-IAC followed by SPE (SPE-IAC-SPE), SPE-IAC 
followed by Ziptip (SPE-IAC-ZIPTIP), SPE-IAC followed by HPLC (SPE-IAC-HPLC1) with 100pmol C-peptide, 
and SPE-IAC-HPLC2 with 250pmol C-peptide,  however no method was found to be superior, and thus the 
SPE-IAC strategy was maintained.  
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Supplemental Figure 6 | (A) As renal loss of free 13C leucine after oral load might theoretically interfere 
in our C-peptide enrichment (t/T) measurement, we tested the addition of 1000mg free 13C leucine 
to urine before our C-peptide purification work-up procedure; free 13C leucine did not alter the our 
enrichment measurements; (B) Addition of 500pmol recombinant C-peptide resulted in lower enrichment 
measurements, when added to 100pmol C-peptide from urine collected after 13C leucine oral intake; in our 
two collected urine examples after addition of 500 pmol recombinant C-peptide (with 0.273 enrichment) 
the enrichment went down from 0.286 to 0.277 and from 0.286 to 0.278, respectively. This corresponded 
with the theoretical estimated lowering effect, which was estimated to go towards ~0.277; and (C) Results 
of an individual who performed our OGTT test with 1gr 13C leucine en 4gr 13C leucine oral ingestion; 
enrichment of Cpeptide in basal urine was the same, but enrichment of C-peptide in collected urine 
increased from 0.300 to 0.324.
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Transcription factor 7-like 2 gene links increased 
in vivo insulin synthesis to type 2 diabetes
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ABSTRACT
Transcription factor 7-like 2 (TCF7L2) is the main susceptibility gene for type 2 diabetes, 
primarily through impairing the insulin secretion by pancreatic β cells. However, the 
exact in vivo mechanisms remain poorly understood. We performed a family study and 
determined if the T risk allele of the rs7903146 in the TCF7L2 gene increases the risk of 
type 2 diabetes based on real-time stable isotope measurements of insulin synthesis 
during an oral glucose tolerance test. In addition, we performed oral minimal model 
(OMM) analyses to assess insulin sensitivity and β cell function indices. Compared to 
unaffected relatives, individuals with type 2 diabetes had lower OMM indices and a 
higher level of insulin synthesis. We found a T allele-dosage effect on insulin synthesis 
and on glucose tolerance status, therefore insulin synthesis was higher among T-allele 
carriers with type 2 diabetes than in wild-type individuals. These results suggest that 
hyperinsulinemia is not only an adaptation to insulin resistance, but also a direct cause 
of type 2 diabetes.
Highlights
• We developed a test to follow insulin synthesis in real-time in vivo and used it in 
type 2 diabetes high-risk families
•  Insulin synthesis was increased in individuals with non-insulin treated type 2 
diabetes 
• A variant of the TCF7L2 gene linked insulin synthesis with type 2 diabetes
Research in context. Transcription factor 7-like 2 (TCF7L2) is the main susceptibility 
gene for type 2 diabetes, predominantly by affecting insulin secretion of pancreatic β 
cells. However the exact in vivo mechanisms remain poorly understood. We  investigated 
the relationship between the TCF7L2 rs7903146 variant and real-time insulin synthesis 
measurements in vivo. We found that genetically increased insulin synthesis contributed 
to development of type 2 diabetes. Our data implies that hyperinsulinemia is a sign not 
only of resistance to insulin but also of intrinsic β cell dysfunction. Our findings can help 
in the understanding and treatment of type 2 diabetes. The glucose-sensitive TFC7L2 
pathway might be a target for intervention.
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INTRODUCTION
Type 2 diabetes has become one of the main threats to human health in the 21st 
century[1]. This complex disease results from interactions between lifestyle and genes 
that are predominantly involved in the development or function of the insulin-secreting 
pancreatic β cells[2, 3]. The rs7903146 T allele of transcription factor 7-like 2 (TCF7L2), a 
Wnt-signaling transcription factor gene, has consistently been linked to type 2 diabetes 
across different ethnicities[4-6]. 
The results of several studies that have looked at the effects of the TCF7L2 variant 
suggest that it has a context-dependent influence on the availability of insulin. For 
example, obesity, insulin resistance, and hyperglycemia appear to enhance the effects 
of the TCF7L2 variant.[7-11]. While the reasons underlying the context-dependent 
influence of the TCF7L2 variant are largely unknown, several mechanisms have been 
proposed for how they might contribute to type 2 diabetes. TCF7L2 variants have 
been associated with impaired incretin-stimulated insulin secretion[12-14] and with 
increased hepatic glucose production.[15, 16] Another mechanism might be that 
TCF7L2 regulates insulin synthesis and processing in β cells, as suggested by the 
expression profiles of human pancreatic islets cells[17]. In human homozygotes for the 
TCF7L2 rs7903146 T allele, pancreatic islet size is increased, β cell volume is relatively 
small, and glucose-stimulated insulin secretion in vitro is reduced[18]. These human data 
suggest a combination of morphological and functional β cell differences based on the 
T allele. Silencing of TCF7L2 in rodent islets or clonal β cell lines also results in reduced 
glucose-stimulated insulin secretion, reduced preproinsulin gene expression, reduced 
incretin-stimulated insulin secretion, and defective exocytosis of the insulin containing 
granules[19]. Clearly, a number of different mechanisms related to regulating insulin 
synthesis and processing in beta cells underlie this type of genetically induced β cell 
dysfunction.
Numerous studies demonstrated a link between the TCF7L2 rs7903146 T allele and 
insulin secretion, but it is unknown if altered de novo insulin synthesis contributes to 
this relationship in vivo and, consequently, if insulin synthesis is a target for preventive 
strategies for type 2 diabetes.
We recently developed a novel method that enables to follow real-time insulin 
synthesis in vivo during an oral glucose tolerance test (OGTT); with stable isotope 13C 
leucine used as a tracer and insulin co-secretory product C-peptide as its target peptide 
for enrichment measurements during OGTT, we are able to detect newly synthesized 
insulin[20]. Here, we applied this technique in family analyses to determine whether 
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individuals with type 2 diabetes have defective insulin synthesis, and used Mendelian 
randomization with TCF7L2 rs7903146 to determine if variation of in vivo insulin 
synthesis is causally related to type 2 diabetes.
MATERIALS AND METHODS
Subjects 
We recruited families with a high risk of type 2 diabetes by systematic family screening 
at the outpatient clinic of the Erasmus University Medical Center as described 
previously[21]. Out of 83 patients with type 2 diabetes we identified 60 high-risk 
families of whom 19 Caucasian and 27 South Asian families decided to participate in 
the present study. Taking patients with type 2 diabetes attending our clinic as index 
cases, we recruited their first-degree relatives, taking two generations into account. 
Both parents of the South Asian probands and relatives were of South Asian origin 
with their roots in Surinam, and Caucasian probands and relatives were born in the 
Netherlands with both parents of Caucasian Dutch origin. All individuals with type 2 
diabetes were only treated with metformin and received dietary advice. Based on the 
frequency of the genetic variant rs7903146 (CT/TT), alpha 0.05, power 80%, and 1:2 
ratio of affected (type 2 diabetes) to unaffected (non-type 2 diabetes), we found that 
32 individuals with type 2 diabetes and 64 without type 2 diabetes were required for 
allelic test of association[22]. We performed our novel insulin synthesis test in 100 of 
these first-degree relatives: 48 (M18 F30) Caucasians and 52 (M26F26) South Asians. For 
the OGTT, individuals were divided in subgroups with normal glucose tolerance (NGT), 
impaired fasting glucose/ impaired glucose tolerance (IFG/IGT), or type 2 diabetes, 
based on World Health Organization criteria. Written informed consent for the study 
was obtained from all participants prior to inclusion in the study. The study protocol 
was approved by the Erasmus University Medical Center Medical Ethics Review 
Board. All procedures followed were in accordance with the ethical standards of the 
responsible committee on human experimentation (institutional and national) and 
with the Helsinki Declaration of 1975, as revised in 2008.
Anthropomorphic data
To determine body mass index (BMI), body height and weight were measured to the 
nearest 0.1 cm and 0.1 kg. Waist circumference was measured in cm halfway between 
the lowest rib and the iliac crest; the maximum circumference of the hips was measured 
in cm in the standing position; and from these measurements, the waist-to-hip (W/H) 
ratio was calculated. 
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13C Leucine bolus as add-on to OGTT
We performed our protocol, immunoassay and enrichment measurements as 
described previously and evaluated extensively[20]. In summary: 75 g of glucose was 
dissolved in 200 ml H2O and administered orally after a ten-hour overnight fast. A bolus 
dose of 1 g of 13C leucine was dissolved in 150 ml H2O and administered orally 45 min 
(-45 min) prior to this oral glucose load. Venous blood samples were drawn before 
the oral intake of the 13C leucine solution (-60 min) and thereafter (-15 min) and at 
several time points until 210 min after the glucose load. Urine voids were collected in 
the fasting state (before oral 13C leucine solution intake) and during OGTT (total urine 
collected in period after 13C leucine solution intake until 210 min after the glucose 
load). In these two collections, urine C-peptide concentrations were measured, which 
reflects endogenous C-peptide secretion[23]. The reasons for using urine voids for our 
enrichment measurements have been published previously[20]. For all subjects, we 
performed enrichment analyses of urinary C-peptide in triplicate from the start of solid 
phase extraction (SPE), which is the first step for purification of C-peptide from urine. 
On top of basal enrichment of urinary C-peptide, an increase in enrichment during 
OGTT represents de novo synthesized insulin.
Details regarding the enrichment measurements are mentioned in a technical 
addendum elsewhere [20]. In summary: All chemicals were of analytical grade and 
all solvents of chromatographic grade and were purchased from VWR International 
(West Chester, Pennsylvania, USA). Buffers and solutions were prepared with deionized 
water (Milli-Q grade). OASIS HLB cartridge columns for SPE were purchased from 
Waters (Milford, MA). The human C-peptide mouse antibodies were purchased from 
HyTest Ltd. (Turku, Finland). Cyanogen-bromide-activated Sepharose 4B required for 
immunoaffinity chromatography (IAC) was purchased from GE Healthcare (Diegem, 
Belgium). 13C leucine (99% purity) was purchased from Cambridge Isotope Laboratories. 
SPE followed by IAC was used for purification of 100 pmol of absolute C-peptide 
from urine. Subsequently, 13C enrichment in purified C-peptide was determined by 
gas chromatography–mass spectrometry (GC-MS) by measuring the fragments 302 
and 303 of naturally occurring and 13C-labeled leucine. GC-MS analyses of purified 
C-peptide from all urine samples were performed with DSQ II Mass Spectrometer 
Detector (Thermo Electron Corporation) and GC column BPX5 column 25m, I.D. 0.22 
mm, film 0.25µm (SGE Analytical Science). The intra and inter-variability coefficient of 
variability of C-peptide enrichment measurements were 1.11% and 2.34%, respectively.
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Calculation of OGTT indices and estimated Glomerular Filtration Rate (eGFR)
The Oral minimal model (OMM) was used to describe the plasma glucose, insulin 
and C-peptide concentrations after oral glucose stimulus.[24] We used the C-peptide 
minimal model to assess the following parameters for beta- cell function: the static 
responsivity of β cells due to glucose potentiation, Φstatic (10
-9 min-1); the dynamic 
responsivity of β cells due to glucose potentiation, Φdynamic (10
-9 ); and the total 
responsivity of β cells due to glucose potentiation, Φoral (10
-9 min-1). We used the 
glucose minimal model to assess the insulin sensitivity index, SI (10-5 dL kg-1 min-1 per 
pM). Parameters from both models were multiplied with each other to calculate the 
respective disposition indices (DI): DIstatic, DIdynamic and DIoral. OMM parameters were 
estimated using SAAM II software.[25] eGFR was estimated with the modification of 
diet in renal disease formula[26].
Calculations for C-peptide enrichment parameters
Enrichment parameters were expressed as tracer/tracee ratio (t/T) derived from the 
levels of purified C-peptide detected in urine at baseline and those in urine collected 
during the 13C leucine OGTT. The fractional synthesis rate (FSR) of de novo C-peptide 
synthesis during OGTT was expressed as a percentage (%/hr) and calculated using 
the following formula: FSR (%/hr) = (Ecollected - Ebasal)/A x 60min x 100%, where Ecollected is 
the enrichment of leucine in purified C-peptide from urine collected during the total 
duration of the 13C leucine OGTT; Ebasal is the natural enrichment in baseline urine; and 
area (A) is the area under the curve in the enrichment of α-ketoisocaproic acid from 90 
min to 210 min during OGTT, and used as substitute for enrichment of precursor pool, 
which was calculated as described previously.[20] The factor 100 is used to convert FSR 
into % per hour. In cases (n=47) where enrichment data for C-peptide from baseline 
urine were missing due to low C-peptide concentrations, we used a t/T ratio of 0.273, as 
this value reflects the natural enrichment which was virtually universal for all individuals 
in our subgroups and corresponds with the calculated theoretical natural isotope ratio 
in leucine. Total insulin synthesis during our 210 min OGTT mentioned in figure 3 was 
calculated as FSR x 2h (period of de novo synthesis between 90-210 min, as mentioned 
previously[20]).
Blood sampling for DNA isolation and gene analysis of TCF7L2 rs7903146 
Genomic DNA was isolated from venous whole blood sampled in ethylenediamine 
tetraacetic acid tubes using a QiAamp DNA Blood Mini Kit (QIAGEN GmbH, Hilden, 
Germany). Synthetic oligonucleotide primers were used for PCR to amplify a fragment 
of the TCF7L2 gene (forward primer GCCGTCAGATGGTAATGCAGAT, reverse primer 
CCAAGCTTCTGAGTCACACAGGCC). Sequence analysis of the PCR product was 
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performed on a 310 Genetic Analyzer (ABI Prism), programmed for POP-6 polymer, 1mL 
syringe, with a 47 cm, 50 i.d. capillary. The retrieved sequence products were used for 
TCF7L2 rs7903146 genotyping.
Statistical analyses
All numerical data were expressed as mean ± SEM. Comparisons between two given 
subgroups were performed with an unpaired t test. Differences were considered 
statistically significant if the P value was < 0.05. For differences between proportions, 
a Chi-squared test was used; differences were considered significant if the P value was 
< 0.05. Pearson's correlations were used to assess the associations between FSR and 
OGTT parameters. Statistical tests were conducted using SPSS version 20.0 for Windows 
(SPSS Inc., Chicago, IL, USA). Multiple regression analyses to explain variance of insulin 
synthesis with given independent variables were performed using the SOLAR software 
package, which takes into account family matrices.[27] Effects of independent variables 
in multiple regression analyses were considered significant if the P value was < 0.05. 
The datasets generated and analyzed during the current study are available from the 
corresponding author on reasonable request.
RESULTS
Insulin synthesis across the stages of glucose tolerance 
Prior to our main analysis, which is the investigation of the relationship between TCF7L2 
rs7903146 and insulin synthesis, we first explored how this novel β cell phenotype 
behaved across the different stages of glucose tolerance. Based on the results of the 
OGTT, we obtained three subgroups; NGT (n=47), IFG/IG (n=22) and non-insulin-
treated type 2 diabetes (n=31). The clinical and biochemical features of the cohorts are 
described in Table 1. Individuals with type 2 diabetes underwent the same modified 
OGTT procedure as the non-type 2 diabetes group, as they were not known with 
renal disease, and as, in comparison to the non-type 2 diabetes group, there was no 
difference in eGFR (100 ± 4 versus 103± 3 mL/min/1.73 m2, respectively, P = 0.48) and 
urine volume during OGTT (443± 60 versus 461± 36 mL, respectively, P = 0.79), and 
as there was no difference in metabolization rate of our tracer 13C leucine between 
both groups (Supplemental Fig. 1). Also, during our C-peptide purification work-up, no 
additional background contamination was observed in urine obtained from individuals 
with type 2 diabetes based on the ratio between amino acids not present in C-peptide 
versus amino acids that are present in C-peptide, as described previously [20]. This 
implies that possible protein loss in urine among individuals with type 2 diabetes did 
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not interfere with our enrichment measurements. Our individuals with type 2 diabetes 
had an average disease duration of 9.8±1.5 year, and they had a higher age (P < 0.001) 
and W/H ratio (P = 0.002) relative to individuals from the non-type 2 diabetes subgroup 
(NGT and IFG/IGT combined). 
In addition, we also assessed indices for insulin sensitivity and β cell function based 
on the OMM, and for insulin synthesis. We found that patients in the type 2 diabetes 
subgroup had a lower SI (P < 0.001) and lower β cell DI parameters (P < 0.001 for DIdynamic; 
P = 0.005 for DIstatic; and P = 0.004 for DIoral) when compared with the non-type 2 diabetes 
subgroup. The type 2 diabetes subgroup had a higher FSR (P = 0.030) when compared 
with the non-type 2 diabetes subgroup (table 1). For all subgroups, OGTT plasma 
glucose, insulin, C-peptide curves and contribution of their respective total insulin 
synthesis during OGTT are provided (Fig. 1a-c), as well as correlation plots between FSR 
and plasma C-peptide area under the curve t0-60min and urinary C-peptide (Fig. 1d-e; 
(r = -0.243, P = 0.015 and r = -0.39, P < 0.001, respectively).
Table 1 | General characteristics of families at high risk of type 2 diabetes. 
NGT IFG/IGT T2D P value *
n 47 22 31
rs7903146: CC/CT/TT 29/10/8 9/10/3 10/20/1 0.004 †
Sex (male/female) 17/30 11/11 16/15 0.330 †
Age (years) 40±2 44±2 56±2 <0.001
BMI (kg/m2) 27.1±0.6 29.3±1.4 29.4±0.8 0.148
W/H ratio 0.86±0.01 0.92±0.2 0.94±0.01 0.002
SI (10-5 dL kg-1 min-1 per pM) 23±3 11±2 6±1 <0.001
DIdynamic (10
-14 dL kg-1 min-1 per pM) 6263±1034 2174±576 545±140 <0.001
DIstatic (10
-14 dL kg-1 min-2 per pM) 496±109 131±29 47±9 0.005
DIoral (10
-14 dL kg-1 min-2 per pM) 569±122 152±33 51±10 0.004
FSR (%/hr) 10.8±0.7 11.1±0.9 13.5±1.3 0.030
Subjects are grouped according to normal glucose tolerance (NGT), impaired fasting glucose/impaired glucose tolerance 
(IFG/IGT) and type 2 diabetes (T2D), with numerical data presented as mean±SEM. BMI is body mass index; W/H ratio is 
waist-to-hip ratio; SI  is insulin sensitivity index derived from oral minimal model (OMM); DIdynamic, DIstatic and DIoral are OMM-
derived β cell disposition indices as described in the material and methods section; FSR is fractional synthesis rate. * P < 
0.05 Student’s unpaired t test of T2D versus non-T2D (NGT and IFG/IGT subgroups combined) unless otherwise stated. † P 
< 0.05 Chi-squared test among given subgroups.  
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Figure 1a-c | Glucose, insulin and C-peptide curves during Oral Glucose Tolerance Test (OGTT) according 
to glucose tolerance state. (A) Plasma glucose, (B) insulin and (C) C-peptide curves during 210 min OGTT 
of individuals with normal glucose tolerance (triangle, dashed line), impaired fasting glucose/impaired 
glucose tolerance (square, thin line) and type 2 diabetes (circle, thick line), respectively (mean±SEM). 
Their corresponding total insulin synthesis measurements made during OGTT are approximately 21.6%, 
22.1% and 27.0% (non-type 2 diabetes subgroups versus type 2 diabetes subgroup; P = 0.03, according to 
Student’s unpaired t test), respectively.
A
B
C
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Figure 1d-e | Correlation plot of fractional synthesis rate (FSR, %/hr) during Oral Glucose Tolerance Test 
(OGTT) with OGTT parameters (D) Pearson's correlations between FSR and plasma C-peptide area under 
curve (AUC) t0-60min (r = -0.243, P = 0.015; above) and (E) between C-peptide in urine during 210 min 
OGTT (r = -0.39, P < 0.001; below), respectively among individuals with normal glucose tolerance (triangle), 
impaired fasting glucose/impaired glucose tolerance (square) or type 2 diabetes (circle). 
D
E
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Figure 2 | Glucose, insulin and insulin/glucose ratio curves during Oral Glucose Tolerance Test (OGTT) in 
type 2 diabetes subgroup according to RS7903146 genotype Plasma glucose (A), insulin (B) and insulin/
glucose ratio (C) curves during 210 min OGTT of individuals with type 2 diabetes with either TCF7L2 
RS7903146 CC wild-type genotype (dashed line, open triangles) or CT/TT carriership (continuous line, closed 
triangles), respectively(mean±SEM). Their corresponding total insulin synthesis measurements during 
OGTT are approximately 20.8% versus 29.9%, respectively; P = 0.041, according to Student’s unpaired t 
test.
A
B
C
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Relationship between T allele of TCF7L2 rs7903146 and insulin synthesis
The proportion of individuals with TCF7L2 rs7903146 CT and TT genotypes increased 
with increasing glucose intolerance (P = 0.004, Table 1). Ordinal regression analysis 
revealed a significant association between the TCF7L2 rs7903146 genotypes (CC, CT or 
TT) and the three WHO OGTT categories (B =1.06, P =0.009). As we found a significant 
interaction of WHO OGTT subgroup with CC, CT or TT carriership on the variance of FSR 
(βinteraction=0.11, P = 0.002), we performed additional subgroup analyses to compare the 
effect of the presence of the T allele on OMM indices and FSR (Table 2). In both non-type 
2 diabetes and type 2 diabetes subgroups, there was a trend for the T-allele carriers to 
have a lower SI and lower DIdynamic (P = 0.043 within non-type 2 diabetes subgroup and 
P = 0.047 within type 2 diabetes subgroup), DIstatic and DIoral (P = 0.029 within type 2 
diabetes subgroup) when compared with wild-type individuals. In the type 2 diabetes 
subgroup, FSR was increased in the T-allele carriers compared with wild-type (P = 0.041). 
Fig. 2a-c illustrates glucose, insulin and insulin/glucose ratio curves with contribution 
of their respective total insulin synthesis during OGTT for type 2 diabetes individuals 
with wild-type and T-allele carriership. Between these groups, there was no difference 
in their average disease duration (wild-type group 9.6±3.0 versus T-allele carriership 
group 9.9±1.8 years, P = 0.93) which could explain the difference in insulin synthesis. 
For further in-depth analysis of the effects of the T allele on insulin synthesis within our 
family matrices, we performed multiple regression analyses in the non-type 2 diabetes 
subgroup and type 2 diabetes subgroup. Next to ethnicity, gender, and age (and in the 
non-type 2 diabetes subgroup also WHO OGTT category), these analyses also included 
testing for a possible influence of obesity (expressed by W/H ratio), insulin resistance 
(expressed as SI), and/or loss of first-phase insulin release (expressed as DIdynamic), and 
we found opposing effects (Table 3). In the non-type 2 diabetes subgroup, the TCF7L2 
rs7903146 variant was associated with reduced insulin synthesis (β -1.986, P = 0.002), 
whereas in the type 2 diabetes subgroup, the TCF7L2 rs7903146 variant was associated 
with increased insulin synthesis (β 29.893, P = 0.01). While in our multiple regression 
models W/H ratio, SI, and DIdynamic did not contribute to FSR, ethnicity did contribute to 
FSR in the non-type 2 diabetes subgroup analyses. Therefore, in our final analysis, we 
also analyzed FSR in the South Asian non-type 2 diabetes and the Caucasian non-type 
2 diabetes subgroups (Supplemental Fig. 2). In the South Asian non-type 2 diabetes 
subgroup, the T-allele carriers had a lower FSR than that of wild-type individuals (P 
= 0.018), while no differences were found within the Caucasian non-type 2 diabetes 
subgroup.
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Table 2 | Differences between transcription factor 7-like 2 CC wild-type genotype and CT/TT carriers in oral 
glucose tolerance test response.
TCF7L2 rs7903146
Non-T2D T2D
CC CT/TT CC CT/TT
n 38 31 10 21
NGT / (IFG/IGT) 29/9 18/13
Sex (male/female) 16/22 12/19 7/3 9/12
Age (years) 42±2 40±2 55±3 56±2
BMI (kg/m2) 27.9±0.9 27.6±0.9 30.9±0.9 28.7±1.0
W/H ratio 0.86±0.01 0.90±0.02* 0.96±0.03 0.93±0.02
SI (10-5 dL kg-1 min-1 per pM) 23±3 15±3 9±2 5±1
DIdynamic (10
-14 dL kg-1 min-1 per pM) 6343±1175 3262±811* 1106±357 278±70*
DIstatic (10
-14 dL kg-1 min-2 per pM) 462±128 278±69 73±16 34±11
DIoral (10
-14 dL kg-1 min-2 per pM) 537±144 313±75 83±19 36±11*
FSR (%/hr) 11.6±0.8 10.0±0.6 10.4±1.2 14.9±1.7*
Non-type 2 diabetes (non-T2D) and T2D subgroups were compared, with numerical data presented as mean±SEM. NGT 
are individuals with normal glucose tolerance; IFG/IGT are individuals with impaired fasting glucose/impaired glucose 
tolerance; BMI is body mass index; W/H ratio is waist-to-hip ratio; SI is oral minimal model (OMM) based insulin sensitivity 
index; DIdynamic, DIstatic and DIoral are OMM derived-disposition indices for β cell function as described in the main text; FSR 
is fractional synthesis rate of insulin synthesis. *P < 0.05 Student’s unpaired t test based on CC wild-type genotype versus 
CT/TT carriers in each subgroup.
Table 3 | Multiple regression analyses on family matrices according to non-type 2 diabetes (non-T2D) and 
T2D subgroups.
Non-T2D T2D
β 95% CI P-value β 95% CI P value
TCF7L2 rs7903146 -1.986 [-3.229;-0.743] 0.002 29.893 [52.768;7.018] 0.010
Ethnicity -2.431 [-4.024;-0.838] 0.003 10.083 [-8.913;29.079] 0.298
Gender 1.325 [-0.500; 3.150] 0.155 -5.415 [-22.502;11.672] 0.535
Age 0.136 [0.065;0.207] <0.001 0.686 [-0.208;1.580] 0.132
W/H ratio -0.04 [-0.124;0.044] 0.352 0.00212 [-0.076;0.081] 0.958
SI 0.059 [-0.037;0.155] 0.229 0.233 [3.336;-2.870] 0.883
DIdynamic 0.0004 [-0.003;0.003] 0.790 -0.034 [-0.085;0.017] 0.191
OGTT category -0.02 [-0.044;0.004] 0.096 - - -
R2 48.5% 52.2%
Model trait: fractional synthesis rate (FSR) during 210 min oral glucose tolerance test (OGTT). Covariates: rs7903146 (CC 
or CT/TT), ethnicity, gender, age, waist/hip (W/H) ratio, oral minimal model (OMM) based insulin sensitivity index (SI) and 
OMM-based disposition index DIdynamic. In the model for the non-T2D subgroup, we also included WHO OGTT category as 
covariate. Bold values indicate P values that reached < 0.05 significance.
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DISCUSSION
The results of this study show that individuals with type 2 diabetes have defective 
insulin synthesis, and that this has a genetic background. We found that the TCF7L2 
rs7903146 T allele has a gene-dose effect on insulin synthesis and on glucose tolerance 
status. Compared to individuals without type 2 diabetes those with type 2 diabetes had 
higher insulin synthesis and lower OMM β cell indices during OGTT, and this increased 
synthesis was more prominent in individuals carrying a T allele.
These findings are based on a stable isotope based method that allows us to assess 
a previously undetectable parameter – newly synthesized insulin. The results suggest 
that individuals with type 2 diabetes, whose response to the OGTT is characterized 
by a reduction in both first-phase and overall insulin release, depend more on insulin 
synthesis during the second phase of insulin release. Although other factors like 
glucotoxicity might lead to β cell dysfunction in type 2 diabetes through reduced 
insulin gene expression, [28, 29] our data demonstrate that among our individuals with 
type 2 diabetes there is actually a shift from readily available insulin towards increased 
de novo insulin synthesis. There is increasing data about heterogeneity of β cells [30] 
and a gradual shift towards expression of specific β cell subpopulations that might 
contribute to the pathogenesis of type 2 diabetes. Out of four subtypes of human β cell 
populations one subtype with specific cell surface markers was related with increased 
impairment of glucose-stimulated insulin secretion in type 2 diabetes[31]. In mouse 
and human pancreas, the pattern of expression of aging markers in β cells suggests 
that β cell heterogeneity is based on the life cycle stage of β cells, and an increase of 
aging markers in β cells was observed during artificial insulin resistance[32]. These 
studies support the concept of β cell stress and apoptosis. Another mechanism for β 
cell deficiency in type 2 diabetes is beta cell dedifferentiation. In several animal models 
it has been demonstrated that hyperglycemic conditions can alter the differentiation 
status of β cells[33-36] with loss of β cell characteristic traits and/or conversion to other 
endocrine cells. The amount of dedifferentiated β cells was found to be more prominent 
in pancreatic islets of humans with type 2 diabetes compared with controls[37]. Further 
research is required whether a preferential secretion of de novo insulin synthesis in our 
individuals with type 2 diabetes is to some degree a marker for β cell heterogeneity 
under OGTT conditions in vivo. However, it is tempting to speculate that among 
individuals with type 2 diabetes, who already have reduced β cell mass secondary to 
apoptosis and/or dedifferentiation, the in vivo higher demand for insulin synthesis 
might further contribute to β cell heterogeneity, exhaustion and eventually apoptosis, 
and consequently also be one of the underlying causes of loss of β cell mass. In 
addition and accompanying increased insulin synthesis, an increased release of insulin-
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co-release products like islet amyloid polypeptide, which has cytotoxic effects on β 
cells[38], as well as ATP, which might increase islet inflammation through activation 
of islet macrophages[39], could contribute to enhanced β cell deterioration. Our 
methodology is less suited for studies of insulin-treated type 2 diabetes, therefore our 
group of individuals with type 2 diabetes may have been in a relatively homogeneous 
early stage of the disease. Future prospective studies focused on how insulin synthesis is 
linked to the duration of the disease are required for additional insights in pathogenesis 
and progression of type 2 diabetes.  
The findings among individuals with type 2 diabetes were even more pronounced 
in T-allele carriers. This increase in insulin synthesis in T-allele carriers who have non-
insulin-treated type 2 diabetes might be explained by other factors that studies 
associated with TCF7L2 SNPs; these include reduced early phase insulin secretion,[9, 
40] reduced exocytosis,[19] impaired proinsulin-to-insulin conversion,[40-42] and 
decreased β cell mass[18]One may even argue that, because the TCF7L2 rs7903146 
variant is associated with type 2 diabetes, all other factors associated with type 2 
diabetes will also be associated with the TCF7L2 variant. However, although TCF7L2 
rs7903146 indeed has a consistent and relatively strong association with type 2 
diabetes, it explains only a negligible fraction of the heritability of type 2 diabetes. One 
could also comment that defective insulin synthesis is not a cause of type 2 diabetes, 
but that it is rather just a secondary factor associated with the disease. However, we 
observed a more intricate relationship based on a significant genetic interaction that 
confirms the effect of the TCF7L2 rs7903146 variant on insulin synthesis within type 
2 diabetes. Also, in our multiple regression model, first-phase insulin release did not 
contribute to FSR. Nevertheless, TCF7L2 is known to influence the expression of multiple 
genes in different pathways[17, 43] and our findings do not rule out this pleiotropy. 
Our finding that South Asian TCF7L2 T-allele carriers without type 2 diabetes had 
lower insulin synthesis than their wild-type counterparts was not unexpected. An 
inability to increase insulin secretion to compensate for insulin resistance has been 
previously demonstrated among healthy T-allele risk carriers in whom insulin resistance 
was artificially induced.[9] Also, in a recently published multi-ethnic cohort study 
comprising of obese adolescents, the TCF7L2 rs7903146 was related to impaired β 
cell function and led to an increased risk of progression from prediabetes to type 2 
diabetes[16]. As insulin resistance is a key characteristic of our South Asian population, 
this might explain the differences between T-allele risk carriers and wild-type that were 
apparent in South Asians without type 2 diabetes, while such differences were not 
seen in Caucasians without type 2 diabetes. This reduction in insulin synthesis might 
contribute to their risk of type 2 diabetes. Strikingly, the average age of onset of type 
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2 diabetes was 12 years earlier in our South Asian population than in the Caucasians. 
This does tie in with the fact that the prevalence of type 2 diabetes is known to be 
nearly fivefold higher among South Asians than among indigenous Dutch.[44, 45] 
Previously, we have reported homogenous insulin-resistant conditions in South Asian 
families regardless of their glucose tolerance,[21] and their insulin resistance might 
also augment the harmful effects of β cell-related gene variants other than those of 
TCF7L2. However, the increase in insulin synthesis that we observed in individuals 
with type 2 diabetes during the OGTT in this study indicates an opposite effect under 
hyperglycemic conditions, underlining the likelihood that glucose levels also influence 
the TCF7L2 variant effect. This previously unrecognized interaction warrants future 
research into the influence of a glucose stimulus on multifunctional aspects of β cell 
pathways, as we cannot exclude the possibility that for other genotypes the β cell 
phenotype will also depend on whether or not the person has type 2 diabetes. Future 
studies with individuals with type 2 diabetes versus controls with artificially increased 
glucose levels are required to provide more insights in this interaction. 
In terms of technical problems, a relatively large number of subjects had very low basal 
C-peptide concentrations in combination with relatively low basal volumes of urine 
and consequently we were unable to harvest enough amounts of absolute C-peptide 
for enrichment measurements. Although subjects were asked to empty their bladders 
at baseline, they might have already emptied their bladders at home prior to the start 
of the OGTT. Despite these technical problems, basal urine C-peptide enrichment 
measurements provided stable values for all subgroups with a small variance and 
corresponds with the calculated theoretical natural isotope ratio in leucine. Although 
we had expected difficulties with the urinary C-peptide enrichment measurements for 
individuals with type 2 diabetes due to protein contamination, such problems did not 
arise, probably because these patients had no history of diabetic nephropathy and they 
were not (yet) taking insulin. Our C-peptide antibodies used for the IAC procedure for 
C-peptide purification have cross-reactivity with insulin precursor proinsulin. However, 
the excretion of proinsulin in urine is negligible compared to C-peptide, with daily 
urinary excretion of 0.05% versus 5-10% of pancreatic secretion, respectively[46]. 
Subsequently, during the process towards actual enrichment measurements of urinary 
C-peptide, we did not find evidence that proinsulin or other insulin precursors played 
a significant role in affecting these measurements. These and other technical issues 
have been described previously[20]. Interestingly, because of the cross-reactivity trait 
of the antibodies used,  future research focused on a similar purification methodology 
in plasma could provide us with in-depth real-time analyses of rs7903146 effects on 
proinsulin processing.
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This is the first time that stable isotope-based tracer technique has been used to measure 
insulin synthesis and secretion in individuals with glucose intolerance, and the first time 
such an approach has been applied to analyze the pathogenesis of type 2 diabetes. 
Our test was able to find differences between individuals with and without type 2 
diabetes as well as between TCF7L2 T-allele carriers and C-allele homozygotes. Based 
on our enrichment data, late phase hyperinsulinemia observed in early stages of type 2 
diabetes not only reflects a decrease of insulin sensitivity and insulin clearance[47], but 
also points at abnormal β cell function with a change in dynamics of insulin secretion 
in the context of a programmed increase of insulin synthesis. Moreover, this altered β 
cell function with increased insulin synthesis itself might be a significant contributor 
for sustaining insulin resistance[48]. In particular, it might partially explain why lifestyle 
intervention in individuals with type 2 diabetes for the overwhelming majority does 
not lead to partial or complete remission of their disease[49]. Future research focused 
on further assessment of the pathophysiology of this increased insulin synthesis state 
may provide opportunities for further development of specific therapies to decrease 
the demand for insulin synthesis.
In conclusion, using a novel stable isotope-based technique to follow de novo insulin 
synthesis in vivo, we have found that the TCF7L2 rs7903146 gene variant provides a link 
between type 2 diabetes and variations in the levels of newly synthesized insulin. Our 
findings suggest that the glucose-sensitive TCF7L2 pathway is a potential target for 
interventions that prevent type 2 diabetes.
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SUPPLEMENTARY MATERIAL
Supplemental Figure 1 | Curves of plasma 13C alpha-ketoisocaproate indicating the metabolization rate of 
the 13C leucine tracer.  At t=-45 min the tracer 13C leucine was applied and at t=0 min the oral glucose bolus 
was administered. The 13C enrichment of alpha-ketoisocaproate (in mole percent excess, MPE, mean±SEM) 
was similar in individuals without type 2 diabetes (n=7; continuous line) and with type 2 diabetes (n=6; 
dashed line) during our Oral Glucose Tolerance Test. Hence, the metabolization rate of our tracer 13C 
leucine was similar in both groups during our test.
Supplemental figure 2 | Insulin synthesis in the non-type 2 diabetes (non-T2D) subgroup according to 
ethnicity. Fractional synthesis rate (FSR, %/hr) during 210 min oral glucose tolerance test (OGTT) among 
Caucasian (Cau) or South Asian (SA) non-T2D subgroups, based on TCF7L2 RS7903146 CC wild-type 
genotype or CT/TT carriership; data are in mean±SEM; P=0.018, according to Student’s unpaired t test.
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DISCUSSION
In the current chapter, I discuss the implications of our findings, and propose a 
pathophysiological model with a role for the increased insulin synthesis state in type 2 
diabetes (T2D) pathogenesis. Hereafter, I present an overview of research opportunities 
that our method provides, with technical considerations.
Implications of our findings in general
Failure of the insulin secreting pancreatic beta cells is essential in T2D pathogenesis[1]. 
Multiple steps are involved in insulin biosynthesis and secretion, including glucose 
sensing, synthesis, storage and release of insulin, which all may contribute to the 
development of T2D. These individual steps are difficult to assess in vivo. Tests that 
can detect qualitative and quantitative changes in beta cell function could be used to 
further unravel the underlying mechanisms and perhaps identify distinct phenotypes 
of T2D. In addition, detailed testing of beta cell function is likely to be of prognostic 
significance, as the available indices for beta cell function have been shown to be 
superior to fasting and 2 hour glucose levels in predicting the onset of T2D during a ten 
year follow-up period[2]. Previously, the fate of in vivo insulin synthesis was unknown 
[3]. We found that improved beta cell phenotyping in vivo with a dynamic stable 
isotope labeling procedure provides crucial information about T2D pathogenesis. 
In the T2D high-risk families, genetically increased insulin synthesis contributes to 
T2D, implying that the delayed hyperinsulinemia is not only an adaptation to insulin 
resistance but also a direct cause of T2D as part of an intrinsic beta cell defect. This 
"final launch" of newly synthesized insulin provides an essential clue in the cascade of 
beta cell exhaustion and deterioration, with the implications of our most characteristic 
findings illustrated in figure 1.
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Our findings fundamentally changed the way how OGTT curves can be interpreted, 
as they add a novel distinction between “new” and “old” insulin. From a beta cell 
perspective, a more delayed insulin response observed in individuals with T2D 
compared to individuals without T2D as illustrated in figure 1b of chapter 8, or in 
carriers of the T risk allele of the rs7903146 in the TCF7L2 gene with T2D versus wildtype 
as illustrated in figure 2b of chapter 8, respectively reflects more dependency on newly 
synthesized insulin. These observations further underline what was stated in chapter 
8, that hyperinsulinemia might be a part of an intrinsic beta cell defect, and actually 
contribute to insulin resistance, as there is evidence that hyperinsulinemia itself impairs 
insulin signaling directly or leads to insulin resistance through other pathways in 
peripheral tissues[4].
Technical considerations and future perspective
Regarding the tracer 13C leucine, the oral bolus dose method instead of the constant 
infusion method was chosen in our clinical setting, as the procedure has a shorter time 
requirement with minimal concern about precursor enrichment, gives comparable intra- 
and extracellular enrichments eliminating uncertainty about precursor enrichment, is 
non-invasive which means less manipulation of the subjects, and with relatively low 
dosage and early timing of administration of the tracer, we did not find a metabolic 
effect on plasma insulin and/or C-peptide concentrations (supplemental figure 2a of 
chapter 6). As the constant infusion method requires a steady-state condition, with the 
bolus dose method we obtained a relatively faster precursor enrichment, this is crucial 
as our target peptide is part of an immediate secretory response during a dynamic 
beta cell stimulus test. One of the main concerns that we had, based on the findings 
of previous literature and our results described in chapter 3, was whether or not a 
decreased catabolism of branched chain amino acids observed in individuals with T2D 
(figure 2), could lead to differences in the rate of the metabolization rate of 13C leucine 
between individuals with and individuals without T2D. In chapter 7 we did not find 
differences in this rate (supplemental figure 1 of chapter 7).
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Figure 2 | Vicious circle in glucose homeostasis in type 2 diabetes (T2D) through amino acid turnover; 
alterations in several key factors involved in catabolism and/or anabolism may lead to rising branched-
chain amino acid (BCAA) concentrations, and subsequently worsen glucose homeostasis. Although there 
are differences in BCAA catabolism between individuals with and without T2D, the metabolization rate of 
our tracer 13C leucine was similar in both groups.  
Regarding the target peptide, a more detailed exploration of insulin synthesis could be 
possible by altering our current method by measuring enrichment of urinary C-peptide 
over multiple collected urine voids with/without the use of an urine catheter, and/or 
by measuring enrichment levels of insulin/C-peptide over multiple (or pooled) time-
points in plasma. For plasma however, we found that our current isolation procedure 
is not suitable as harvesting of the target peptide still requires improvement (data 
not shown) and further reduction of background noise to perform actual enrichment 
measurements is required. As future improvements, we could increase our target 
peptide enrichment by increasing the orally administered 13C leucine dose, however 
an accompanying increase in metabolic effects due to the tracer itself is warranted. 
Alternatively, we could also maintain the current dose but use 6 13C atom labeled 13C 
leucine instead of the present single 13C. Also, cross reactivity of the antibodies used 
in our immunoaffinity chromatography (IAC) step might play a more significant role in 
plasma (figure 3).
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Figure 3 | Schematic overview of immunoaffinity chromatography (IAC): 1) sample goes through IAC 
column 2) Binding of specific peptides in column and loss of contamination 3) elution of isolated target 
peptide. Cross reactivity with other insulin related metabolites with the antibodies used might provide 
unique opportunities. 
Genetic, epigenetic and posttranslational defects could lead to abnormal insulin 
and C-peptide variants with antagonistic properties, which could contribute to 
insulin resistance and T2D development. The antagonistic properties are believed to 
be more prominent when there are changes to the alpha chain of insulin, as it is the 
most bioactive part in in vitro studies[5].The variants include abnormal metabolites 
through amino acid alterations, impaired insulin precursor processing ((pre)proinsulin), 
truncation, glycation and protein complex formation of insulin[6-12]. These variants 
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might also contribute to discrepancies observed between quantification methods 
based on antibody assays. In contrast, mass spectrometry (MS) is considered to 
be a reference standard for quantification, and when compared to immunoassay 
measurements (IA) in urine and plasma, generally demonstrates lower insulin and 
C-peptide concentrations[13-19]. We also had a similar outcome in an exploratory 
study, as we compared plasma insulin concentrations between IA (Immunolite 2000 
produced by EURO/DBC®) versus MS (Triple-Quad LC-MS from Agilent Technologies®; 
bovin insulin was used as internal standard), from 40 human plasma heparin samples 
that were obtained from healthy and diabetic males and females from our T2D high-risk 
families included in our study as mentioned in chapter 2 and consisted out of samples 
at fasting state and a random selection of non-fasting samples. There was a significant 
linear relationship between both types of measurements (fig 4a; r=0.90, p<0,0001). 
Although the difference between measurements using these two methods were within 
the limits of agreement (fig 4b), Bland-Altman analysis predominantly showed a non-
concentration dependent positive residual between IA insulin versus MS insulin (fig 4b 
and 4c), and this was more prominent among individuals with T2D.
This difference suggests the presence of abnormal variants, and MS studies have 
indeed demonstrated several abnormal insulin and C-peptide variants, increasing 
with an abnormal glucose state[9, 10, 20]. It would be interesting to investigate 
how an increased insulin synthesis relates to insulin processing in vivo, as proinsulin 
misfolding and aggregation could contribute to beta cell failure due to increased 
endoplasmatic reticulum stress, a decreased conversion to insulin which in turn might 
lead to a vicious cycle with an even more increased demand for insulin synthesis[21]. 
We can follow this processing in more detail and real-time with our stable isotope 
method, as the C-peptide antibody used in our IAC procedure for urinary C-peptide 
isolation also has cross reactivity with insulin related metabolites, including proinsulin. 
In contrast to urine, insulin precursors in plasma are present in high abundance and 
the dynamics of proinsulin processing could be followed in more detail, with separate 
fractional synthesis rate (FSR) measurements for both C -peptide and proinsulin (figure 
5). By comparing the enrichment we could confirm whether or not “old” proinsulin is 
secreted from an already available pool of granules, or that it is actually actively newly 
synthesized but wrongly processed and intact proinsulin released during OGTT.
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Figure 4 | (A) Relationship between immunoassay (IA) and mass spectrometry (MS) insulin measurements( 
r=0,90, p<0,0001). (B) and (C): Relative and absolute Bland-Altman analysis between IA and MS 
measurements, respectively.
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Figure 5 | Proinsulin processing towards insulin and C-peptide after cleavage by prohormone convertase 
enzymes. All precursors of insulin and C-peptide could be released into plasma. With our stable isotope 
method we used C-peptide as target peptide, however the enrichment in precursors could be measured 
as well.
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In addition to a more accurate interpretation of insulin secretion after glucose load, 
our stable isotope method has potential for integration in other stress tests and/
or studies of (simultaneously) measuring the synthesis of other peptide hormones. 
We used an oral glucose tolerance test (OGTT), one of the most standardized tests, 
which incorporates our physiological enteral response[22], other target peptides for 
enrichment measurements within OGTT could be the incretin hormones and/or other 
beta cell secretory proteins such as amylin. 
As our stable isotope method provides real-time measurements of insulin synthesis, it 
could be integrated in existing models, most notably in the oral minimal model[23]: 
we used the C-peptide minimal model indices based on our OGTT in several studies, 
and could also add more detail to the model itself (figure 6a). The secretion rate 
is divided in a dynamic compartment (directly releasable insulin: SRd) and a static 
compartment (replenishment insulin: SRs). Based on our data, the SRs could actually 
be divided in two secretion rates, one for already made replenishment insulin and one 
for newly synthesized replenishment insulin, with their own secretion time, for the 
latter based on when the novo insulin synthesis actually is secreted. This new SRs beta 
cell parameter could be multiplied with the insulin sensitivity index derived from the 
Glucose minimal model (figure 6b), to obtain a disposition index, to correct this beta 
cell function parameter for insulin resistance. Further research would be required with 
more detailed FSR analyses preferably in plasma before evaluating the additional value 
of these beta cell function parameters. Also, the concept of insulin resistance can be 
investigated further from a beta cell perspective. We primarily used IAC to isolate our 
target peptide in urine, but we could also use this procedure with insulin antibodies for 
plasma and specifically isolate and test the capability of our isolated products on insulin 
signaling in vitro by adding the isolates from human plasma from different moments in 
time during OGTT to a cell model (figure 6b).
One final aspect that has not been addressed is how the stable isotope measurements 
might relate to beta cell mass. Estimating beta cell mass separate from function in vivo 
is essential, as it gives insights if drugs or other interventions not only enhance beta 
cell function but also preserve mass, leading to measures for preventing apoptosis 
and/or reverse dedifferentiation. Similar to factually all pancreas stress tests, the 
insulin response during an OGTT is a result of both beta cell function and mass. In 
vivo imaging techniques are currently developed with an optimal imaging probe to 
specifically quantify beta cell mass, including positron emission tomography, single-
photon emission computed tomography and/or magnetic resonance imaging[25]. 
Hopefully, these novel imaging methods will enable to visualize changes of the beta 
cells during life. As mentioned in chapter 7, insulin synthesis could reflect beta cell
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Figure 6 | (A) Modified version of C-peptide minimal model with integration of our novel beta cell 
phenotype. (B) The Glucose minimal model, with below addition of an in vitro variant with a human 
peripheral tissue cell line for assessment of insulin sensitivity with recombinant insulin. The latter could 
also be performed from the perspective of beta cell function by adding endogenous insulin and related 
precursors after isolation with immunoaffinity chromatography to a cell model to test the efficiency for 
insulin signaling in this cell model. Figure 6 a and b have been adapted and altered from figure 2 of ref [24] 
and modified with permission from the publisher.
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heterogeneity with a specific population or populations of beta cells responsible for de 
novo synthesis, or a coordinated secretory response to glucose of the whole spectrum 
of beta cells in different degrees. Combining future imaging techniques with in-depth 
beta cell profiling could give crucial insights about the contributions to T2D of beta 
cell function and mass, and whether insulin synthesis also reflects beta cell mass or 
purely elasticity. As a surrogate measure, we could also relate our insulin synthesis 
measurements with the current best estimate of beta cell mass, by performing a test 
investigating the glucose potentiation of the first-phase insulin response induced by 
arginine in the same study group. 
In summary, we performed extensive in-depth profiling of beta cell function in T2D 
high-risk families, introducing a novel stable isotope method to follow insulin synthesis 
in vivo. We believe our findings will give rise to new concepts about T2D, its prevention 
and treatment. Of course, these routes will be long and in that respect the findings are 
preliminary, but this work will certainly change our thinking about hyperinsulinemia 
and T2D pathogenesis.
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Summary
SUMMARY
In chapter 1 the normal physiology of insulin biosynthesis is described including the 
biphasic pattern of insulin secretion from the perspective of the storage-limited model 
and its regulatory mechanisms, beta cell pathogenesis and current available tests to 
characterize beta cell function and mass. In addition, I explained the value of stable 
isotope techniques to an existing standardized model for measurement of newly 
synthesized insulin as part of an in-depth analysis of beta cell function in vivo.
In chapter 2 the relationship between early and late beta cell response and type 2 
diabetes (T2D) in South Asian and Caucasian individuals from T2D high-risk families 
was investigated. Based on classical oral glucose tolerance test (OGTT) indices, South 
Asians on average had lower insulin sensitivity (ISI) with rapid decline of their early 
and late beta cell response. Adjusted early insulin secretion rate (ISR) was significantly 
associated with both glucose disposal and with late ISR in South Asians, but not in 
Caucasians, with significant interaction between ethnicity and early ISR. Ordinal 
regression analyses confirmed that glucose tolerance state among South Asians was 
solely predicted by early ISR and not by ISI as insulin resistance was a homogenous 
feature, while in Caucasian families both ISI and early ISR were related to glucose 
tolerance state. In conclusion, in South Asian individuals, rapid beta cell deterioration 
might occur under insulin resistant conditions, and alterations in beta cell dynamics 
may give an explanation to their extreme early onset of T2D.
In chapter 3 metabolic syndrome traits were characterized among South Asian and 
Caucasian individuals from T2D high-risk families. Individuals from both ethnicities were 
classified in three groups according to the occurrence of metabolic syndrome (MetS) 
and T2D. ISI and disposition indices (dynamic and static DIs) for beta cell function were 
calculated with the use of oral minimal model (OMM). Similarly to my findings in chapter 
2, South Asians without MetS were more insulin resistant than Caucasians without 
MetS. In the South Asians, ISI, dynamic DI, and static DI were associated significantly 
with plasma high-density lipoprotein cholesterol and triglycerides. In the Caucasians, 
ISI was associated with waist-to-hip ratio and systolic and diastolic blood pressure, 
while static DI was related to the systolic blood pressure. These findings suggest that 
there are ethnic differences with distinct metabolic syndrome phenotypes.
In chapter 4 these metabolic syndrome phenotypes were further addressed in the same 
families with amino acid profiling, as insulin resistance and glucose intolerance have 
been associated with increased plasma levels of branched-chain amino acids (BCAA). 
BCAA levels were measured in fasting plasma together with alanine, phenylalanine, 
184
Addendum
and tyrosine. Insulin sensitivity and beta cell function were assessed with classical OGTT 
indices. BCAA levels were higher in diabetic than in normoglycemic family members 
in the Caucasians but not in the South Asians. In both groups in stepwise regression 
analyses, BCAA levels were associated with waist-hip ratio but not with indices of 
insulin sensitivity or beta cell function. Adding fasting plasma BCAA levels, combined 
with phenylalanine, tyrosine and alanine to fasting glucose improved discriminative 
ability for the prediabetic state within Asian Indian families at risk for T2DM. BCAA levels 
may serve as biomarkers for early development of glucose intolerance in these families. 
In chapter 5, I investigated how renal loss of both C-peptide and glucose during 
OGTT relate to and affect plasma-derived OMM indices. In South Asian and Caucasian 
individuals from T2D high-risk families, plasma glucose, insulin, and C-peptide 
concentrations were analyzed as area under curves (AUCs) during OGTT, OMM estimate 
of renal C-peptide secretion, and OMM beta cell and insulin sensitivity indices were 
calculated to obtain disposition indices. Urinary glucose corresponded well with plasma 
glucose AUC, beta cell and insulin sensitivity analyses. Urinary C-peptide corresponded 
well to plasma C-peptide AUC and OMM estimate of renal C-peptide secretion. Renal 
glucose secretion during OGTT did not influence OMM indices in any subgroup based 
on glucose tolerance state. C-indices of urinary glucose to detect various stages of 
glucose intolerance were excellent. The limited role of renal glucose secretion validates 
the neglecting of urinary glucose secretion in kinetic models of glucose homeostasis 
using plasma glucose concentrations. Both C-peptide and glucose in urine collected 
during OGTT might be used as non-invasive measures for endogenous insulin secretion 
and glucose tolerance state. 
In chapter 6 I introduce my in vivo stable isotope based method to determine the ratio 
between readily available and newly synthesized insulin after a beta cell stimulus in 
humans by labelling newly synthesized insulin. Stable isotope tracer 13C leucine with 
urinary C-peptide as target peptide was administered prior to an extended OGTT. I 
also collected urine, which has a high content of C-peptide, at basal level and during 
OGTT. I established optimal conditions under which the tracer was administered for 
enrichment purposes and describe the techniques to isolate C-peptide from urine 
under highly purified circumstances. Among healthy Caucasian individuals with 
normal glucose tolerance, I found that newly synthesized insulin is present in vivo 
and contributed approximately 20 % of total insulin secretion. The pattern of isotope 
enrichment obtained by collecting multiple urine voids was suggestive that de novo 
insulin contributes to the late phase of insulin secretion.  In conclusion, it is possible to 
measure newly synthesized insulin in healthy individuals. 
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In chapter 7 my stable isotope based method was used as an in-depth beta cell 
assessment to understand the role of transcription factor 7-like 2 (TCF7L2), the main 
susceptibility gene for type 2 diabetes, in beta cell pathogenesis. I performed a study 
in T2D high-risk families and determined if the T risk allele of the rs7903146 in the 
TCF7L2 gene increases the risk of type 2 diabetes based on real-time stable isotope 
measurements of insulin synthesis. In addition, OMM analyses were performed to 
assess insulin sensitivity and beta cell function indices. Compared to unaffected 
relatives, individuals with type 2 diabetes had lower OMM indices and a higher level 
of insulin synthesis. I found a T allele-dosage effect on insulin synthesis and on glucose 
tolerance status, therefore insulin synthesis was higher among T-allele carriers with type 
2 diabetes than in wild-type individuals. These results suggest that hyperinsulinemia is 
not only an adaptation to insulin resistance, but also a direct cause of type 2 diabetes. 
In chapter 8, I propose a pathophysiological model for T2D pathogenesis which 
includes my insulin synthesis findings. In addition, I described how my insulin synthesis 
findings have implications for insulin curve interpretation after stimulus in general, 
but also for the current concepts of hyperinsulinemia. Finally, suggestions for further 
research options are made.  
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In hoofdstuk 1 wordt de normale fysiologie van insuline biosynthese beschreven 
inclusief het bifasische patroon van insuline secretie vanuit het perspectief van het 
storage-limited model, de betrokken regulatoire mechanismen, bètacel pathogenese 
en beschikbare testen om bètacel functie en massa te karakteriseren. Voorts heb 
ik de toegevoegde waarde van stabiele isotoop technieken aan een bestaande 
gestandaardiseerde model besproken, om zo nieuw gesynthetiseerde insuline te 
meten als onderdeel van een diepgaande fenotypering van de bètacellen in vivo.
In hoofdstuk 2 wordt de relatie tussen vroege en late bètacel respons en diabetes 
mellitus type 2 (DM type 2) in Zuid-Aziatische en Kaukasische individuen afkomstig 
uit families met hoog risico voor DM type 2 onderzocht. Op basis van klassieke indices 
welke gebaseerd zijn op de orale glucose tolerantie test (OGTT), hadden Zuid-Aziaten 
gemiddeld een lagere insuline gevoeligheid (ISI) met snellere achteruitgang van de 
vroege en late bètacel respons. De gecorrigeerde vroege insulin secretion rate (ISR) 
was significant geassocieerd met zowel de glucose klaring als de late ISR bij de Zuid-
Aziaten, maar niet bij de  Kaukasiërs, met een significante interactie tussen etniciteit 
en vroege ISR. Ordinale regressie analyses bevestigden dat de glucose tolerantie status 
bij de Zuid-Aziatische families alleen werd voorspeld door de vroege ISR en niet door 
ISI, daar de ISI een homogene kenmerk was voor deze groep, terwijl in Kaukasische 
families zowel ISI als vroege ISR gerelateerd waren aan de glucose tolerantie status. 
Concluderend kan in insuline resistente Zuid-Aziatische individuen een snellere verval 
van bètacellen plaatsvinden, en veranderingen in de bètacel dynamiek kunnen een 
verklaring geven voor het voor hen kenmerkende extreem vroeg optreden van DM 
type 2.
In hoofdstuk 3 werden kenmerken van het metabool syndroom van Zuid-Aziatische 
en Kaukasische individuen gekarakteriseerd. Individuen van beide etniciteiten werden 
ingedeeld in drie groepen op basis van het voorkomen van metabool syndroom 
(MetS) en T2D. ISI en disposition indices (dynamische en statische DI's) voor bètacel 
functie werden berekend met behulp van de oral minimal model (OMM). Net als de 
bevindingen in hoofdstuk 2 waren Zuid-Aziaten zonder MetS meer insulineresistent 
dan Kaukasiërs zonder MetS. In de Zuid-Aziaten waren ISI, dynamische DI en 
statische DI significant geassocieerd met het high-density lipoproteïne cholesterol en 
triglyceriden in plasma. In de Kaukasiërs was ISI geassocieerd met de waist-to-hip ratio 
en de systolische en diastolische bloeddruk, terwijl statische DI gerelateerd was aan de 
systolische bloeddruk. Dit suggereert dat er etnische verschillen zijn met verschillende 
fenotypes van het metabool syndroom. 
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In hoofdstuk 4 werden deze fenotypes van het metabool syndroom verder onderzocht 
in dezelfde families middels aminozuur profilering, omdat insulineresistentie en 
glucose-intolerantie in verband zijn gebracht met verhoogde plasma waardes van 
vertakte keten aminozuren (BCAA). BCAA waardes werden gemeten in nuchter 
afgenomen plasma samen met alanine, fenylalanine en tyrosine. Insulinegevoeligheid 
en bètacel functie werden beoordeeld met klassieke indices verkregen uit een OGTT. 
De BCAA waarden waren hoger bij diabetische dan bij normoglycemische familieleden 
onder de Kaukasiërs maar dit was niet het geval in de Zuid-Aziatische families. In beide 
groepen werden BCAA waarden in stapsgewijze regressieanalyses geassocieerd met 
waist-to-hip ratio maar niet met indices voor insulinegevoeligheid of bètacel functie. 
Het toevoegen van de nuchtere BCAA waarden gecombineerd met fenylalanine, 
tyrosine en alanine aan het nuchtere glucose verbeterde het discriminerend vermogen 
in het aantonen van de prediabetische toestand binnen Zuid-Aziatische families met 
een hoog risico op DM type 2. BCAA waarden kunnen dienen als biomarkers voor de 
vroege ontwikkeling van glucose intolerantie in deze families.
In hoofdstuk 5 heb ik onderzocht hoe renaal verlies van zowel C-peptide als glucose 
tijdens een OGTT associeert met en invloed heeft op de OMM indices. In Zuid-
Aziatische en Kaukasische individuen uit families met een hoog risico voor DM type 
2 werden glucose, insuline en C-peptide concentraties in plasma tijdens de OGTT 
geanalyseerd als oppervlakte onder de curve (AUC's), voorts berekende ik middels 
de OMM een schatting van de te verwachten renale C-peptide-uitscheiding, en OMM 
bètacel functie indices en ISI indices werden berekend om DI’s te verkrijgen. De glucose 
in urine kwam goed overeen met de glucose AUC in plasma, de bètacel functie indices 
en ISI. Urine C-peptide kwam goed overeen met de C-peptide AUC in plasma en met 
de vanuit de OMM verkregen schatting van renale C-peptide secretie. Renale glucose 
secretie tijdens de OGTT had geen invloed op de indices verkregen uit de OMM in alle 
subgroepen, verdeeld op basis van glucose tolerantie status. C-indices van glucose 
in de urine om verschillende stadia van glucose intolerantie te detecteren waren 
uitstekend. De beperkte rol van renale glucose secretie valideert het verwaarlozen van 
het verlies van glucose in urine tijdens de OGTT in kinetische modellen voor glucose 
homeostase welke zijn gebaseerd op glucose concentraties in plasma. Zowel C-peptide 
als glucose in urine verzameld tijdens de OGTT kunnen worden gebruikt als non-
invasieve metingen voor endogene insuline secretie en de glucose tolerantie status.
In hoofdstuk 6 introduceer ik de in vivo stabiele isotoop methode om de ratio vast te 
stellen tussen reeds aanwezige en nieuw gesynthetiseerde insuline na een bètacel 
stimulus in mensen middels het labelen van nieuw gesynthetiseerde insuline. Stabiele 
isotoop 13C leucine, met C-peptide in urine als target peptide, werd toegediend 
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vooraf aan een verlengde OGTT. Ik verzamelde ook urine, wat een grote hoeveelheid 
C-peptide bevat, basaal en tijdens de OGTT. De optimale condities waaronder de tracer 
toegediend kan worden voor verrijkingsdoeleinden werd gevonden en de technieken 
om zeer zuiver C-peptide uit urine te isoleren werden opgezet. In gezonde Kaukasische 
individuen met een normale glucose tolerantie detecteerde ik de aanwezigheid van 
nieuw gesynthetiseerde insuline in vivo welke voor ongeveer 20% bijdroeg aan de 
totale insuline secretie. Het patroon van de verrijking verkregen door het verzamelen 
van meerdere urine porties was suggestief dat de de novo insuline bijdraagt aan de late 
fase van insuline secretie. Concluderend is het mogelijk om nieuw gesynthetiseerde 
insuline te meten in gezonde individuen.
In hoofdstuk 7 werd de nieuwe stabiele isotoop methode gebruikt voor bètacel 
fenotypering om de rol van transcriptie factor 7-like 2 (TCF7L2), het voornaamste 
vatbaarheidsgen voor DM type 2, in de pathogenese van bètacellen te begrijpen. Ik 
voerde een studie uit in families met hoog risico voor DM type 2 en onderzochten of 
het T risico allel van de rs7903146 in het TCF7L2 gen het risico op DM type 2 verhoogt 
op basis van real-time stabiele isotoop metingen van de insuline synthese. Aanvullend 
werden OMM analyses verricht om ISI en bètacel functie indices te verkrijgen. 
Vergeleken met familieleden zonder DM type 2, hadden individuen met DM type 2 
lagere OMM waardes en was de insuline synthese verhoogd. Het T allel had een dosis-
afhankelijk effect op insuline synthese en glucose tolerantie status: de insuline synthese 
was hoger bij T allel dragers met DM type 2 vergeleken met wild-type. Blijkbaar is 
hyperinsulinemie niet slechts een aanpassing aan insuline resistentie, maar ook een 
directe oorzaak voor DM type 2.
In hoofdstuk 8 stel ik een pathofysiologisch model voor de pathogenese van DM 
type 2 welke mijn insuline synthese bevindingen integreert. Aanvullend heb ik 
beschreven welke  implicaties mijn bevindingen hebben voor de interpretatie 
van insuline curves na een stimulus in het algemeen, maar ook voor de huidige 
concepten van hyperinsulinemie. Tenslotte doe ik suggesties voor toekomstige 
onderzoeksmogelijkheden. 
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voor onderzoek, en jij was degene die in mij geloofde toen je me aanstelde als arts-
onderzoeker voor dit onderzoek. En het mooie is dat het onderzoek doen op het 
gebied van diabetes op dat moment voor jou ook relatief nieuw was, we stonden voor 
de drempel van het onbekende, een avontuurlijker begin kon er niet zijn. Felix, wat 
me altijd bij zal blijven zijn de gesprekken die ik met je had waar ik jouw ware gave 
merkte, namelijk je ogenschijnlijk oneindige creativiteit. Ondanks dat er tegenslagen 
waren met het opzetten van een nieuwe methode, je was in je gedachten alweer 3 
stappen vooruit met hoe we het probleem mogelijk wel zouden kunnen oplossen. 
Maar je stond ook klaar voor adviezen buiten het onderzoek. Financieel advies nodig? 
192
Addendum
Of reis adviezen? Lastige klinische raadsels? Bel Felix, hij is van alle markten thuis! En 
nog een ding, je geeft nooit op. Ik ben enorm dankbaar dat jij mijn copromotor was 
en ik vond het een enorme eer dat ik op je afscheidssymposium in het kader van je 
pensionering een presentatie mocht houden. Mieke ik wil jou ook bedanken, ook voor 
jouw gastvrijheid, de feestelijke avond die jullie georganiseerd hadden bij jullie thuis in 
Gouda vanwege de formele afsluiting van mijn promotietijd op het lab zullen Chinta en 
ik niet vergeten.
Ik wil de leden van de kleine commissie bedanken voor het voortvarend lezen en 
beoordelen van mijn proefschrift, prof. dr. E.F.C. van Rossum, prof. dr. J.L.C.M. van 
Saase en prof. dr. C. Stettler. Beste Liesbeth, ik vind het een enorme eer dat jij de rol 
van secretaris hebt aangenomen. Beste Jan, ik wil je ook enorm bedanken dat je in de 
commissie zit, ik heb je nog meegemaakt als opleider en ik ben dankbaar dat je mij 
destijds hebt aangenomen voor de opleiding Interne Geneeskunde. Dear Christoph, 
while I am finishing this text I am residing in Switzerland to contribute to new research 
directions in the field of diabetes with dr. Lia Bally at your department. Thank you for 
taking part in the thesis committee and also for your hospitality during my stay in 
Switzerland. De overige leden behorende bij de grote commissie wil ik uiteraard ook 
bedanken voor hun tijd, inzet en bereidheid om op deze dag aanwezig te zijn. Edith 
Padberg, beste Edith, bedankt voor al je hulp met het geregel van alle zaken rondom 
de promotie.
Ik wil mijn paranimfen Jurjen Versluis en Beatrice van der Matten bedanken. Ik heb 
er niet lang over moeten nadenken wie ik moest kiezen, en ik ben dankbaar dat jullie 
ja hebben gezegd. Jurjen, ik ken je vanuit het Amphia ziekenhuis, en er was meteen 
een klik, een soort bromance, niet dat Chinta jaloers hoefde te zijn ofzo, Joy maak jij 
je ook geen zorgen, maar ik weet wat ik aan je heb en dat is me veel waard. Beatrice, 
we begonnen samen aan onze vasculaire geneeskunde fellowship en dat leidde 
meteen tot een soort kameraadschap, ik heb met veel plezier met je samengewerkt 
(nog steeds) en we hebben onze lief en leed altijd zeer laagdrempelig kunnen delen, 
dit reikte tot ver buiten het domein van de kliniek. Ik ben blij dat ik jullie ken. Nogmaals 
dank aan beiden!
Dank aan alle medeauteurs. Thanks to all co-authors. Dr. A.J. Isaacs, dear Aaron, thank 
you for giving me the skills and tools to perform family analyses. Dr. A.J.M. Verhoeven, 
beste Adrie, bedankt voor je kritische en scherpe blik, de snelheid van jouw vermogen 
om gegevens over een bepaald onderwerp te absorberen en daar essentiële 
vraagstellingen, opmerkingen of kritiek bij te bedenken verbaast me altijd weer. Dr. J.G. 
Langendonk, beste Janneke, dank voor al je hulp met name ook in het begin toen je de 
193
Dankwoord (acknowledgements)
METC aanvraag van het project in goede banen leidde. Dear Thekla, thank you for your 
help with the characterization of metabolic syndrome in our population, I have enjoyed 
your stay with us, and I wish you all the best.
Dit proefschrift was nooit tot stand gekomen zonder de toewijding van de laboratorium 
analisten, waarbij er zelfs in weekenden werd gewerkt om dat te doen wat gedaan 
moest worden. Trinet Rietveld, lieve Trinet, dank je wel voor al je hulp, zowel binnen 
als buiten mijn PhD traject. Je bent niet alleen een goede en scherpe analist, maar ook 
een goed mens. Je hebt naast deze eigenschappen ook je geweldige unieke droge 
humor altijd behouden ondanks de vele tegenslagen die horen bij het opzetten van 
een nieuwe methode, en dat je altijd gewoon jezelf bent gebleven gedurende deze 
periode heeft ook een positieve weerslag gehad op mijn eigen relativeringsvermogen. 
Bedankt dat je ook laagdrempelig bereikbaar was na je pensioen voor eventuele 
adviezen. Darcos Wattimena, beste Darcos, jij hebt zoveel werk verricht voor vrijwel alle 
artikels, ook in je eigen vrije tijd, en ondanks meerdere technische problemen met de 
massa spectrometer, heb je jezelf steeds gewoon weer opgepakt en ben je gewoon 
weer doorgegaan, waarvoor enorm veel respect. Ik heb nog de foto die we gemaakt 
hebben toen we elkaar puur bij toeval zagen op een of andere strand op Lombok, 
Indonesië. Een uniek moment. Ik mis jouw reisverhalen. Rita Koole, lieve Rita, jij hebt me 
in het begin onder je hoede genomen op het lab en me wegwijs gemaakt in genetisch 
onderzoek en celkweken. Je zorgde hierbij altijd voor een veilige omgeving waarin ik 
me op het lab kon ontplooien. Hierbij moet ik ook de altijd goed gehumeurde Janneke 
Spelt bedanken, die een deel van deze praktische begeleiding onder jouw toezicht 
uitvoerde. Maar er was zoveel meer dan dat, dat kan ik hier allemaal niet opnoemen. 
Jouw bizarre efficiëntie heeft me het meest doen verwonderen. Als er vraagstukken 
naar boven kwamen op het gebied van genetische screening, dan had jij, tussen de 
routine diagnostiek, celkweken en je overige commissietaken door, opeens al een plan 
van aanpak klaar en was er meestal binnen een paar weken uitzicht op een antwoord. 
Chinta en ik hopen weer eens een keer met jou en Jaap af te spreken. Joram van Miert. 
Fawaka! Sorry man, ik vind het toch wel pijnlijk dat jouw Surinaams zoveel beter is dan 
die van mij. Je kwam erbij in een moeilijke periode, maar je hebt de uitdaging voor de 
verrijkingsmetingen met beide handen geweldig aangepakt, bedankt Joram.  Ik wil ook 
graag Annie Edixhoven, Martin Kroos, Harvey Weder en Ingrid van Sebille bedanken 
voor hun hulp en voor de leuke tijd op het lab.
Edwin Burggraaff en dr. A.H. Bootsma, bedankt voor jullie begeleiding tijdens mijn 
keuze onderzoek. Beste Aart, jij was een van de originals verbonden aan het onderzoek 
en je offerde je op om mijn eerste proefpersoon te zijn die ik aan de gemodificeerde 
OGTT kon onderwerpen, ik zal dat als mijn eerste kennismaking met de klinische 
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wetenschap nooit vergeten en ik waardeer nog altijd je support van destijds. Ik wil 
ook graag Sjaan Poldermans en Evelien Jäger bedanken voor hun hulp bij het bloed 
afnemen bij onze deelnemers, als het vaatsysteem wat lastiger toegankelijk was of 
als er meerdere mensen tegelijk moesten worden gesampled. Sjaan, ik heb ook echt 
uitstekend met je samengewerkt tijdens de EPP studies naast mijn hoofdproject en 
kijk er met veel plezier naar terug. Dr. M. Yazdan Panah, dear Moygan, thank you for 
introducing me for the first time into the world of statistics. Enrique Campos-Nanez, 
dear Enrique thank you for developing the Oral Minimal Model together with me. Dr. 
R. Hovorka, thank you for introducing me to your ISEC program. Ik wil ook een aantal 
individuen bedanken die destijds als student meewerkten aan het project: Christine 
Bruijn, Laila el Barkani, Mardin Rashid, Maarten Nuver, Varsha Lachman, Tahmiena Miry 
en Meddy Karmaoui.
Prof. dr. J.H.P. Wilson, beste Paul, ik had al die jaren niet door dat je met pensioen was 
totdat Felix me het recent een keer vertelde. Het is een enorme eer geweest dat je de tijd 
nam om met me te sparren wat betreft de manuscripten. Pas na jouw adviezen merkte 
ik mijn soms wat bekrompen visie op sommige onderdelen van mijn thesis en daarna 
hield ik (denk ik) wel de nodige gepaste afstand. Bedankt voor alle leermomenten. Dr. 
J.A.M.J.L. Janssen, beste Joop, je bent een pure wetenschapper met een grenzeloze 
passie voor research, ook jij bent een geduchte sparringpartner, we hebben met name 
in het begin van mijn PhD traject met enige regelmaat in de avonden gedineerd in het 
Erasmus MC, ik liep erna steeds weer weg met een sensatie meest passend bij BPPD en 
te veel stof om na te denken.
Collega onderzoekers van de legendarische Bd-289, met wie ik lange tijd een 
superkwartet heb gevormd: Luit ten Kate, Thijs van Herpt en Stijn van den Oord. Het 
waren altijd wel boeiende dagen in ons “kantoor”. Luit, jouw unieke humor maar 
vooral kritische, anti-main stream blik over de zaken des levens hebben mij behoorlijk 
veranderd, ik denk in positieve zin. Het was alsof ik opeens opnieuw maar totaal 
anders kennis maakte met de wereld, en er is inmiddels geen weg meer terug. Ik ben 
blij voor jou en Hilde met de geboorte van Jinte. Thijs, we hebben veel “heftige” en 
“intense” avonturen doorgemaakt, en niet alleen in de wetenschap. Van een wanhopige 
maar gefaalde joint effort om het recept achter de overheerlijke Dijkers rempeng 
bal te ontrafelen (onze mail naar de chef kok bevatte maar liefst 13 complimenten, 
komop zeg), naar onze gedeelde waardering voor de Chinese Chi krachten tot onze 
gezamenlijke passie voor lokale amateur toneelstukken, je hebt bij mij street credit 
opgebouwd homie, je weet zelf. Je werkt momenteel in Breda, mijn huidige hometown, 
ik verwacht je snel een keer bij ons te zien. Stijn, mijn held, altijd degelijk en correct, een 
man onder de mannen. Een ware gentleman pur sang, het is alleen de vraag of deze 
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eigenschappen nog terug te zien zullen zijn als je eenmaal cardioloog bent. Misschien 
zie ik jou ook nog eens in Prinsenbilly, de rest van je familie in ieder geval wel. Ik wil 
ook graag de andere promovendi bedanken waaronder Sven Bos, Reyhana Yahya, en 
uiteraard alle nefro boys aan de overkant van de Bd. Arthur Moes, jouw humor, en Nils 
van der Lubbe, jouw afkeurende blik als reactie, priceless.
Mijn klinische skills zijn met name gevormd in het Amphia ziekenhuis, alwaar ik mijn 
vooropleiding voor de interne geneeskunde heb gedaan. Ik wil de opleiders bedanken, 
dr. C van Guldener en dr. J.W.J. van Esser. Beste Coen, ik startte op unit 26 en deed 
daar mijn eerste klinische ervaringen op. Ik heb de alom bekende Grote Visite met het 
superduo in de vorm van jou en dr. G.P. Verburg inclusief de grote ladingen aan cake, 
taart en koekjes mogen meemaken. Ik heb enorm veel van je geleerd,  de rust die je 
uitstraalt ook op de meest acute momenten op de SEH,  het geduld wat je hebt om 
de AIOS weer eens op een hoger niveau te tillen, en een gevoel voor humor met de 
meest geweldige goed getimede droge opmerkingen die zeker niet zouden misstaan 
in een programma als Fawlty Towers. Joost, jij werd de nieuwe opleider gedurende mijn 
periode in het Amphia ziekenhuis. Ik kende je het eerste jaar eigenlijk niet zo goed 
vanwege de aard van mijn initiële stages, maar dat veranderde dramatisch tijdens mijn 
polikliniek- en consultenstage op de Langendijk. Ik heb het ervaren als een van de 
hoogtepunten van de opleiding. Persoonlijk gezien was ik in een fase dat ik momentum 
aan het verliezen was met het PhD traject en dat er vooruitgang, een come-back als je 
wil, moest komen, jij gaf toen op een bepaalde moment een geweldige peptalk waarbij 
je onder andere aangaf dat het niet gaat om het onderzoek zelf, maar om het karakter 
en doorzettingsvermogen van de onderzoeker om de eindtaak te volbrengen, het was 
eigenlijk een soort innerlijke strijd tegen jezelf. Joost, bedankt dat je me toen de “come-
back kid” heb gemaakt. Ik wil ook de overige internisten en MDL-artsen bedanken, 
waaronder dr. T.T. Cnossen. Beste Nienke, bedankt voor je oprechte interesse en extra 
ruimte die je gaf om aan een artikel te werken tijdens mijn nefrologie stage. Ook wil 
ik de specialisten van mijn overige stages in het Amphia ziekenhuis bedanken. Dr. F.J. 
Schuitemaker, beste Frits, bedankt voor je briljante begeleiding op de IC, de tijd en 
moeite die je neemt, ondanks de vaak hoog complexe zorg op de IC, om kennis over 
te willen brengen, en jouw passie voor het willen doorgronden van fenomenen die je 
waarneemt in de kliniek maken jou een voorbeeld voor elke AIOS. Ik wil ook alle arts-
assistenten en verpleegkundigen bedanken, inclusief de verpleegkundige specialisten. 
Danick, het was altijd lachen met jou in de flexruimte!
Ik wil dr. S.C.E. Klein Nagelvoort Schuit en dr. A. Zandbergen bedanken voor hun 
laagdrempelige begeleiding als opleiders, evenals de rest van de bazen en arts-
assistenten van de interne geneeskunde in het Erasmus MC. In 2017 ben ik gestart met 
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de opleiding tot vasculair geneeskundige. Ik wil het vasculaire/diabetes team bedanken: 
Jeanine Roeters van Lennep, Jorie Versmissen, Mandy van Hoek, Behiye Özcan, Willy 
Visser en Annette Galema-Boers, evenals de diabetes en research verpleegkundigen, 
diëtistes en de geweldige dames van de poliklinische ondersteuning. Kirsten,  Zuzana, ik 
vind het jammer dat ik geen polikliniek meer tegelijk met jullie heb op de maandagen, 
bij wie moet ik nu binnenlopen? Leggen jullie dat maar eens aan me uit. Sofia, ik heb 
het genoegen gehad om jou mee te maken in de afronding van je opleiding en heb je 
alleen maar enorm zien groeien in je rol, je komt er makkelijk. Hanny, we kennen elkaar 
al zo lang, daar is geen stamboom tussen te krijgen. Joy, jij maakt van elke spreekuur 
weer een ware feest. Ik wil naast Beatrice ook mijn andere directe vasculaire collega’s 
bedanken: Leonora Louter, Leo, Super Leo, vóór de evolutie dat nieuwbouw heet 
was er een andere realiteit, namelijk onze vasculaire hok diep verscholen in de meest 
duistere kelder van het Erasmus MC. Mensen die jou kennen weten exact waar ik het 
over heb, maar zelfs deze ruimte lichtte op door jouw aanwezigheid, en zelfs planten 
liet jij daar nog bloeien! Je bent zo vol positieve energie en een echte sfeermaakster, je 
trok zo een blik versieringen open voor een verjaardag hier of een kerstdag daar. Maar 
daarnaast ben je ook een topclinicus en ik heb veel bewondering voor je. En uiteraard 
jij en Dennis van harte gefeliciteerd met jullie dochter Fae. Marianne van Schie, stoere 
Marianne, je was in het begin van mijn fellowship een soort magische Orakel waardoor 
ik steeds weer op het juiste vasculaire pad werd gehouden, bedankt voor al je tips in 
deze voor mij warrige periode. Jan Steven Burgerhart, beste Jan Steven, onze zoons 
zijn kort na elkaar geboren in het voorjaar. Ik kende je sinds kort maar zag je al snel als 
een goede vriend, een uitstekende collega en een geweldige discussiepartner, en niet 
alleen als het gaat om onze gezamenlijke passie voor de obese medemens. Ik hoop dat 
we in lengte van jaren de vasculaire hot topics kunnen blijven bediscussiëren.
Ik wil mijn familie bedanken. Adjai, bedankt voor je hulp en je rol als oudste 
broer. Ook ik heb je helaas niet opgevolgd aan de TU Delft voor de studie lucht- en 
ruimtevaarttechniek, maar ik hoop in ieder geval dat je de cover kan waarderen. Djas 
en Amar, we hebben jarenlang tijdens onze studietijd samengewoond, het was een 
van de mooiste tijden uit mijn leven in jawel, Rotterdam-Zuid. Djas en Rekha, het is 
een bijzondere jaar met de geboorte van jullie Nandini, geniet ervan. Ratna, je staat 
altijd voor iedereen klaar terwijl je het zelf zo druk heb met je eigen bv, thanks big Sis. 
Soeredj, Wiekram, Indra en Chandra, er was een tijd dat ik jullie de kleintjes noemde, 
en die tijd is nog niet voorbij, sorry. Just showin' some love y'all! Chandra ik hoop 
dat je je bijnaam “kleine Sjaam” meer kan waarderen nu. Indra, je woont en werkt 
momenteel in Japan, je zult begrijpelijkerwijs niet bij mijn verdediging zijn, maar het 
eerste boekje dat ik verzonden heb is naar jou, en ik zal je alvast verklappen dat ik me 
op de dag van de verdediging weer eens van mijn beste kant heb laten zien, je zou 
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zoals gewoonlijk weer enorm trots zijn, maak je dus geen zorgen, je hebt niets gemist. 
Onze ouders zijn er niet meer, maar we weten waar we vandaan komen en dat zorgt 
voor een verbintenis die zijn weerga niet kent. Bedankt voor jullie onvoorwaardelijke 
support. Ik wil ook mijn schoonfamilie bedanken. I want to thank my mother in law for 
all her support throughout these years, it means a lot to me. Ook mijn schoonvader 
wil ik graag bedanken, u staat altijd klaar om te helpen. En niet te vergeten de altijd 
goedlachse Shamir en Gosia, wat een bijzonder jaar is dit voor jullie met de geboorte 
van jullie Abigail en met het behalen van de Master voor Gosia. 
Neil, je bent als ik dit schrijf net over de 7 maanden, je geniet intussen van het 
omrollen, je kunt je fruithapjes steeds meer waarderen en je plast papa eindelijk niet 
meer onder. Mocht je dit over een aantal jaar gaan lezen, wellicht slechts ter motivatie 
voor een routine basisschool werkstuk, en je afvragen: "Wat was 2018 voor een jaar?". 
Een kleine greep uit de gebeurtenissen in jouw geboortejaar 2018: Met Stephen 
Hawkings overlijden verliezen we een van de grootste genieën ooit, je weet wel, ik lees 
altijd voor uit zijn boeken voor het slapen gaan. De Engelse prins Harry trouwt met 
de Amerikaanse actrice Meghan Markle en geloof me, de ceremonie was fabulous. Het 
Frans elftal wint het WK 2018 en Nederland doet helaas voor de zoveelste keer weer 
eens niet mee aan een eindtoernooi. Donald Trump zit officieel in het tweede jaar van 
zijn presidentschap en ondanks alle sceptici bestaat de planeet Aarde nog. En er is 
dit jaar pijnlijk genoeg geen Game of Thrones, deze serie leg ik je later wel uit. Neil nu 
een samenvatting van jouw wereld zoals die was in 2018: gevoed worden, slapen en 
volle luiers 24/7. Enne, dat somt het eigenlijk wel op, ja. Sorry little buddy! Nee papa 
maakt maar een grap, mama en ik houden van je, we zijn zeer trots op je en je bent een 
"verrijking" in ons leven, no pun intended.
Ja daar zijn we dan Chinta, eindelijk. Je ben mijn steun en toeverlaat in al die jaren 
geweest. Ik heb het dan ook enorm getroffen met jou. Bedankt voor al je geduld en 
al je liefde. Ik weet nog niet hoe ik het kan terugbetalen, maar dat komt wel goed, ik 
kijk er namelijk naar uit. De dag dat ik getuige mocht zijn hoe jij en Neil elkaar voor het 
eerst recht in de ogen aankeken, zal ik nooit, maar dan ook nooit, vergeten, het geeft 
me nog steeds kippenvel. Je bent een geweldige moeder, een geweldige echtgenote, 
en een betrouwbare steunpilaar voor ons, je familie en je vrienden. Alleen met deze 
woorden zou ik mijn dankwoord kunnen en willen afsluiten. 
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A summary of PhD training and teaching activities
PhD candidate: Sjaam Jainandunsing
Erasmus MC Department: Pharmacology, Vascular and Metabolic Diseases
Research school: Cardiovascular Research School Erasmus University
 Rotterdam
Period: Aug 2009-Dec 2012
Promotor: Prof. Dr. E.J.G. Sijbrands
Co-promotor: Dr. F.W.M. de Rooij
PhD training Year
Workload 
(ECTS):
General academic skills
Course Center for Patient Oriented Research 2009 0.7
Course biomedical English writing and communication 2011 3.0
Research skills
Course NIHES introduction to data-analysis 2010 5.7
Course NIHES principles of research in medicine and epidemiology 2010 5.7
Course NIHES family based genetic analysis 2011 5.7
Course NIHES regression analysis 2011 1.0
Course NIHES repeated measurements 2011 5.7
In-depth courses
Course MOLMED biomedical research techniques 2009 1.5
Course MOLMED molecular biology in cardiovascular disease 2011 5.7
Conferences and presentations
Science Days Internal Medicine, Antwerp, Belgium: Analysis of phenotype and 
genotype with regard to beta cell function in T2D within South Asians living in 
the Netherlands (poster)
2009 0.6
Science Days Internal Medicine, Antwerp, Belgium: Diabetes and Alzheimer 
Congres, Paris, France
2010 0.8
Characterization of insulin biosynthesis and secretion in T2D high-risk families 
(oral presentation)
2011 0.6
Science Days Internal Medicine , Antwerp, Belgium: Early impairment of 
branched-chain amino acid kinetics among South Asians (poster)
2012 0.6
Resolve project TU Eindhoven, modeling the interplay of fat and carbohydrate 
metabolism with application in metabolic syndrome and type 2 diabetes, 
Eindhoven, The Netherlands: Oral minimal model applied in T2D high‐risk 
families (oral presentation)
2013 0.6
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PhD training Year
Workload 
(ECTS):
Seminars 
Vascular Rounds 2009-2012
Diabetes Platform 2009-2012
Dutch Lipopprotein Club 2010-2011
PhD Day 2011 
Vascular Lectures 2009-2012 2.1
Workshops
Workshop Photoshop and Illustrator CS5 2011 0.3
Workshop Indesign CS5 2011 0.2
Workshop Graphing styles and plot versus tables 2012 0.2
Scientific meetings
AIO/post-doc meetings at the department of Pharmacology, Vascular and 
Metabolic Diseases
2009-2012
Journal club at the department of Pharmacology, Vascular and Metabolic 
Diseases
2009-2012
Teaching activities
Vascular Lecture: Defining the concept of insulin resistance (oral presentation) 2009 0.4
Research Seminar “diagnosis and risk of ischemic heart disease”: Predicting 
type 2 diabetes (oral presentation)
2010 0.4
Scientific internship Junior Med School students 2009-2012 2.0
Supervising third-year medical students 2009-2012 1.0
Supervising doctorate of medical students 2009-2012 3.0
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